<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Fine chemical</title><meta name="description" content="In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="fine chemicals"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Fine_chemical"/><meta property="og:title" content="Fine chemical"/><meta property="og:description" content="In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced..."/><meta property="og:url" content="https://grokipedia.com/page/Fine_chemical"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Fine chemical"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.076Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Fine chemical"/><meta name="twitter:description" content="In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="69432687dc75000121eec12988b9d8ea-eba016a32a4f544d-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=69432687dc75000121eec12988b9d8ea,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.8100928544107795,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fine-chemical" class="transition-opacity hover:opacity-100 opacity-50">Fine chemical</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#definition-of-fine-chemicals-as-opposed-to-commodities-and-specialties" class="transition-opacity hover:opacity-100 opacity-50">Definition of Fine Chemicals (as opposed to Commodities and Specialties)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#products" class="transition-opacity hover:opacity-100 opacity-50">Products</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#small-molecules" class="transition-opacity hover:opacity-100 opacity-50">Small molecules</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#big-molecules" class="transition-opacity hover:opacity-100 opacity-50">Big molecules</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#technologies" class="transition-opacity hover:opacity-100 opacity-50">Technologies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#traditional-chemical-synthesis" class="transition-opacity hover:opacity-100 opacity-50">Traditional chemical synthesis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biotechnology" class="transition-opacity hover:opacity-100 opacity-50">Biotechnology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cell-cultures" class="transition-opacity hover:opacity-100 opacity-50">Cell Cultures</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#the-fine-chemical-industry" class="transition-opacity hover:opacity-100 opacity-50">The Fine Chemical Industry</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#the-industry" class="transition-opacity hover:opacity-100 opacity-50">The Industry</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fine-chemical--custom-manufacturing-companies" class="transition-opacity hover:opacity-100 opacity-50">Fine Chemical / Custom Manufacturing Companies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#contract-research-organizations" class="transition-opacity hover:opacity-100 opacity-50">Contract Research Organizations</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research-and-development" class="transition-opacity hover:opacity-100 opacity-50">Research and development</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#objectives" class="transition-opacity hover:opacity-100 opacity-50">Objectives</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#project-management" class="transition-opacity hover:opacity-100 opacity-50">Project management</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#markets" class="transition-opacity hover:opacity-100 opacity-50">Markets</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#market-size" class="transition-opacity hover:opacity-100 opacity-50">Market size</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#target-markets" class="transition-opacity hover:opacity-100 opacity-50">Target markets</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmaceuticals" class="transition-opacity hover:opacity-100 opacity-50">Pharmaceuticals</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#agrochemicals" class="transition-opacity hover:opacity-100 opacity-50">Agrochemicals</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#other-specialty-chemical-industries" class="transition-opacity hover:opacity-100 opacity-50">Other specialty chemical industries</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#target-products-and-services" class="transition-opacity hover:opacity-100 opacity-50">Target products and services</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#custom-manufacturing" class="transition-opacity hover:opacity-100 opacity-50">Custom manufacturing</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#standard-products" class="transition-opacity hover:opacity-100 opacity-50">Standard products</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#financials" class="transition-opacity hover:opacity-100 opacity-50">Financials</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#investment-costs" class="transition-opacity hover:opacity-100 opacity-50">Investment costs</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#manufacturing-costs" class="transition-opacity hover:opacity-100 opacity-50">Manufacturing costs</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#profitability" class="transition-opacity hover:opacity-100 opacity-50">Profitability</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#outlook" class="transition-opacity hover:opacity-100 opacity-50">Outlook</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="fine-chemical" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Fine chemical<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="definition-of-fine-chemicals-as-opposed-to-commodities-and-specialties" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Definition of Fine Chemicals (as opposed to Commodities and Specialties)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In <span class="inline text-[1em] leading-7">chemistry</span>, <strong>fine chemicals</strong> are complex, single, pure <span class="inline text-[1em] leading-7">chemical substances</span>, produced in limited quantities in multipurpose plants by multistep batch chemical or <span class="inline text-[1em] leading-7">biotechnological</span> processes. They are described by exacting specifications, used for further processing within the <span class="inline text-[1em] leading-7">chemical industry</span> and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced intermediates or <span class="inline text-[1em] leading-7">active ingredients</span>), or the type of business transaction, namely standard or exclusive products.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Fine chemicals are produced in limited volumes (&lt; 1000 tons/year) and at relatively high prices (&gt; $10/kg) according to exacting specifications, mainly by traditional <span class="inline text-[1em] leading-7">organic synthesis</span> in multipurpose <span class="inline text-[1em] leading-7">chemical plants</span>. Biotechnical processes are gaining ground. Fine chemicals are used as starting materials for <span class="inline text-[1em] leading-7">specialty chemicals</span>, particularly <span class="inline text-[1em] leading-7">pharmaceuticals</span>, <span class="inline text-[1em] leading-7">biopharmaceuticals</span> and <span class="inline text-[1em] leading-7">agrochemicals</span>. <span class="inline text-[1em] leading-7">Custom manufacturing</span> for the <span class="inline text-[1em] leading-7">life science</span> industry plays a big role; however, a significant portion of the fine chemicals total production volume is manufactured in-house by large users. The industry is fragmented and extends from small, privately owned companies to divisions of big, diversified chemical enterprises. The term &quot;fine chemicals&quot; is used in distinction to &quot;heavy chemicals&quot;, which are produced and handled in large lots and are often in a crude state.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Since the late 1970s, fine chemicals have become an important part of the chemical industry. As of 2025, their global total production value is approximately $211 billion, split about 60-40 between in-house production in the life-science industryâ€”the products&#x27; main consumersâ€”and companies producing them for sale.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The latter pursue both a &quot;supply push&quot; strategy, whereby standard products are developed in-house and offered ubiquitously, and a &quot;demand pull&quot; strategy, whereby products or services determined by the customer are provided exclusively on a &quot;one customer / one supplier&quot; basis. The products are mainly used as building blocks for proprietary products. The hardware of the top tier fine chemical companies has become almost identical. The design, lay-out and equipment of the plants and laboratories have become practically the same globally. Most chemical reactions performed go back to the days of the dyestuff industry. Numerous regulations determine the way labs and plants must be operated, thereby contributing to the uniformity.</span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The term &quot;fine chemicals&quot; was in use as early as 1908.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The emergence of the fine chemical industry as a distinct entity dates to the late 1970s, when the overwhelming success of the histamine H<sub>2</sub> receptor antagonists Tagamet (cimetidine) and Zantac (ranitidine hydrochloride) created a strong demand for advanced organic chemicals used in their manufacture. As the in-house production capacities of the originators, the pharmaceutical companies Smith, Kline, &amp; French and Glaxo, could not keep pace with the rapidly increasing requirements, both companies (now merged as GlaxoSmithKline) outsourced part of the manufacturing to chemical companies experienced in producing relatively sophisticated organic molecules. Lonza, Switzerland, which already had supplied an early intermediate, methyl acetoacetate, during drug development, soon became the main supplier of more and more advanced precursors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> The signature of a first, simple supply contract is generally acknowledged as the historical document marking the beginning of the fine chemical industry.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>The beginning: supply contract between Smith Kline French and Lonza for cimetidine precursors</strong></span>
<span class="mb-4 block break-words text-[1em] leading-7">In subsequent years, the business developed and Lonza was the first fine chemical company entering in a strategic partnership with SKF. In a similar way, Fine Organics, UK became the supplier of the thioethyl-N&#x27;-methyl-2-nitro-1,1-ethenediamine moiety of ranitidine,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> the second H<sub>2</sub> receptor antagonist, marketed as Zantac by Glaxo. Other pharmaceutical and agrochemical companies gradually followed suit and started outsourcing the procurement of fine chemicals. Examples include partnerships for precursors of the benzodiazepine class of tranquilizers, such as Librium (chlordiazepoxide HCl) and Valium (diazepam).</span>
<span class="mb-4 block break-words text-[1em] leading-7">The growing complexity and potency of new pharmaceuticals and agrochemicals requiring production in multipurpose, instead of dedicated plants and, more recently, the advent of biopharmaceuticals had a major impact on the demand for fine chemicals and the evolution of the fine chemical industry as a distinct entity. For many years, the life science industry continued considering captive production of the active ingredients of their drugs and agrochemicals as a core competency. Outsourcing was used only in exceptional cases, such as capacity shortfalls, processes requiring hazardous chemistry or new products, where uncertainties existed about the chance of a successful launch.</span>
<h1 id="products" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">In terms of molecular structure, one distinguishes first between low-molecular-weight (LMW) and high-molecular-weight (HMW) products. The generally accepted threshold between LMW and HMW is a molecular weight of about 700 g/mol. LMW fine chemicals, also designated as small molecules, are produced by traditional chemical synthesis, by microorganisms (fermentation or biotransformation), or by extraction from plants and animals. In the production of modern life science products, total synthesis from petrochemicals prevails. The HMW products, respectively large molecules, are obtained mainly through biotechnology processes. Within LMWs, the N-heterocyclic compounds are the most important category; within HMWs they are the peptides and proteins.</span>
<h3 id="small-molecules" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Small molecules<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">As aromatic compounds have been exhausted to a large extent as building blocks for life science products, N-heterocyclic structures prevail nowadays. They are found in many natural products, such as chlorophyll, hemoglobin, and the vitamins biotin, folic acid, niacin (PP), pyridoxine (vitamin B6), riboflavin (vitamin B2), and thiamine (vitamin B1). In synthetic life science products, N-heterocyclic moieties are widely used in both pharmaceuticals and agrochemicals. Thus, Î²-lactams are structural elements of penicillin and cephalosporin antibiotics, imidazoles are found both in modern herbicides, e.g. Arsenal (imazapyr) and pharmaceuticals, e.g. the antiulcerants Tagamet (cimetidine. see above) and Nexium (omeprazole), the antimycotics Daktarin (miconazole), Fungarest (ketoconazole) and Travogen (isoconazole). Tetrazoles and tetrazolidines are pivotal parts of the &quot;sartan&quot; class of hypertensives, e.g. Candesartan cilexetil (candesartan), Avapro (irbesartan), Cozaar (losartan) and Diovan (valsartan).</span>
<span class="mb-4 block break-words text-[1em] leading-7">A vast array of pharmaceuticals and agrochemicals are based on pyrimidines, such as Vitamin B1 (thiamine), the sulfonamide antibiotics, e.g. Madribon (sulfadimethoxime) and â€“half a century laterâ€“ the sulfonyl urea herbicides, e.g. Eagle (amidosulfuron) and Londax (bensulfuron-methyl). Benzodiazepine derivatives are the pivotal structural elements of breakthrough CNS Drugs, such as Librium (chlordiazepoxide) and Valium (diazepam). Pyridine derivatives are found in both well-known Diquat and Chlorpyrifos herbicides, and in modern nicotinoid insecticides, such as Imidacloprid. Even modern pigments, such as diphenylpyrazolopyrazoles, quinacridones, and engineering plastics, such as polybenzimidazoles, polyimides, and triazine resins, exhibit an N-heterocyclic structure.</span>
<h3 id="big-molecules" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Big molecules<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><em><em>Big molecules</em></em>, also called <em><em>high molecular weight</em></em> (HMW) molecules, are mostly oligomers or polymers of small molecules or chains of amino acids. Thus, within pharmaceutical sciences, peptides, proteins and oligonucleotides constitute the major categories.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Peptides and proteins</strong> are oligomers or polycondensates of amino acids linked together by a carboxamide group.<!-- --> The threshold between the two is as at about 50 amino acids. Because of their unique biological functions, a significant and growing part of new drug discovery and development is focused on this class of biomolecules. Their biological functions are determined by the exact arrangement or sequence of different amino acids in their makeup. For the synthesis of peptides, four categories of fine chemicals, commonly referred to as peptide building blocks (PBBs), are key, namely amino acids (=starting materials), protected amino acids, peptide fragments and peptides themselves. Along the way, the molecular weights increase from about 102 up to 104 and the unit prices from about $100 up to $105 per kilogram. However, only a small part of the total amino acid production is used for peptide synthesis. In fact, L-glutamic acid, D, L-methionine, L-aspartic acid and L-phenylalanine are used in large quantities as food and feed additives. Over 80 peptide therapeutics have been approved worldwide as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> The global market for peptide APIs was valued at approximately $9.2 billion in 2023, with the peptide therapeutics market exceeding $117 billion in 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_108qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The bulk of the production of peptide drugs, which comprise also the first generation anti-AIDS drugs, the &quot;...navirs&quot;, is outsourced to a few specialized contract manufacturers, such as Bachem, Switzerland; Chengu GT Biochem, China; Chinese Peptide Company, China; Lonza, Switzerland, and Polypeptide, Denmark.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The number of amino acids that make up a specific peptide varies widely. At the low end are the dipeptides. The most important drugs with a dipeptide (L-alanyl-L-proline) moiety are the &quot;-pril&quot; cardiovascular drugs, such as Alapril (lisinopril), Captoril (captopril), Novolac (imidapril) and Renitec (enalapril). Also the artificial sweetener Aspartame (N-L-Î±-Aspartyl-L-phenylalanine 1-methyl ester) is a dipeptide. At the high end there is the anticoagulant hirudin, MW â‰ˆ 7000, which is composed of 65 amino acids.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Apart from pharmaceuticals, peptides are also used for diagnostics and vaccines.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Proteins</strong> are &quot;very high-molecular-weight&quot; (MW &gt; 100,000) organic compounds, consisting of amino acid sequences linked by peptide bonds. They are essential to the structure and function of all living cells and viruses and are among the most actively studied molecules in biochemistry. They can be made only by advanced biotechnological processes; primarily mammalian cell cultures. Monoclonal antibodies (mAb) prevail among human-made proteins. Over 130 of them have been approved as pharmaceuticals worldwide as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Important modern products are EPO (Binocrit, NeoRecormon, erythropoietin), Enbrel (etanercerpt), Remicade (infliximab); MabThera/Rituxin (rituximab), and Herceptin (trastuzumab). PEGylation is a big step forward regarding administration of peptide and protein drugs. The method offers the two-fold advantage of substituting injection by oral administration and reducing the dosage, and therefore the cost of the treatment. The pioneer company in this field is Prolong Pharmaceuticals which has developed a PEGylated erythropoietin (PEG-EPO).</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Oligonucleotides</strong> are a third category of big molecules. They are oligomers of nucleotides, which in turn are composed of a five-carbon sugar (either ribose or desoxyribose), a nitrogenous base (either a pyrimidine or a purine) and 1â€“3 phosphate groups. The best known representative of a nucleotide is the coenzyme ATP (=Adenosine triphosphate), MW 507.2. Oligonucleotides are chemically synthesized from protected phosphoramidites of natural or chemically modified nucleosides. The oligonucleotide chain assembly proceeds in the direction from 3&#x27;- to 5&#x27;-terminus by following a procedure referred to as a &quot;synthetic cycle&quot;. Completion of a single synthetic cycle results in the addition of one nucleotide residue to the growing chain. The maximum length of synthetic oligonucleotides hardly exceeds 200 nucleotide components. From its current range of applications in basic research as well as in drug target validation, drug discovery, and therapeutic development, the potential use of oligonucleotides is foreseen in gene therapy (antisense drugs), disease prevention and agriculture.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong><span class="inline text-[1em] leading-7">Antibody-drug conjugates</span></strong> (ADC) constitute a combination between small and big molecules. The small molecule parts, up to four different APIs, are highly potent cytotoxic drugs. They are linked with a monoclonal antibody, a big molecule which is of little or no therapeutic value in itself, but extremely discriminating for its targets, the cancer cells. The first commercialized ADCs was Pfizer&#x27;s (formerly Wyeth) Mylotarg (gemtuzumab ozogamicin). Examples of approved ADCs include Enhertu (trastuzumab deruxtecan), Kadcyla (ado-trastuzumab emtansine), and Trodelvy (sacituzumab govitecan). As of 2024, 15 ADCs have been approved globally.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<h1 id="technologies" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Technologies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Several key technologies are used for the production of fine chemicals, including</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Chemical synthesis, either from petrochemical starting materials or from natural products extracts</li>
<li class="text-[1em]">Biotechnology, for small molecules <span class="inline text-[1em] leading-7">biocatalysis</span> (enzymatic methods), <span class="inline text-[1em] leading-7">biosynthesis</span> (fermentation), and, for big molecules, cell culture technology</li>
<li class="text-[1em]">Extraction from animals, microorganisms, or plants; isolation and purification, used, for example, for alkaloids, <span class="inline text-[1em] leading-7">antibacterials</span> (especially penicillins), and steroids</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Hydrolysis</span> of proteins, especially when combined with ion exchange chromatography, used, for instance, for amino acids</li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Chemical synthesis and biotechnology are most frequently used; sometimes also in combination.</span>
<h2 id="traditional-chemical-synthesis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Traditional chemical synthesis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">A large toolbox of chemical reactions is available for each step of the synthesis of a fine chemical. The reactions have been developed on laboratory scale by academia over the last two centuries and subsequently adapted to industrial scale, for instance for the manufacture of dyestuffs &amp; pigments. The most comprehensive handbook describing organic synthetic methods is <em>Methods of Molecular Transformations</em>. About 10% of the 26,000 synthetic methods described therein are currently used on an industrial scale for fine chemicals production. <span class="inline text-[1em] leading-7">Amination</span>, <span class="inline text-[1em] leading-7">condensation</span>, <span class="inline text-[1em] leading-7">esterification</span>, <span class="inline text-[1em] leading-7">Friedelâ€“Crafts</span>, <span class="inline text-[1em] leading-7">Grignard</span>, <span class="inline text-[1em] leading-7">halogenation</span> (esp. chlorination), and <span class="inline text-[1em] leading-7">hydrogenation</span>, respectively reduction (both catalytic and chemical) are most frequently mentioned on the websites of individual companies. Optically active <span class="inline text-[1em] leading-7">cyanohydrins</span>, cyclopolymerization, <span class="inline text-[1em] leading-7">ionic liquids</span>, <span class="inline text-[1em] leading-7">nitrones</span>, oligonucleotides, peptide (both liquid- and solid-phase), <span class="inline text-[1em] leading-7">electrochemical reactions</span> (e.g., perfluorination) and <span class="inline text-[1em] leading-7">steroid synthesis</span> are promoted by only a limited number of companies. With the exception of some <span class="inline text-[1em] leading-7">stereospecific</span> reactions, particularly biotechnology, mastering these technologies does not represent a distinct competitive advantage. Most reactions can be carried out in standard multipurpose plants. The very versatile <span class="inline text-[1em] leading-7">organometallic reactions</span> (e.g., conversions with lithium aluminum hydride, boronic acids) may require temperatures as low as -100 Â°C, which can be achieved only in special cryogenic reaction units, either by using liquefied nitrogen as coolant or by installing a low-temperature unit. Other reaction-specific equipment, such as filters for the separation of catalysts, <span class="inline text-[1em] leading-7">ozone</span> or <span class="inline text-[1em] leading-7">phosgene</span> generators, can be purchased in many different sizes. The installation of special equipment generally is not a critical path on the overall project for developing an industrial-scale process of a new molecule.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Since the mid-1990s the commercial importance of <em><span class="inline text-[1em] leading-7">single-enantiomer</span></em> fine chemicals has increased steadily. They constitute about half of both existing and developmental drug APIs. In this context, the ability to synthesize <span class="inline text-[1em] leading-7">chiral</span> molecules has become an important competency. Two types of processes are used, namely the physical separation of the enantiomers and the stereo specific synthesis, using chiral catalysts. Among the latter, enzymes and synthetic <span class="inline text-[1em] leading-7">BINAP</span> (2,2&#x27;â€“Bis(diphenylphosphino)â€“1,1&#x27;â€“binaphthyl) types are used most frequently. Large volume (&gt; 103 mtpa) processes using chiral catalysts include the manufacture of the perfume ingredient l-Menthol and Syngenta&#x27;s <span class="inline text-[1em] leading-7">Dual</span> (metolachlor) as well as BASF&#x27;s <span class="inline text-[1em] leading-7">Outlook</span> (dimethenamid-P) herbicides. Examples of originator drugs, which apply asymmetric technology, are <span class="inline text-[1em] leading-7">AstraZeneca</span>&#x27;s <span class="inline text-[1em] leading-7">Nexium</span> (esomeprazole) and <span class="inline text-[1em] leading-7">Merck &amp; Co</span>&#x27;s <span class="inline text-[1em] leading-7">Januvia</span> (sitagliptin). The physical separation of chiral mixtures and purification of the desired enantiomer can be achieved either by classical <span class="inline text-[1em] leading-7">fractional crystallization</span> (having a &quot;low-tech&quot; image but still widely used), carried-out in standard multipurpose equipment or by various types of chromatographical separation, such as standard column, simulated moving-bed (SMB) or <span class="inline text-[1em] leading-7">supercritical fluid</span> (SCF) techniques.</span>
<span class="mb-4 block break-words text-[1em] leading-7">For <em>peptides</em> three main types of methods are used, namely chemical synthesis, extraction from natural substances, and biosynthesis. Chemical synthesis is used for smaller peptides made of up to 30â€“40 amino acids. One distinguishes between &quot;liquid phase&quot; and &quot;solid phase&quot; synthesis. In the latter, reagents are incorporated in a resin that is contained in a reactor or column. The synthesis sequence starts by attaching the first amino acid to the reactive group of the resin and then adding the remaining amino acids one after the other. In order to ascertain a full selectivity, the amino groups have to be protected in advance. Most developmental peptides are synthesized by this method, which lends itself to automation. As the intermediate products resulting from individual synthetic steps cannot be purified, a selectivity of effectively 100% is essential for the synthesis of larger-peptide molecules. Even at a selectivity of 99% per reaction step, the purity will drop to less than 75% for a dekapeptide (30 steps). Therefore, for industrial quantities of peptides not more than 10â€“15 amino acid peptides can be made using the solid-phase method. For laboratory quantities, up to 40 are possible. To prepare larger peptides, individual fragments are first produced, purified, and then combined to the final molecule by liquid phase synthesis. Thus, for the production of Roche&#x27;s anti-AIDS drug <span class="inline text-[1em] leading-7">Fuzeon</span> (enfuvirtide), three fragments of 10â€“12 amino acids are first made by solid-phase synthesis and then linked together by liquid-phase synthesis. The preparation of the whole 35 amino acid peptide requires more than 130 individual steps.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Microreactor</span> <em>Technology</em> (MRT), making part of &quot;process intensification&quot;, is a relatively new tool that is being developed at several universities,<!-- --> as well as leading fine chemical companies, such as <span class="inline text-[1em] leading-7">Bayer Technology Services</span>, Germany; <span class="inline text-[1em] leading-7">Clariant</span>, Switzerland; Evonik-Degussa, Germany; <span class="inline text-[1em] leading-7">DSM</span>, The Netherlands; <span class="inline text-[1em] leading-7">Lonza</span>, Switzerland; PCAS, France, and <span class="inline text-[1em] leading-7">Sigma-Aldrich</span>, US. The latter company produces about 50 fine chemicals up to multi-kilogram quantities in microreactors. From a technological point of view, MRT, a.k.a. continuous flow reactors, represents the first breakthrough development in reactor design since the introduction of the stirred-tank reactor, which was used by Perkin &amp; Sons, when they established a factory on the banks of what was then the Grand Junction Canal in London in 1857 to produce mauveÃ¯ne, the first-ever synthetic purple dye. For a comprehensive coverage of the subject see <em>Micro Process Engineering</em>.<!-- --> Examples for reactions that have worked in microreactors include aromatics oxidations, <span class="inline text-[1em] leading-7">diazomethane</span> conversions, <span class="inline text-[1em] leading-7">Grignards</span>, <span class="inline text-[1em] leading-7">halogenations</span>, <span class="inline text-[1em] leading-7">hydrogenations</span>, <span class="inline text-[1em] leading-7">nitrations</span>, and <span class="inline text-[1em] leading-7">Suzuki couplings</span>. According to experts in the field, 70% of all chemical reactions could be done in microreactors; as of 2024, adoption has increased with the market exceeding USD 500 million, though only 20-30% are economically justified for fine chemicals production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">With the exception of some stereospecific reactions, particularly biotechnology, mastering these technologies does not represent a distinct competitive advantage. Most reactions can be carried out in standard multipurpose plants. Reaction-specific equipment, such as ozone or phosgene generators, is readily available. The installation generally is not a critical path on the overall project for developing an industrial-scale process of a new molecule.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Whereas the overall demand for outsourced pharmaceutical fine chemicals is expected to increase moderately (<em>see</em> Chapter 8), the estimated annual growth rates for the above-mentioned niche technologies are much higher. Microreactors and the SMB separation technology are expected to grow at a rate of even 50â€“100% per year. The total size of the accessible market typically does not exceed a few hundred tons per year at best.</span>
<h2 id="biotechnology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Biotechnology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Industrial biotechnology, also called &quot;<span class="inline text-[1em] leading-7">white biotechnology</span>&quot;, is increasingly impacting the chemical industry, enabling both the conversion of <span class="inline text-[1em] leading-7">renewable resources</span>, such as sugar or vegetable oils, and the more efficient transformation of conventional raw materials into a wide range of commodities (e.g., <span class="inline text-[1em] leading-7">cellulose</span>, <span class="inline text-[1em] leading-7">ethanol</span> and <span class="inline text-[1em] leading-7">succinic acid</span>), fine chemicals (e.g. 6-aminopenicillanic acid), and specialties (e.g., food and feed additives).<!-- --> As opposed to green and red biotechnology, which relate to agriculture and medicine, respectively, white biotechnology seeks to improve the economic and sustainable production of existing products, and provide access to new products, especially biopharmaceuticals. As of 2024, revenues from white biotechnology account for approximately 4-5%, or USD 250-350 billion, of the global chemical market of about USD 6.7 trillion, with projections to reach USD 400-600 billion by 2030. In ten to 15 years from 2011 it was expected that most amino acids and vitamins and many specialty chemicals would be produced by means of biotechnology; as of 2025, a significant portion (over 50%) of amino acids and vitamins are now biotech-derived, with ongoing expansion into specialties. Three very different process technologies -biocatalysis, biosynthesis (microbial fermentation), and cell cultures- are used.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1ohqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_20hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Biocatalysis</span>, a.k.a. <span class="inline text-[1em] leading-7">biotransformation</span> and <span class="inline text-[1em] leading-7">bioconversion</span>, makes use of natural or modified isolated <span class="inline text-[1em] leading-7">enzymes</span>, enzyme extracts, or whole-cell systems for enhancing the production of small molecules. It has much to offer compared to traditional organic synthesis. The syntheses are shorter, less energy intensive and generate less waste, hence are both environmentally and economically more attractive. About 2/3 of chiral products produced on large industrial scale are already made using biocatalysis. In the manufacture of fine chemicals, enzymes represent the single most important technology for radical cost reductions. This is particularly the case in the synthesis of molecules with chiral centres. Here, it is possible to substitute the formation of a salt with a chiral compound, e.g., (+)-Î±-phenylethylamine, crystallization, salt breaking and recycling of the chiral auxiliary, resulting in a theoretical yield of not more than 50%, with a one step, high yield reaction under mild conditions and resulting in a product with a very high <span class="inline text-[1em] leading-7">enantiomeric excess</span> (ee). An example is <span class="inline text-[1em] leading-7">AstraZeneca</span>&#x27;s blockbuster drug <span class="inline text-[1em] leading-7">Crestor</span> (rosuvastatin), see Chemical / Enzymatic Synthesis of Crestor.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Chemical / Enzymatic Synthesis of Crestor (rosuvastatin)</span>
<span class="mb-4 block break-words text-[1em] leading-7">Further examples of modern drugs, where enzymes are used in the synthesis, are <span class="inline text-[1em] leading-7">Pfizer</span>&#x27;s <span class="inline text-[1em] leading-7">Lipitor</span> (atorvastatin), where the pivotal intermediate R-3-Hydroxy-4-cyanobutyrate is now made with a <span class="inline text-[1em] leading-7">nitrilase</span>, and Merck &amp; Co.&#x27;s <span class="inline text-[1em] leading-7">Singulair</span> (montelukast), where the reduction of a ketone to S-alcohol, which had required stoichiometric amounts of expensive and moisture sensitive &quot;(-)-DIP chloride&quot; is now replaced by a ketoreductase enzyme catalyst step. Similar rewarding switches from chemical steps to enzymatic ones have also been achieved in steroid synthesis. Thus, it has been possible to reduce the number of steps required for the synthesis of <span class="inline text-[1em] leading-7">Dexamethasone</span> from bile from 28 to 15. Enzymes differ from chemical catalysts particularly with regard to <span class="inline text-[1em] leading-7">stereoselectivity</span>, <span class="inline text-[1em] leading-7">regioselectivity</span>, and <span class="inline text-[1em] leading-7">chemoselectivity</span>. They can also be modified (&quot;reshuffled&quot;) for specific reactions, for use in chemical synthesis. &quot;<span class="inline text-[1em] leading-7">Immobilized enzymes</span>&quot; are those fixed on solid supports. They can be recovered by filtration after completion of the reaction. Conventional plant equipment can be used with no, or only modest, adaptations. The <em>International Union of Biochemistry and Molecular Biology</em> (IUBMB)<!-- --> has developed a classification for enzymes. The main categories are <span class="inline text-[1em] leading-7">Oxidoreductases</span>, <span class="inline text-[1em] leading-7">Transferases</span>, <span class="inline text-[1em] leading-7">Hydrolases</span>, <span class="inline text-[1em] leading-7">Lipases</span> (subcategory), <span class="inline text-[1em] leading-7">Lyases</span>, Isomerases and <span class="inline text-[1em] leading-7">Ligases</span>, Companies specializing in making enzymes are <span class="inline text-[1em] leading-7">Novozymes</span>, <span class="inline text-[1em] leading-7">Danisco</span> (Genencor). <span class="inline text-[1em] leading-7">Codexis</span> is the leader in modifying enzymes to specific chemical reactions. The highest-volume chemicals made by biocatalysis are <span class="inline text-[1em] leading-7">bio-ethanol</span> (70 million metric tons), <span class="inline text-[1em] leading-7">high-fructose corn syrup</span> (2 million metric tons); <span class="inline text-[1em] leading-7">acrylamide</span>, <span class="inline text-[1em] leading-7">6-aminopenicillanic acid</span> (APA), <span class="inline text-[1em] leading-7">L-lysine</span> and other amino acids, <span class="inline text-[1em] leading-7">citric acid</span> and <span class="inline text-[1em] leading-7">niacinamide</span> (all more than 10,000 metric tons).</span>
<span class="mb-4 block break-words text-[1em] leading-7"><em><span class="inline text-[1em] leading-7">Biosynthesis</span></em> i.e. the conversion of organic materials into fine chemicals by microorganisms, is used for the production of both small molecules (using enzymes in whole cell systems) and less complex, non-glycosylated big molecules, including peptides and simpler proteins. The technology has been used for 10,000 years to produce food products, like alcoholic beverages, cheese, yogurt, and vinegar. In contrast to biocatalysis, a biosynthetic process does not depend on chemicals as starting materials, but only on cheap natural feedstock, such as glucose, to serve as nutrient for the cells. The enzyme systems triggered in the particular microorganism strain lead to the excretion of the desired product into the medium, or, in the case of HMW peptides and proteins, to the accumulation within so-called <span class="inline text-[1em] leading-7">inclusion bodies</span> in the cells. The key elements of fermentation development are strain selection and optimization, as well as media and process development. Dedicated plants are used for large-scale industrial production. As the volume productivity is low, the bioreactors, called fermenters, are large, with volumes that can exceed 250 m3. Product isolation was previously based on large-volume extraction of the medium containing the product. Modern isolation and membrane technologies, like <span class="inline text-[1em] leading-7">reverse osmosis</span>, ultra- and nano-filtration, or <span class="inline text-[1em] leading-7">affinity chromatography</span> can help to remove salts and by-products, and to concentrate the solution efficiently and in an environmentally friendly manner under mild conditions. The final purification is often achieved by conventional chemical crystallization processes. In contrast to the isolation of small molecules, the isolation and purification of microbial proteins is tedious and often involves a number of expensive large-scale chromatographic operations. Examples of large-volume LMW products made by modern industrial microbial biosynthetic processes are <span class="inline text-[1em] leading-7">monosodium glutamate</span> (MSG), <span class="inline text-[1em] leading-7">vitamin B2</span> (riboflavin), and <span class="inline text-[1em] leading-7">vitamin C</span> (ascorbic acid). In vitamin B2, riboflavin, the original six- to eight-step synthetic process starting from <span class="inline text-[1em] leading-7">barbituric acid</span> has been substituted completely by a microbial one-step process, allowing a 95% waste reduction and an approximately 50% manufacturing cost reduction. In ascorbic acid, the five-step process (yield â‰ˆ 85%) starting from <span class="inline text-[1em] leading-7">D-glucose</span>, originally invented by <span class="inline text-[1em] leading-7">Tadeus Reichstein</span> in 1933, is being gradually substituted by a more straightforward fermentative process with 2-ketogluconic acid as pivotal intermediate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2kjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> After the discovery of penicillin in 1928 by Sir Alexander Fleming from colonies of the bacterium <span class="inline text-[1em] leading-7">Staphylococcus aureus</span>, it took more than a decade before a powdery form of the medicine was developed. Since then, many more antibiotics and other <span class="inline text-[1em] leading-7">secondary metabolites</span> have been isolated and manufactured by microbial fermentation on a large scale. Some important antibiotics besides penicillin are <span class="inline text-[1em] leading-7">cephalosporins</span>, <span class="inline text-[1em] leading-7">azithromycin</span>, <span class="inline text-[1em] leading-7">bacitracin</span>, <span class="inline text-[1em] leading-7">gentamicin</span>, <span class="inline text-[1em] leading-7">rifamycin</span>, <span class="inline text-[1em] leading-7">streptomycin</span>, <span class="inline text-[1em] leading-7">tetracycline</span>, and <span class="inline text-[1em] leading-7">vancomycin</span>.</span>
<h3 id="cell-cultures" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cell Cultures<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><em>Cell Cultures</em> Animal or plant cells, removed from tissues, will continue to grow if cultivated under the appropriate nutrients and conditions. When carried out outside the natural habitat, the process is called cell culture. <em>Mammalian cell culture</em> fermentation, also known as <span class="inline text-[1em] leading-7">recombinant DNA technology</span>, is used mainly for the production of complex big molecule therapeutic proteins, a.k.a. biopharmaceuticals.<!-- --> The first products made were <span class="inline text-[1em] leading-7">interferon</span> (discovered in 1957), <span class="inline text-[1em] leading-7">insulin</span>, and <span class="inline text-[1em] leading-7">somatropin</span>. Commonly used cell lines are <span class="inline text-[1em] leading-7">Chinese hamster ovary</span> (CHO) cells or plant cell cultures. Several biopharmaceuticals now exceed thousands of kilograms per year in production, including legacy products like rituximab (Rituxan), etanercept (Enbrel), and infliximab (Remicade), as well as newer ones like adalimumab (Humira) and pembrolizumab (Keytruda). Fine chemical production by mammalian cell culture is a much more demanding operation than conventional biocatalysis and â€“synthesis. The bioreactor batch requires more stringent controls of operating parameters, since mammalian cells are heat and shear sensitive. In addition, the growth rate of mammalian cells is very slow, lasting from days to several months. While there are substantial differences between microbial and mammalian technologies (e.g., the volume / value relationships are 10 <span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mi>k</mi><mi>g</mi><mi>a</mi><mi>n</mi><mi>d</mi><mn>100</mn><mi>t</mi><mi>o</mi><mi>n</mi><mi>s</mi><mi>f</mi><mi>o</mi><mi>r</mi><mi>m</mi><mi>i</mi><mi>c</mi><mi>r</mi><mi>o</mi><mi>b</mi><mi>i</mi><mi>a</mi><mi>l</mi><mo separator="true">,</mo><mn>1</mn><mo separator="true">,</mo><mn>000</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">/kg and 100 tons for microbial, 1,000,000 </annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:1em;vertical-align:-0.25em"></span><span class="mord">/</span><span class="mord mathnormal" style="margin-right:0.03148em">k</span><span class="mord mathnormal" style="margin-right:0.03588em">g</span><span class="mord mathnormal">an</span><span class="mord mathnormal">d</span><span class="mord">100</span><span class="mord mathnormal">t</span><span class="mord mathnormal">o</span><span class="mord mathnormal">n</span><span class="mord mathnormal">s</span><span class="mord mathnormal" style="margin-right:0.10764em">f</span><span class="mord mathnormal" style="margin-right:0.02778em">or</span><span class="mord mathnormal">mi</span><span class="mord mathnormal">cro</span><span class="mord mathnormal">bia</span><span class="mord mathnormal" style="margin-right:0.01968em">l</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">000</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">000</span></span></span></span>/kg and 10 kilograms for mammalian technology; the cycle times are 2â€“4 and 10â€“20 days, respectively), they are even more pronounced between mammalian and synthetic chemical technology (see Table 1).</span>
<span class="mb-4 block break-words text-[1em] leading-7">**Table 1: Key Characteristics of Biotechnological and Chemical API Manufacturing<!-- --> ** (indicative as of 2024)</span>
















































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Characteristic</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Mammalian cell technology</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Chemical technology</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Worldwide reactor volume</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">&gt;10,000 m3 (fermenters)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 80,000 m3</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Investment per m3 reactor volume</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ $5 million</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ $500,000</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Production per m3 reactor volume and year</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">several 100-1000 kg</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">several 1000 kg</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sales per m3 reactor volume and year</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ $5 â€“ 10 million</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ $250,000 - 500,000</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Value of 1 batch</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ $5 million (20,000 liter fermenter)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ $500,000</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Product concentration in reaction mixture</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 5 - 10 g / Liter</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 100 g / Liter (10%)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Typical reaction time</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 20 days</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 6 hours</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Process development time</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 3 years (one step)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2 â€“ 3 months per step</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Capacity expansion projects</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">many, doubling of actual capacity</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">few, mainly in Far East</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Governing rules</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">cGMP, BLA [Biological License Application (product specific)]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">cGMP, ISO 14000</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Scale-up factor (1st lab process to industrial scale)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 109 (Î¼g â†’ 1 ton)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰ˆ 106 (10 g â†’ 10 tons)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Plant construction time</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4 â€“ 6 years</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2 â€“ 3 years</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">share of outsourcing early stage</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">60%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">25% of chemical production</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">share of outsourcing commercial</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">50%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">45% of chemical production</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The mammalian cell production process, as used for most biopharmaceuticals, is divided into the four main steps: (1) Cultivation, i.e. reproduction of the cells; (2) Fermentation, i.e. the actual production of the protein, typically in 10,000 Liter, or multiples, bioreactors; (3) Purification, i.e. separation of the cells from the culture medium and purification, mostly by chromatography, (4) Formulation, i.e. conversion of the sensitive proteins to a stable form. All steps are fully automated. The low productivity of the <span class="inline text-[1em] leading-7">animal culture</span> makes the technology expensive and vulnerable to contamination. Actually, as a small number of bacteria would soon outgrow a larger population of animal cells. Its main disadvantages are low volume productivity and the animal provenance. It is conceivable that other technologies, particularly plant cell production, will gain importance in future. Given the fundamental differences between the two process technologies, plants for mammalian cell culture technologies have to be built ex novo.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The pros and cons of an involvement of a fine chemical company in cell culture technology are listed below:</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Pros:</strong></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Strong growth of demand: As of 2024, biopharmaceuticals account for approximately USD 450 billion, or 30% of the total pharmaceutical market. They continue to grow at rates of 8-10% per year, outpacing small-molecule drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></li>
<li class="text-[1em]">The likelihood of developing a new biopharmaceutical successfully is significantly greater than in traditional drug development. Biopharmaceuticals have a higher success rate, approximately 13% from preclinical to approval, compared to about 5% for small-molecule drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8goabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></li>
<li class="text-[1em]">The traditionally large share of outsourcing.</li>
<li class="text-[1em]">Small number of custom manufacturers with industrial-scale manufacturing capabilities in this demanding technology. In the Western hemisphere, primarily <span class="inline text-[1em] leading-7">Boehringer-Ingelheim</span> of Germany and <span class="inline text-[1em] leading-7">Lonza</span> of Switzerland; in the Eastern hemisphere <span class="inline text-[1em] leading-7">Nicholas Piramal</span> of India (through the acquisition of a former Avecia operation) and the joint ventures between AutekBio and Beijing E-Town Harvest International in China and between <span class="inline text-[1em] leading-7">Biocon</span> in India and <span class="inline text-[1em] leading-7">Celltrion</span> in South Korea.</li>
<li class="text-[1em]">Same customer category: life science, especially the pharmaceutical industry.</li>
<li class="text-[1em]">Similar business types: custom manufacturing of proprietary drugs; opportunities for generic versions, called <span class="inline text-[1em] leading-7">biosimilars</span>.</li>
<li class="text-[1em]">Similar regulatory environment: FDA regulations, especially GMP.</li>
<li class="text-[1em]">Existing infrastructure (utilities, etc.) can be used.</li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">As of 2024, eight of the top ten drugs by sales are biopharmaceuticals, including Humira (adalimumab), Keytruda (pembrolizumab), and Dupixent (dupilumab).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Cons:</strong></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">High entry barriers because of demanding technology. The construction of a large-scale plant for the production of biopharmaceuticals by cell culture fermentation costs around $500 million and takes four to six years.</li>
<li class="text-[1em]">As the specifications of the plant and process types for biopharmaceuticals differ substantially from traditional chemical synthesis, they cannot be produced in conventional multipurpose fine chemical plants.</li>
<li class="text-[1em]">High financial exposure: (1) high capital intensity (&#x27;massive investments are needed at a time when chances of success are still very low&#x27; and (2) risk of batch failures (<span class="inline text-[1em] leading-7">contamination</span>).</li>
<li class="text-[1em]">Unlike the biopharmaceutical start-ups, the emerging big biopharmaceutical companies are adopting the same opportunistic outsourcing policy as larger pharmaceutical companies. Thus, <span class="inline text-[1em] leading-7">Amgen</span>, <span class="inline text-[1em] leading-7">Biogen Idec</span>, <span class="inline text-[1em] leading-7">Eli Lilly</span>, <span class="inline text-[1em] leading-7">Johnson &amp; Johnson</span> (J&amp;J), <span class="inline text-[1em] leading-7">Medimmune</span>, <span class="inline text-[1em] leading-7">Novartis</span>, <span class="inline text-[1em] leading-7">Roche</span>/<span class="inline text-[1em] leading-7">Genentech</span> and <span class="inline text-[1em] leading-7">Pfizer</span> are investing heavily in in-house manufacturing capacity. With three plants in the US, two in Japan and one each in Germany and Switzerland, Roche has the largest production capacity.</li>
<li class="text-[1em]">New developments in expression systems for mammalian and plant cell technology could reduce capacity requirements substantially. Actually, the titer in large-scale mammalian production, actually 2â€“3 grams/liter. is expected to double to 5â€“7 by 2015 and once more to 10 by 2020. Furthermore, the widespread application of &#x27;single-use disposable bioprocessing technology&#x27;, considered by experts as &#x27;the hottest buzz in town&#x27;. It advantageously substitutes for stainless steel production trains, at least for short production campaigns.</li>
<li class="text-[1em]">New transgenic production systems are emerging. They (e.g. transgenic moss, <span class="inline text-[1em] leading-7">lemna</span>, fungal or yeast expression systems, <span class="inline text-[1em] leading-7">transgenic animals</span> and plants, such as tobacco plants possess the potential to become economically and industrially successful.</li>
<li class="text-[1em]">Legislation and regulation of biotechnology is not well defined yet and leads to differences in interpretation and other uncertainties. In the US, legislation is not yet in place for biosimilars, the generic counterpart of generics in small molecule pharmaceuticals.</li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">The inherent risks of the mammalian cell technology led several companies to opt out of mammalian cell technology or to substantially reduce their stake. Examples are Cambrex and Dowpharma in the US, <span class="inline text-[1em] leading-7">Avecia</span>, <span class="inline text-[1em] leading-7">DSM</span> and Siegfried in Europe and WuXi App Tech in China. In conclusion, biocatalysis should be, or become, part of the technology toolbox of any fine chemical company. Mammalian cell culture fermentation, on the other hand, should be considered only by large fine chemical companies with a full war chest and a long-term strategic orientation.</span>
<h1 id="the-fine-chemical-industry" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">The Fine Chemical Industry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="the-industry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">The Industry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Within the chemical universe, the fine chemical industry is positioned between the commodity, their suppliers, and specialty chemical industries, their customers. Depending on the services offered, there are two types of fine chemical companies. The <em>Fine Chemical Companies</em> are active in industrial scale production, both of standard and exclusive products. If the latter prevails, they are referred to as Fine Chemical / <em>Custom Manufacturing Organizations (CMOs)</em>. The main assets of the <span class="inline text-[1em] leading-7">Contract Research Organizations</span> (CROs) are their research laboratories. CRAMS; Contract Research and Manufacturing Organizations<!-- --> are hybrids (see section 4.2).</span>
<h3 id="fine-chemical--custom-manufacturing-companies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Fine Chemical / Custom Manufacturing Companies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><em>Fine chemical / Custom Manufacturing companies</em> in the narrower sense are active in process scale up, pilot plant (trial) production, industrial-scale exclusive and non-exclusive manufacture and marketing. Their product portfolios comprise exclusive products, produced by custom manufacturing, as main activity, non-exclusive products, e.g. API-for Generics, and standard products. Characteristics are high asset intensity, batch production in campaigns in multipurpose plants, above-industry-average R&amp;D expenditures and close, multi-level and multi-functional relationships with industrial customers. The industry is very fragmented. 2000 â€“ 3000 fine chemical companies exist globally, extending from small, &quot;garage-type&quot; outfits in China making just one product, all the way to the big, diversified enterprises, resp. units. As of 2024, the global fine chemicals market is estimated at around $200 billion, with significant growth in Asia and a focus on sustainable manufacturing. The main reason for the fragmentation is the lack of economy of scale (see below).</span>
<span class="mb-4 block break-words text-[1em] leading-7">The industry is subject to a high degree of regulation<!-- --> even more so than the chemical industry as a whole, particularly if pharmaceutical fine chemical production is involved. The most important regulatory authorities are the <em>(US) Food and Drug Administration (FDA)</em> and <em>National Medical Products Administration (NMPA)</em>, respectively. Their main responsibilities comprise formulating comprehensive supervision policies (&quot;<span class="inline text-[1em] leading-7">Good Manufacturing Practice</span>&quot;) and control the implementation, to be in charge of drug registration, draw up criteria for marketing authorization and formulate national essential medicines lists. The European correspondent is the <em><span class="inline text-[1em] leading-7">European Medicines Agency</span> (EMA)</em>, which is mainly responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. The role of <span class="inline text-[1em] leading-7">REACH</span> (Registration, Evaluation, Authorization and Restriction of Chemicals) is self-explanatory. The <em><span class="inline text-[1em] leading-7">U.S. Pharmacopeia</span></em> codifies quality standards for Active Pharmaceutical Ingredients. As these standards are observed worldwide, they contribute also to the emergence of a uniform worldwide set-up of the top tier fine chemical companies. In terms of size, resources, and complexity of the chemical process technologies mastered, the fine chemical companies can be broadly divided into three segments, each of them accounting for approximately the same turnover, namely about $10 billion (as of 2009). The top tier, about twenty, has sales in excess of $250 million per year (see Table 3). Most are not pure players but divisions or b.u.&#x27;s of large, multinational companies. Their share varies between one percent or less for <span class="inline text-[1em] leading-7">BASF</span> and <span class="inline text-[1em] leading-7">Pfizer</span>, all the way to 100% for Cambrex, USA; <span class="inline text-[1em] leading-7">Divi&#x27;s Laboratories</span>, India, and F.I.S. Italy. All have extensive resources in terms of chemists and other specialists, plants, process knowledge, backwards integration, international presence, etc.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 3: Leading Fine Chemical Companies (resp. Units) (as of 2009)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></strong></span>

















































































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Rank</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Company</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Location</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Sales 2009 ($ million)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">F.C. unit</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Sales 2009 ($ million)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Remarks</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Lonza</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Switz.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2600</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Custom. Manuf.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1370</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">HMW/LMW~55/45</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Boehringer-Ingelheim</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Germany</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">18,300</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fine Chem.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">950</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">HMW/LMW=84/16</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">DSM</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">The Netherlands</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">11,300</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fine Chem.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">850aE</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sumitomo Chemical</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Japan</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">17,420</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fine Chem.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">730</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">incl. some polymer additives</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Merck KGaA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Germany</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">11,200</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Life Science Solutions</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">580</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">#1 in liquid crystals</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sigma-Aldrich</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">USA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2148</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">SAFC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">570E</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">7</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">BASF</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Germany</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">73,000</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fine Chem.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5502E</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">incl. some excipients</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">8</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">CSPC Shijiazhuang Pharmaceutical Group</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">China</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1500</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fine Chem.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">550E</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">API-for-Generics, e.g. HIV / AIDS, sartans</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">9</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Lanxess</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Germany</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">7280</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Saltigo</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">550E</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">a.o. agrochemicals</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Albemarle</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">USA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2005</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fine Chem.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5002</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">a.o. ibuprofen</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Total Top Ten</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>~7200</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">The combined revenues of the top 20 fine chemical companies amounted to $10 billion in 2009, representing about 30% of the figure for the whole industry (external production). The external fine chemicals market has since expanded significantly, estimated at over $80 billion as of 2024. The leading companies are typically divisions of large, diversified chemical companies. In terms of geography, 9 of the top 20 are located in Europe, which is recognized as the cradle of the fine chemical industry. This is e.g. the case for the world&#x27;s #1 company, Lonza, headquartered in Basel. Switzerland. Custom manufacturing prevails in northern Europe; the manufacture of active substances for generics, in southern Europe. The second largest geographic area is Asia, housing 7 of the top 20. With 4 large companies, the US rank last.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Whereas the European and U.S. pharma industry constitutes the main customer base for most fine chemical companies, some have a significant share of products and services for the agrochemical industry. Examples are Archimica, CABB, Saltigo (all Germany), DSM (The Netherlands) and Hikal, India. Several large pharmaceutical companies market fine chemicals as subsidiary activity to their production for captive use, e.g. <span class="inline text-[1em] leading-7">Abbott</span>, USA; <span class="inline text-[1em] leading-7">Bayer Schering Pharma</span>, <span class="inline text-[1em] leading-7">Boehringer-Ingelheim</span>, Germany; <span class="inline text-[1em] leading-7">Daiichi-Sankyo</span> (after the takeover of <span class="inline text-[1em] leading-7">Ranbaxy</span>), Japan; Johnson &amp; Johnson, USA; <span class="inline text-[1em] leading-7">Merck KGaA</span>, Germany; <span class="inline text-[1em] leading-7">Pfizer</span> (formerly Upjohn), US. Large fine chemical companies, in contrast to mid-sized and small ones, are characterized by</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><em>A Lack of Economy in Size</em>. As most fine chemicals are produced in quantities of not more than a few 10 tons per year in multipurpose plants, there is little or no economy of size. The reactor trains of these plants are similar throughout the industry (see production train of a multipurpose plant). Regardless of the size of the companies, their main constituents, the reaction vessels, have a median size of the 4â€“6 m3. Various products are made throughout a year in campaigns. Therefore, the unit cost per m3 per hour does practically not vary with the size of the company.</li>
<li class="text-[1em]"><em>A Dichotomy between Ownership and Management</em>. The company&#x27;s shares are listed on stock exchanges, and their performance is scrutinized by the financial community. Postponement of a single important shipment can affect a quarterly result. In the small and mid-sized companies the owners typically are the major shareholders, often members of the same family. Their shares are not traded publicly and fluctuations in their financial performance are more easily coped with.</li>
<li class="text-[1em]"><em>Complicated Business Processes</em>. Flexibility and Responsiveness are in jeopardy. Customer complaints, for instance, are difficult to resolve in a straightforward manner.</li>
<li class="text-[1em]"><em>A Heterogeneous portfolio of small companies, accumulated over time through M &amp;A activities</em>. The key functions, such as production, R&amp;D, and M&amp;S, are located on different sites, often in different countries.</li>
<li class="text-[1em]"><em>A Cohabitation with Other Units</em>.</li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">A comprehensive list of about 1400 fine chemical companies (including traders) can be found in the &quot;event catalogue&quot; of the CPhI exhibition.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The <em>second tier</em> consists of several dozens of <em>midsized</em> companies with sales in the range of $100â€“$250 million per year. Their portfolios comprise both custom manufacturing and API-for-generics. They include both independents and subsidiaries of major companies. A number of these companies are privately owned and have grown mainly by reinvesting the profits. Examples are <span class="inline text-[1em] leading-7">Bachem</span>, Switzerland; Dishman, India; F.I.S. and Poli Industria Chimica, Italy; Hikal, India, and <span class="inline text-[1em] leading-7">Hovione</span>, Portugal. Customers prefer to do business with mid-sized companies, because communications are easier â€”they typically deal directly with the decision makerâ€” and they can better leverage their purchasing power. The <em>third tier</em> includes thousands of <em>small independents</em> with sales below $100 million per year. Most of them are located in Asia. They often specialize in niche technologies. The minimum economical size of a fine chemical company depends on the availability of infrastructure. If a company is located in an industrial park, where analytical services; utilities, safety, health, and environmental (SHE) services, and warehousing are readily available, there is practically no lower limit. New fine chemical plants have come on-stream mostly in Far East countries over the past few years. Their annual turnover rate rarely exceeds $25 million. All big and medium-size fine chemical companies have cGMP-compliant plants that are suitable for the production of pharmaceutical fine chemicals. With the exception of biopharmaceuticals, which are manufactured by only a few selected fine chemical companies, (see section 3.2.2), the technology toolboxes of all these companies are similar. This means that they can carry out practically all types of chemical reactions. They differentiate on the basis of the breadth and quality of the service offering.</span>
<h3 id="contract-research-organizations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Contract Research Organizations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Contract research organizations (CROs) provide services to the life science industries along product development. There are more than 2000 CROs operating worldwide, representing revenues of approximately $85 billion (as of 2024). One distinguishes between &quot;Product&quot; and &quot;Patient&quot; CROs. Whereas the production sites of CMOs are multipurpose plants, allowing for the production of tens to hundreds of tons of fine chemicals, the work places of patient CROs are the test persons (volunteers) for the clinical trials and those of the product CROs are the laboratory benches. Major customers for CRO services are the large global pharmaceutical companies. Half a dozen companies (Pfizer, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Johnson &amp; Johnson, and Merck &amp; Co.) alone absorb about one third of all CRO spending. As for CMOs also for CROs, biotech start-up companies with their dichotomy between ambitious drug development programs and limited resources are the second most promising prospects. Product CROs (chemical CROs) are providing primarily sample preparation, process research and development services. An overlap between the latter and CMOs exists with regard to pilot plants (100 kg quantities), which are part of the arsenal of both types of enterprise. There are more 100 product CROs. Most of them are privately held and have revenues of $10â€“$20 million per year or less, adding up to a total business in the range of $1.5-$2 billion. Their tasks are described in Chapter 5, Examples of are:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">In <em>North America</em> : Alphora; Delmar; NAEJA, all Canada. AMRI; Aptuit; Cambridge Major; ChemBridge; <span class="inline text-[1em] leading-7">Innocentive</span>; Irix Pharmaceuticals, PharmEco, all USA.</li>
<li class="text-[1em]">In <em>Europe</em> ; Carbogen-Amcis, Switzerland; Chemcomm, Germany; <span class="inline text-[1em] leading-7">ChemDiv</span>, Russia; Clauson-Kaas, Denmark; Enamine Ltd, Ukraine; Girindus, Germany; Nerviano Medical Sciences, Italy; <span class="inline text-[1em] leading-7">Recipharm</span>, Sweden; Serichim, Italy; Solvias, Switzerland, Netherlands.</li>
<li class="text-[1em]">In <em>Asia</em> : BioDuro, Medicilon, Pharmaron; <span class="inline text-[1em] leading-7">WuXi AppTec</span>, all China; Acoris; Aptuit Laurus; Biocon / Syngene; Chembiotek; Chempartner; ProCitius, all India; NARD Institute, <span class="inline text-[1em] leading-7">Riken</span>, both Japan.</li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">The business of CROs is usually done through a &quot;pay for service&quot; arrangement. Contrary to manufacturing companies, invoicing of CROs is not based on unit product price, but on full-time equivalents (FTEs), that is, the cost of a scientist working one year on a given customer assignment. Companies offering both contract research and manufacturing services (CRAMS) combine the activities of CROs and CMOs. Their history is either a forward integration of a CRO, which adds industrial scale capabilities or backwards integration of a CMO. As there are only limited synergies (e.g. &gt; 90% of the projects end at the sample preparation stage). It is questionable, though, whether one-stop shops really fulfil a need. Actually, the large fine chemical companies consider the preparation of samples more as marketing tool (and expense ...) rather than a profit contributor.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The offerings of Patient CROs (Clinical CROs) comprise more than 30 tasks addressing the clinical part of pharmaceutical development at the interface between drugs, physicians, hospitals, and patients, such as the clinical development and selection of lead new drug compounds. As <span class="inline text-[1em] leading-7">clinical trials</span> represent the largest expense in pharmaceutical research, the market for patient CROs is larger than for their product counterparts. Thus, the sales of the top tier firms, IQVIA, ICON plc, Parexel, PPD (part of Thermo Fisher Scientific), Charles River Laboratories, all USA-based or global, are in the $5â€“$15 billion range (as of 2023), whereas the largest product CROs have revenues of a few 100 million dollars.</span>
<h1 id="research-and-development" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Research and development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">The overall emphasis of fine chemical R&amp;D is more on development than on research. Recent developments include the integration of artificial intelligence (AI) for predicting chemical properties, optimizing synthetic routes, and accelerating discovery, potentially reducing R&amp;D costs by up to 40% and development time by 50%.<!-- --> Additionally, frameworks like the European Union&#x27;s Safe and Sustainable by Design (SSbD) initiative guide the development of chemicals with minimized environmental and health impacts, promoting innovation in sustainable processes as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> The main tasks are (1) designing, respectively duplicating and adapting in case of custom manufacture, and developing laboratory procedures for new products or processes; (2) transferring the processes from the laboratory via <span class="inline text-[1em] leading-7">pilot plant</span> to the industrial scale (the scale up factor from a 10g sample to a 1-ton batch is 100,000); and (3) to optimize existing processes. At all times during this course of action it has to be ensured that the four critical constraints, namely, economics, timing, safety, ecology and sustainability are observed . R&amp;D expenditures in the fine chemical industry are higher than in the commodities industry. They represent around 5â€“10% versus 2â€“5% of sales. On the business side, product innovation must proceed at a more rapid pace, because life cycles of fine chemicals are shorter than those of commodities. Therefore, there is an ongoing need for substitution of obsolete products. On the technical side, the higher complexity of the products and the more stringent regulatory requirements absorb more resources. Many economic and technical parameters have been proposed to enable a meaningful assessment of single projects and project portfolios. Examples are attractiveness, strategic fit, innovation, gross/net present value, expected profits, R&amp;D expenditures, development stage, probability of success, technology fit, potential conflicts with other activities of the company and realization time. Most of these parameters cannot be determined quantitatively, at least during the early phases of a project. The best way to take advantage of a project portfolio is to develop and use it in an iterative way. By comparing the entries at regular intervals, for instance, every 3 months, the directions that the projects take can be visualized. If a negative trend persists with one particular project, the project should be put on the watch list.</span>
<h2 id="objectives" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Objectives<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">R&amp;D has to manage the following functions in order to deliver the requested services: <em><span class="inline text-[1em] leading-7"><em>Literature</em> and Patent Research</span></em>. Provisions have to be made for a periodic examination of all acquired research results to safeguard <span class="inline text-[1em] leading-7">Intellectual Property Rights</span> (IPR) and to determine whether patent applications are indicated. Patent research is particularly important for evaluation of the feasibility of taking up R&amp;D for new APIs-for-generics. <em><span class="inline text-[1em] leading-7"><em>Process Research</em></span></em> has to design new synthetic routes and sequences. Two approaches are feasible. For simple molecules, the &quot;bottom-up&quot; approach is the method of choice. The researcher converts a commercially available starting material and sequentially adds more reagents until the target molecule is synthesized. For more complex molecules, a &quot;top-down&quot; approach, also known as retro synthesis, or de-construction, is chosen. Key fragments of the target molecule are first identified, then synthesized individually, and finally combined to form the desired molecule through convergent synthesis. <em><span class="inline text-[1em] leading-7"><em>Process Development</em></span></em> focuses on the design of new, efficient, stable, safe, and scalable synthetic routes to a target fine chemical. It represents an essential link between process research and commercial production. The resulting &quot;base process&quot; description provides the necessary data for the determination of preliminary raw material and product specifications, the manufacture of semi commercial quantities in the pilot plant, the assessment of the ecological impact, the regulatory submissions and <span class="inline text-[1em] leading-7">technology transfer</span> to manufacture at industrial scale, and an estimate of the manufacturing costs in an industrial-scale plant. If the base process is provided by the customer as part of the technology transfer, process, research has to optimize it so that it can be transferred to the bench-scale laboratory or pilot plant. Furthermore, it has to be adapted to the specific characteristics of available production trains. <em><span class="inline text-[1em] leading-7"><em>Bench-scale Laboratory, kg-lab and Pilot Plant Development</em></span>.</em> Depending on the volume requirements, three different types of equipment are used for process research, development and optimization, namely bench-scale laboratories for gram to 100 gram, kilo-labs for kg to 10 kg and pilot plants for 100 kg to ton quantities. Particularities of laboratory processes that have to be eliminated include the use of large numbers of <span class="inline text-[1em] leading-7">unit operations</span>, dilute reaction mixtures, vast quantities of solvents for extraction, evaporation to dryness, drying of solutions with hygroscopic salts. Although modern <span class="inline text-[1em] leading-7">reaction calorimeters</span> consent to foresee the effects of these different conditions to a certain extent, a direct transfer of a process from the laboratory to the industrial scale is not recommended, because of the inherent safety, environmental, and economic risks. In development, the viability of the process on a semi commercial scale has to be demonstrated. Trial quantities of the new fine chemical have to be manufactured for market development, clinical tests, and other requirements. The necessary data have to be generated to enable the engineering department to plan the modifications of the industrial-scale plant and in order to calculate production costs for the expected large-volume requirements. Both equipment and plant layout of the pilot plant reflect those of an industrial multipurpose plant, except for the size of reaction vessels (bench-scale laboratory ~10â€“60 liters; pilot plant ~100â€“2500 liters) and the degree of process automation. Before the process is ready for transfer to the industrial-scale plant, the following activities have to be completed: Adaptation of the laboratory process to the constraints of a pilot plant, hazard and operability (HAZOP) analysis, execution of demonstration batches. The main differences between laboratory synthesis and industrial scale production are shown in Table 4.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 4: Laboratory Synthesis vs. Industrial Scale Process<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></strong></span>


















































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Task</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Laboratory synthesis</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Industrial scale process</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Operator</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Laboratory chemist</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Chemical engineer</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Economy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Yield</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Throughput (kg/m3/hour)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Units</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G, mL, mol; min. hours</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Kg, ton, hours, shift</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Equipment</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Glass flask</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Stainless steel, glass lined</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Process control</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Manual</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Automatic [reaction vessel]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Critical path</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Reaction time</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Heating / cooling</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Liquid handling</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pouring</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pumping</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Liquid / solid sep.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Filtration</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Centrifugation</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">In case of cGMP fine chemicals also a <span class="inline text-[1em] leading-7">process validation</span> is required. It consists of the three elements <span class="inline text-[1em] leading-7">process design</span>, <span class="inline text-[1em] leading-7">process qualification</span> and <span class="inline text-[1em] leading-7">continued process verification</span>. <em><span class="inline text-[1em] leading-7"><em>Process Optimization</em></span></em>. Once a new chemical process has been introduced successfully on an industrial scale, process optimization is called upon to improve the economics. As a rule of thumb it should be attempted to reduce the costs of goods sold (COGS) by 10-20%, every time the yearly production quantity has doubled. The task extends from fine tuning the currently used synthetic method all the way to the search for an entirely different second generation process. Specific provisions are the increase of overall yield, the reduction of the number of steps, raw material cost, solvent, catalyst, enzyme consumption, environmental impact.</span>
<h2 id="project-management" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Project management<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">There are two main sources of new research projects, namely ideas originating from the researchers themselves (&quot;supply push&quot;) and those coming from customers (&quot;demand pull&quot;). Ideas for new processes typically originate from researchers, ideas for new products from customers, respectively customer contacts. Particularly in custom manufacturing, &quot;demand pull&quot; prevails industrial reality. The &quot;new product committee&quot; is the body of choice for evaluating new and monitoring ongoing research activities. It has the assignment to evaluate all new product ideas. It decides whether a new product idea should be taken up in research, reassesses a project at regular intervals and, last but not least decides also about the abandonment of a project, once it becomes evident that the objectives cannot be reached. In a typical project the overall responsibility for the economic and technical success lies with the <span class="inline text-[1em] leading-7">project champion</span>. He is assisted by the <span class="inline text-[1em] leading-7">project manager</span>, who is responsible for the technical success. In custom manufacturing, a typical project starts with the acceptance of the product idea, which originates mainly from business development, by the new product committee, followed by the preparation of a laboratory process, and ends with the successful completion of demonstration runs on industrial scale and the signature of a multiyear supply contract, respectively. The input from the customer is contained in the &quot;technology package&quot;. Its main constituents are (1) reaction scheme, (2) target of project &amp; deliverables (product, quantity, required dates, specifications), (3) list of <span class="inline text-[1em] leading-7">analytical methods</span>, (4) process development opportunities (stepwise assessment), (5) list of required reports, (6) <span class="inline text-[1em] leading-7">Safety, Health and Environment</span> (SHE) issues, (7) materials to be supplied by customer and (8) packaging &amp; shipping information The technical part of a project usually determines its duration. Depending on the quality of the information contained in the &quot;technology package&quot; received from the customer and the complexity of the project as such, particularly the number of steps that have to be performed; it can be any time between 12 and 24 months. Depending on the number of researches involved, the total budget easily amounts to several million US dollars.</span>
<h1 id="markets" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Markets<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Fine chemicals are used as starting materials for <span class="inline text-[1em] leading-7">specialty chemicals</span>. The latter are obtained either by direct formulation or after chemical/biochemical transformation of intermediates to active substances. Life sciences, primarily pharmaceutical, agrochemical and food and feed industries are the main consumers of fine chemicals.</span>
<h3 id="market-size" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Market size<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">As of 2023, the global chemical industry was valued at approximately $6.67 trillion USD, dominated mainly by oil-, gas-, and mineral-derived commodities (~40%) on one hand and a large variety of specialty chemicals at the interface between industry and the public on the other hand (~55%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Fine chemicals account for about 4% of this universe. The global production value of fine chemicals is estimated at $222 billion in 2024, of which about 2/3, or $148 billion are produced captively and $74 billion represent the global revenues of the fine chemical industry. The corresponding figures for the major user, the pharmaceutical industry, are $149 billion and an estimated $60 billion merchant, respectively. For a number of reasons, such as the lack of statistical data and the somewhat equivocal definition it is not possible to exactly determine the size of the fine chemical market. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 5: Breakdown of Fine Chemicals Market by Major Applications (estimated as of 2024)</strong></span>









































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Application</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Size ($ billion) total A.I.</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">captive</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">merchant</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Life sciences</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pharmaceuticals</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">149</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">89</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">60</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Agrochemicals</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">33</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">24</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">9</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Various specialty chemicals</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">40</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">35</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Total fine-chemical industry</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">222</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">148</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">74</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">In Table 5, the approximately $222 billion fine chemical market is subdivided into major applications according to their relevance, namely, fine chemicals for pharmaceuticals, agrochemicals and specialty chemicals outside life sciences. Furthermore, a distinction is made between captive (in-house) production and merchant market. Pharmaceutical fine chemicals (PFCs) account for two-thirds of the total. Out of the PFC value of $149 billion, about $60 billion (~40%) are traded, and $89 billion (~60%) are the production value of the pharma industry&#x27;s in-house production. Within life science products, fine chemicals for agro, and â€”at a distanceâ€” for veterinary drugs follow in importance. The production value for fine chemicals used for specialty chemicals other than pharmaceuticals and agrochemicals is estimated at $40 billion. As the leading specialty chemical companies, <span class="inline text-[1em] leading-7">Akzo Nobel</span>, <span class="inline text-[1em] leading-7">Dow</span>, <span class="inline text-[1em] leading-7">DuPont</span>, <span class="inline text-[1em] leading-7">Evonik</span>, <span class="inline text-[1em] leading-7">Chemtura</span> and <span class="inline text-[1em] leading-7">Mitsubishi</span> are backward-integrated, the share of in-house production is estimated at ~88%, leaving a merchant market of approximately $5 billion.</span>
<h3 id="target-markets" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Target markets<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<h4 id="pharmaceuticals" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Pharmaceuticals<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">The pharmaceutical industry constitutes the most important customer base for the fine chemical industry (see Table 4). Leading companies include Pfizer (USA), Roche (Switzerland), Novartis (Switzerland), Sanofi (France), GSK (UK), Novo Nordisk (Denmark), and Eli Lilly (USA). All are active in R&amp;D, manufacturing and marketing. Pharmaceuticals containing more than 2000 different active ingredients are in commerce today; a sizable number of them are sourced from the fine chemical industry. The industry also has a track record of above-average growth. The fine chemical industry has a keen interest in the top-selling or &quot;blockbuster drugs&quot;, i.e. those with worldwide annual sales in excess of $1 billion. The number of blockbusters has continued to grow, exceeding 100 as of 2024, driven largely by biologics and innovative therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 6: Top 10 Proprietary Drugs 2024</strong></span>

























































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Rank</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Brand</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">API</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Company</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">sales 2024 ($ bn)</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Keytruda</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">pembrolizumab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Merck</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">29.5</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Ozempic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">semaglutide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Novo Nordisk</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">16.9</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Biktarvy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">bictegrivir/emtricitabine/tenofovir alafenamide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Gilead</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">13.4</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Eliquis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">apixaban</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Bristol-Myers Squibb/Pfizer</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">13.3</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dupixent</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">dupilumab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sanofi/Regeneron</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">13.0</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Skyrizi</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">risankizumab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">AbbVie</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">11.7</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">7</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Darzalex</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">daratumumab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Johnson &amp; Johnson/Genmab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">11.6</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">8</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Stelara</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">ustekinumab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Johnson &amp; Johnson</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10.4</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">9</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Humira</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">adalimumab</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">AbbVie</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">9.0</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Gardasil</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">HPV vaccine</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Merck</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">8.6</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Total Top 10</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>137.4</strong></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Sales of the top 10 blockbuster drugs are reported in Table 6 as of 2024. The APIs of 3 of them are small molecules (plus one combination). Averaging a MW of around 450 for small molecules, they have quite complex structures. They typically show multiple cyclic moieties. Most exhibit heterocyclic moieties. Eight of the top 10 are biologics or vaccines, up significantly from five in 2010, reflecting the shift toward biopharmaceuticals. The largest-selling non-proprietary drugs are paracetamol, omeprazole, ethinylestradiol, amoxicillin, pyridoxine, and ascorbic acid. The innovator pharma companies require mainly custom manufacturing services for their proprietary drug substances. The demand is driven primarily by the number of new drug launches, the volume requirements and the industry&#x27;s &quot;make or buy&quot; strategy. A summary of the pro&#x27;s and con&#x27;s for outsourcing from the pharma industry&#x27;s perspective is given in Table 7. As extended studies at the Stern Business School of the New York City University have shown, financial considerations clearly favor the &quot;buy&quot; option.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 7: Pro&#x27;s and Con&#x27;s for Outsourcing API Manufacture<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></strong></span>













<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Pro&#x27;s</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Con&#x27;s</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">**concentrate on core activities (innovation &amp; marketing) **</span><br/><span class="text-[1em] leading-7"></span><strong>deploy your financial resources for more profitable investments</strong><br/><span class="text-[1em] leading-7">benefit from F.C. industry&#x27;s know how and expertise</span><br/><span class="text-[1em] leading-7">eliminate long lead times to build and validate a manufacturing facility</span><br/><span class="text-[1em] leading-7">free capacity for new product introductions</span><br/><span class="text-[1em] leading-7">avoid risks of using hazardous chemistry</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">loss of tax benefits resulting from production of APIs in tax havens</span><br/><span class="text-[1em] leading-7">dissemination of Intellectual Property</span><br/><span class="text-[1em] leading-7">loss of know how</span><br/><span class="text-[1em] leading-7">job losses</span><br/><span class="text-[1em] leading-7">under-utilization of in-house production capacity</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Teva</span> and <span class="inline text-[1em] leading-7">Sandoz</span> are by far the largest <em>generics companies</em> (see also chapter 6.3.2). They differ from their competitors not only in sales revenues but also because they are strongly backwards integrated and have proprietary drugs in their portfolios. They also vie for the promising biosimilars market, projected to reach ~$100 billion by 2025. </span>
<span class="mb-4 block break-words text-[1em] leading-7">Several thousand <em>small</em> or <em>virtual pharma</em> companies focus on R&amp;D. albeit on just a few lead compounds. They typically originate mostly from academia. Therefore, their R&amp;D strategy is more focused on the elucidation of the biological roots of diseases rather than developing synthesis methods.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent trends in the pharmaceutical sector include the explosive growth of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for diabetes and obesity, which, while mostly biologics, increase demand for supporting fine chemicals in formulation and delivery systems.</span>
<h4 id="agrochemicals" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Agrochemicals<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Agrochemical companies are the second largest users of fine chemicals. Most products have a &quot;pharmaceutical heritage&quot;. As a consequence of an intensive M&amp;A activity (Mergers and Acquisitions) over the past 10â€“20 years, the industry now is more consolidated than the pharmaceutical industry. The top companiesâ€”Bayer CropScience (Germany, including Monsanto), Syngenta Group (China/Switzerland), Corteva Agriscience (USA), BASF (Germany), and FMC (USA)â€”have a share of approximately 80-90% of the total ~$250 billion global agrochemicals market as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Since the 1990s the R&amp;D effort is focused mainly on <span class="inline text-[1em] leading-7">gene modified (GM) seeds</span>. At both Bayer and Corteva&#x27;s seed businesses, GM seed accounts for more than 50% of total sales. Between 2010 and 2023, fewer than 50 new LMW agrochemicals were launched globally. However, only a handful achieved sales in excess of $100 million per year, reflecting a shift toward biologicals and sustainable solutions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Generics play a bigger role in the agro than in the pharma industry. They represent some 70% of the global market. China National Chemical Corp, a.k.a. ChemChina Group (owner of Syngenta), is the world&#x27;s largest supplier of generic farm chemicals. Makhteshim Agan (now ADAMA), Israel, and <span class="inline text-[1em] leading-7">Cheminova</span> (now part of FMC), Denmark follow on the ranks 2 and 3. Apart from these multibillion-dollar companies, there are hundreds of smaller firms with sales of less than $50 million per year, mainly in India and China. The incidence of the cost of the active ingredient is about 33%; i.e., much higher than in drugs. Depending on the climatic conditions affecting crop yields, consumption and prices of agrochemicals are subject to wide fluctuations from year to year, impacting also the suppliers.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The molecular structures of modern agrochemicals are much more complex than in older products, but lower than of their pharma counterparts.<!-- --> The average molecular weight of the top 10 is 330, as compared with 477 for the top 10 pharma small molecules. In comparison to reagents used in pharmaceutical fine chemical syntheses, hazardous chemicals, e.g. <span class="inline text-[1em] leading-7">sodium azide</span>, <span class="inline text-[1em] leading-7">halogens</span>, <span class="inline text-[1em] leading-7">methyl sulfide</span>, <span class="inline text-[1em] leading-7">phosgene</span>, <span class="inline text-[1em] leading-7">phosphorus chlorides</span>, are more frequently used. Agrochemical companies sometimes outsource just these steps, which require specialized equipment, on toll conversion deals. With exception of the <span class="inline text-[1em] leading-7">pyrethroids</span>, which are photostable modifications of naturally occurring pyrethrums, active ingredients of agrochemicals rarely are chiral. Examples within <em><span class="inline text-[1em] leading-7">herbicides</span></em> are the world&#x27;s longstanding top-selling product, Bayer&#x27;s <span class="inline text-[1em] leading-7">Roundup</span> (glyphosate). Syngenta&#x27;s cyclohexadione-type <span class="inline text-[1em] leading-7">mesotrione</span> and <span class="inline text-[1em] leading-7">paraquat dichloride</span>. Within <em><span class="inline text-[1em] leading-7">insecticides</span></em> , the traditional <span class="inline text-[1em] leading-7">organophosphates</span>, like <span class="inline text-[1em] leading-7">malathion</span>, and pyrethroids such as <span class="inline text-[1em] leading-7">Î³-cyhalothrin</span> are being substituted for by <span class="inline text-[1em] leading-7">neonicotinoids</span>, like Bayer&#x27;s <span class="inline text-[1em] leading-7">imidacloprid</span> and Syngenta&#x27;s <span class="inline text-[1em] leading-7">thiamethoxam</span> and pyrazoles, such as BASF&#x27;s <span class="inline text-[1em] leading-7">fipronil</span>. Chlorantraniliprole is the most important representative of Corteva&#x27;s anthranilic diamide family of broad spectrum insecticides. Within <em><span class="inline text-[1em] leading-7">fungicides</span></em> , the <span class="inline text-[1em] leading-7">strobilurins</span>, a new class, are growing rapidly and already have captured more than 30% of the $10 billion global fungicide market. Syngenta&#x27;s <span class="inline text-[1em] leading-7">azoxystrobin</span> was the first product launched. Also BASF&#x27;s F-500 Series, a.o. <span class="inline text-[1em] leading-7">pyraclostrobin</span> and kresoxim-methyl, Bayer CropScience, and Corteva are developing new compounds in this class. Combination pesticides, such as Bayer&#x27;s XtendiMax and Corteva&#x27;s Enlist are more and more frequently used.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent developments in agrochemicals emphasize sustainable practices, with increasing use of biological controls and reduced reliance on synthetic chemicals due to regulatory pressures.</span>
<h4 id="other-specialty-chemical-industries" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Other specialty chemical industries<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Apart from life sciences, specialty chemicals -and therefore also their active ingredients, commodities or fine chemicals, as the case may be- are used ubiquitously, in both industrial applications, such as <span class="inline text-[1em] leading-7">biocides</span> and <span class="inline text-[1em] leading-7">corrosion inhibitors</span> in cooling water towers, and consumer applications, such as <span class="inline text-[1em] leading-7">personal care</span> and household products. The active ingredients extend from high-price / low-volume fine chemicals, used for <span class="inline text-[1em] leading-7">liquid crystal displays</span> to large-volume / low-price amino acids used as <span class="inline text-[1em] leading-7">feed additives</span>.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 8: Other Specialty Chemicals Industries (as of 2024)</strong></span>

































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Industry</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Sales ($ billion)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Attractiveness</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Products</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Animal Health</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 50</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦â™¦â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Typical a.h. products derive from human medicines, e.g. Reconzile, dubbed &quot;puppy Prozac&quot;. Paraciticides are the largest product category. Good growth prospects in fish farming.</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Adhesives &amp; Sealants</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 70</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Uses extend from household, e.g. paper gluing, to high-tech specialty products for assembling electronic parts, automotive and aircraft construction. </span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Biocides</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 12</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Largest applications are wood conversation and water treatment. A.I.&#x27;s mainly commodities </span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Catalysts &amp; Enzymes</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 40</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Catalysts (automotive, polymers, petroleum processing, chemicals) / enzymes (detergents / technical enzymes, food &amp; feed) = 80 / 20</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dyestuffs &amp; Pigments</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 45</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mostly based on large volume aromatic compounds, e.g., letter acids .Asian dyestuff prod, &gt; 106 mtpa. Some niche products, e.g. colour shifting pigments</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Electronic Chemicals</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 80</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦â™¦â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sizeable and growing demand for fine chemicals, e.g. octafluorocyclobutane for etching. for liquid crystals and organic light emitting diodes (OLED).</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Flavours &amp; Fragrances</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~ 35</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~3000 molecules are used, e.g. (-) menthol [20,000 tons], polycyclic musks [10,000 tons], vanilline, linalool, geraniol, heterocyclics, 2-phenylethanol)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Food &amp; Feed Additives</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">80-100</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mainly amino acids (L-lysine [106 tons], L-methionine, ...), vitamins (C [&gt; 105 tons], niacin, riboflavin, ...), artificial sweeteners (aspartame, splenda) and carotenoids</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Specialty Polymers</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">NA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â™¦â™¦</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Aerospace: Fluorinated poly ethylene/propylene,[30,000 tons], Polyether ether ketones [PEEK], Polyimides, Precision parts: Aramides [25,000 t], polybenzazoles</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">*fine chemicals merchant market size, growth potential</span>
<span class="mb-4 block break-words text-[1em] leading-7">Examples of applications in eight areas, ranging from <span class="inline text-[1em] leading-7">adhesives</span> to specialty polymers, are listed in Table 8. Overall, the attractiveness for the fine chemical industry is smaller than the life science industry. The total market, expressed in finished product sales, amounts to $150â€“200 billion, or about one fourth of the pharma market. The embedded fine chemicals account for an estimated $40 billion (see Table 5). Further disadvantages are the backward integration of the big players, e.g. <span class="inline text-[1em] leading-7">Akzo-Nobel</span>, Netherlands; <span class="inline text-[1em] leading-7">Ajinomoto</span>, Japan; <span class="inline text-[1em] leading-7">Danone</span>, France; Everlight Chemical Industrial Corp., Taiwan; Evonik-Degussa, Germany; <span class="inline text-[1em] leading-7">Givaudan</span> and <span class="inline text-[1em] leading-7">NestlÃ©</span>, Switzerland, <span class="inline text-[1em] leading-7">Novozymes</span>, Denmark, <span class="inline text-[1em] leading-7">Procter &amp; Gamble</span>, and <span class="inline text-[1em] leading-7">Unilever</span> USA. Last but not least, innovation is rather based on new formulations of existing products, rather than the development of new fine chemicals. It is most likely to happen in application areas unrelated to human health (where NCEs are subject to very extensive testing).</span>
<h3 id="target-products-and-services" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Target products and services<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">As of 2024, the global pharmaceutical market is approximately $1.65 trillion, with proprietary drugs accounting for about 73% (<del>$1.2 trillion) and generics about 27% (</del>$450 billion) by value, though generics represent a larger share by volume (~30% on an API volume basis).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<h4 id="custom-manufacturing" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Custom manufacturing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">The products and services offered by the fine chemical industry fall into two broad categories: (1) &quot;Exclusives&quot;, a.k.a. custom manufacturing (CM) and (2) &quot;standard&quot; or &quot;catalogue&quot; products. &quot;Exclusives&quot;, provided mostly under contract research or custom manufacturing arrangements, prevail in business with life science companies; &quot;standards&quot; prevail in other target markets. Service-intense custom manufacturing (CM) constitutes the most prominent activity of the fine chemical industry. CM is the antonym of <span class="inline text-[1em] leading-7">outsourcing</span>. In custom manufacturing, a specialty-chemicals company outsources the process development, pilot plant, and, finally, industrial-scale production of an active ingredient, or a predecessor thereof, to one, or a few, fine chemical companies. The intellectual property of the product, and generally also the manufacturing process, stay with the customer. The customer-supplier relationship is governed by an exclusive supply agreement. At the beginning of cooperation, the customer provides a &quot;tech package&quot;, which in its simplest version, includes a laboratory synthesis description and SHE recommendations. In this case, the whole scale up, which comprises a factor of about one million (10 gram â†’ 10 ton quantities), is done by the fine chemical company.</span>
<span class="mb-4 block break-words text-[1em] leading-7">With the rise of biologics, custom manufacturing increasingly includes support for bioprocessing and conjugation chemistries.</span>
<h4 id="standard-products" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Standard products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Non-exclusives, &quot;standard&quot; or &quot;catalogue products&quot; constitute the second most important outlet for fine chemicals after custom manufacturing. API-for-Generics are the most important sub-category. Because of patent expiries, over 60 of the top 200 drugs alone, representing aggregated sales of over $150 billion, have fallen into the public domain within the past decade. This, along with government-backed incentives, are causing global sales of generics to rapidly increase.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> Asian companies currently dominate the API-for-Generics business. They have multiple advantages of their low cost basis, their large home markets, and significant previous manufacturing experience compared to western manufacturers in producing for their domestic and other non-regulated markets.</span>
<h1 id="financials" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Financials<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="investment-costs" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Investment costs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Investment costs for multipurpose plants are high in comparison with product output. However, they vary considerably, depending on the location, size of equipment and degree of sophistication (e.g., automation, containment, quality of equipment, complexity of infrastructure). An example for a cGMP multipurpose plant built in the US is shown in Table 9 (as of 2011). The investment cost of $21 million comprises just the equipment and installation. The building, property and external services are excluded. For comparison purposes, the investment cost per mÂ³ reactor volume is used. In this case, it is $0.9 million. The amount includes the cost of the reaction vessel itself plus an equitable part of the ancillary equipment, like feeding tanks, piping, pumps &amp; process control. If larger or smaller reactors were installed, the unit cost per mÂ³ would decrease or increase with the exponent 0.5, respectively. Hence, by increasing the equipment size manufacturing costs on a per kilogram (kg<sup>-1</sup>) basis typically decrease substantially. Also, costs for a plant that is used for the production of non regulated intermediates only would be substantially lower. Pharma companies tend to spend up to ten times more for a plant with the same capacity. In contrast, investment costs in developing countries, particularly in India or China, are considerably lower.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 9: Investment Cost for a cGMP Multipurpose Plant (2011)</strong></span>

















































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Description of main equipment</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Numbers</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Production trains</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Reactor vessels (volume = 4 mÂ³)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Total reactor volume</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">24 mÂ³</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Filtration units</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dryers</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Capital investment</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Total capital investment</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$21 million</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Investment per production train</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$11.5 million</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Investment per piece of main equipment</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$2.1 million</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Investment per mÂ³ reactor volume</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$0.9 million</span></td></tr></tbody></table></div>
<h2 id="manufacturing-costs" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Manufacturing costs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The raw material consumption and the conversion cost are the two elements that establish the manufacturing cost for a particular fine chemical. The former is determined primarily by the unit consumption and the purchasing cost of the materials used; the latter, by the throughput in kilograms per day in a given production bay. A precise calculation of the conversion cost is a demanding task. Different products with widely differing throughputs are produced in campaigns in multipurpose plants, occupying the equipment to different extents. Therefore, both the production capacity and the equipment utilization for a specific fine chemical are difficult to determine. Moreover, cost elements such as labor, capital, utilities, maintenance, waste disposal, and quality control cannot be allocated unambiguously.</span>
<span class="mb-4 block break-words text-[1em] leading-7">An approximative calculation can be done by an experienced process development or pilot plant chemist on the basis of (1) the laboratory synthesis procedure and (2) by breaking down the process into unit operations, the standard costs of which have been determined previously Controlling has to be involved for a more in-depth costing.. The problems it has to address are how to fairly allocate costs for production capacity, which is not used. This can be due to the fact that part of a production bay is idle, because of lack of demand or because, e.g., a reactor is not required for a particular process.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Manufacturing costs usually are reported on a per kilogram product basis. For the purpose of benchmarking (both internal and external), the volume x time / output (VTO), as mentioned above, is a useful aid.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Table 10: Indicative Cost Structure of a Fine Chemical Company (2011)</strong></span>























































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Cost elements</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Details</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Share</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">raw materials</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">inclusive solvents</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">30%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">conversion cost</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">plant specific</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">utilities and energy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">electric power, steam, brine</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4â€“5 %</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">plant labor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">shift and daytime work</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10â€“15 %</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">capital cost</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">depreciation and interest on capital</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">15%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">plant overhead</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">QC, maintenance, waste disposal, etc.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10 %</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">research &amp; development</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">inclusive pilot plant</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">8 %</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">marketing &amp; sales</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">inclusive promotion</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">general overhead</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">administrative services</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">15 %</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">An indicative cost structure for a fine chemical company is shown in Table 10. Nowadays, a full 7-day/week operation, consisting of four or five shift teams, each working 8h per day, has become the standard. In terms of production costs, this is the most advantageous scheme. Higher salaries for night work are more than offset by better fixed cost absorption. As part of the budgeting process, standard costs for a production campaign of a particular fine chemical are determined on the basis of past experience. The actual results of the campaign are then compared with the standard. The capability of a fine chemical company to make dependable manufacturing cost forecasts is a distinct competitive advantage. Recent trends (as of 2023) indicate rising energy costs, with a global increase of 19% affecting production expenses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<h2 id="profitability" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Profitability<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The fine chemical industry has undergone several boom and bust phases during its almost 30 years of existence (as of 2011). The biggest boom took place in the late 1990s, when high-dosage, high volume anti-AIDS drugs and COX-2 inhibitors gave a big boost to custom manufacturing. After the end of the &quot;irrational exuberance&quot; in 2000, the industry suffered a first bust in 2003, as a result of capacity expansions, the advent of Asian competitors and a ruinous M&amp;A activity, several billion dollars of shareholder value were destroyed. The most recent â€“minor- boom is associated with stockpiling of GlaxoSmithKline&#x27;s <span class="inline text-[1em] leading-7">Relenza</span> (zanamivir) and Roche&#x27;s <span class="inline text-[1em] leading-7">Tamiflu</span> (oseltamivir phosphate) by many countries in order to prepare for a possible avian flu epidemic. Surprisingly, the main cause for the 2009 slump had not been the general recession, but slow-downs of the growth and, even more so, inventory adjustments by the pharma industry. They resulted in postponements or cancellations of orders. The unfavorable development was in sharp contrast to the very optimistic growth forecasts, which many fine chemical companies, had announced. They had been based on equally promising sector reports from investment banks, which in turn had evolved from forward projections of the preceding boom period. In most cases, these projections have been missed by a large margin.</span>
<span class="mb-4 block break-words text-[1em] leading-7">At the end of the &quot;irrational exuberance&quot; at the turn of the millennium and again in 2009 almost half of the industry achieved a return on sales (ROS) of more than 10%, and less than 10% an ROS below 5%. In the worst years, 2003 and 2009, almost half of the companies suffered from an ROS of less than 5%. Whereas during the period under review, 2000â€“2009. the average EBITDA / sales and EBIT / sales ratios of representative companies, resp. divisions were 15% and 71â„2%, respectively, in the period 2000â€“2009, the numbers were 20% and 10â€“13% in the boom, and 10% and 5% in the bust phases. The factor 2 between the high and low numbers reflects the volatility of the industry&#x27;s profitability. All in all, as of 2009, the average Western fine-chemical firms have been making a return below the cost of capital, i.e. they are not reinvestment grade.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Since 2020, the industry has faced additional volatility from the COVID-19 pandemic, supply chain disruptions, and geopolitical tensions, but showed recovery by 2024. Global chemical profits for top firms rose 8.1% to $56.8 billion in 2024, with specialty chemical producers (including fine chemicals) reporting strong gains, such as over 100% profit increases for some like Asahi Kasei. R&amp;D spending increased 3% to $12.3 billion, supporting innovation in high-value fine chemicals. Projections for 2025 indicate 3.5% global chemical production growth, driven by pharmaceuticals (over 60% of fine chemicals demand).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<h1 id="outlook" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Outlook<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Two main trends impinge on the industry. On the <em>supply side</em> , biotechnology is rapidly gaining importance. In the synthesis of small molecule fine chemicals, the use of biocatalysts and microbial fermentation enable both a more sustainable and economic production than conventional organic chemistry. In the synthesis of big molecules, such as biopharmaceuticals, it is the method of choice. Biopharmaceuticals are projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2025 to 2030, faster than the overall pharmaceutical market&#x27;s ~6% CAGR.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> As of 2024, seven of the top ten best-selling drugs worldwide are biopharmaceuticals, reflecting the ongoing shift toward biologics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On the <em>demand side</em> , the main customer base for fine chemicals, the pharmaceutical industry, is faced with slower growth of demand, patent expirations of many lucrative blockbuster drugs and stalling new product launches. Recent trends include the rise of GLP-1 receptor agonists for obesity and diabetes, which are biopharmaceuticals driving demand for advanced fine chemicals. In order to restrain these challenges, the leading companies are implementing restructuring programs. They comprise a reduction of in-house chemical manufacturing and plant eliminations. Outsourcing is moving up from a purely opportunistic to a strategic approach, with the biopharmaceutical contract development and manufacturing organization (CDMO) market projected to grow at 8.8% CAGR through 2030.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> It is difficult to make a judgment, whether the positive or negative effects of these initiatives will prevail. In a worst-case scenario, a condition could develop, whereby even top-tier mid-sized, family-owned<!-- --> fine-chemical companies with state-of-the-art plants and processes could be relegated to producing small quantities of fine chemicals for new life-science products in late stage of development. In agro fine chemicals, the active ingredients become more sophisticated and performing. Therefore, they require multipurpose instead of dedicated plants prevailing in the industry so far. At the same token, outsourcing is gaining ground.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><em>Globalization</em> results in a shift of fine chemical production from the industrialized to developing countries. The latter benefit not only from a &quot;low cost / high skill&quot; advantage, but also from a rapidly rising domestic demand for Western medicine. Despite the mantras of Western industry leaders, the cost advantage of the Asian producers is going to persist.<!-- --> As the pharmemerging countries mainly use generics, their market share continues to grow to the detriment of originator pharmaceuticals and agrochemicals. This is also the case for biosimilars, the generic versions of biopharmaceuticals. As a consequence of the harsh business climate, many Western fine chemical companies or divisions created during the &quot;irrational exuberance&quot; at the end of the 20th century already have exited from the sector. Others will follow suit or will be acquired by private equity firms. Survival strategies include implementation of lean production principles originally developed by the automotive industry and extending the business model to include also contract research at the beginning and active drug formulation towards the end of the added value chain. This latter strategy, however, is not finding unanimous approval by industry experts. The industry is also emphasizing sustainability and digital technologies, such as AI for process optimization, to enhance resiliency amid volatile supply chains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Although the demand for fine chemicals on the merchant market has not grown to the extent originally anticipated, fine chemicals still provide attractive opportunities for well-run companies, which are fostering the critical success factors, namely running fine chemicals as a core business, pursuing niche technologiesâ€”primarily biotechnologyâ€”and taking advantage of the opportunities offered by the Asian market. The global fine chemicals market is projected to grow from approximately USD 186 billion in 2025 to USD 341 billion by 2035.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.futuremarketinsights.com/reports/fine-chemicals-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.futuremarketinsights.com/reports/fine-chemicals-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.futuremarketinsights.com/reports/fine-chemicals-market</a></span></div></li><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Stahl, A. F. (1908). <a href="https://books.google.com/books?id=OvgwAQAAMAAJ&amp;pg=PA956" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;XX.- Fine Chemicals, Alkaloids, Essential Oils, &amp; Extracts&quot;</a>. <em>The Journal of the Society of Chemical Industry</em>. <strong>27</strong> : 956.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">A. Kleemann; J. Engel; B. Kutscher; D. Reichert (2009). <a href="https://archive.org/details/pharmaceuticalsu00klee_318" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Pharmaceutical Substances</em></a> (5th ed.). pp. <a href="https://archive.org/details/pharmaceuticalsu00klee_318/page/n311" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">291</a>â€“292. <span class="inline text-[1em] leading-7">ISBN</span> 9781621983774.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">A. Kleemann; J. Engel; B. Kutscher; D. Reichert (2009). <a href="https://archive.org/details/pharmaceuticalsu00klee_318" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Pharmaceutical Substances</em></a> (5th ed.). pp. <a href="https://archive.org/details/pharmaceuticalsu00klee_318/page/n1209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1189</a>â€“1191. <span class="inline text-[1em] leading-7">ISBN</span> 9781621983774.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">E. Reeder; L. H. Sternbach (1968). <em>US 3371085</em>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hughes, Andrew B. (2011). <em>Amino Acids, Peptides and Proteins in Organic Chemistry</em>. Volumes 1-5: John Wiley &amp; Sons, Hoboken.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location (link)</span></div></li><li id="https://www.biotechprimer.com/pills-peptides-proteins/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biotechprimer.com/pills-peptides-proteins/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biotechprimer.com/pills-peptides-proteins/</a></span></div></li><li id="https://www.transparencymarketresearch.com/peptide-api-market.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.transparencymarketresearch.com/peptide-api-market.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.transparencymarketresearch.com/peptide-api-market.html</a></span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market</a></span></div></li><li id="https://www.antibodysociety.org/resources/approved-antibodies/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.antibodysociety.org/resources/approved-antibodies/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.antibodysociety.org/resources/approved-antibodies/</a></span></div></li><li id="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01704-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01704-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01704-3</a></span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Examples: Swiss Federal Institute of Technology (ETHZ), Switzerland; Massachusetts Institute of Technology (MIT), USA; Institut fÃ¼r Mikrotechnik (IMM), Germany; University of Washington (WU), USA; Micro-Chemical ProcessTechnology Research Association (MCPT), Japan.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">V. Hessel; A. Renken; J.C. Shouten; J. Yoshida (2009). <em>Micro Process Engineering</em>. Wiley-VCH Verlag, Weiheim.</span></div></li><li id="https://www.skyquestt.com/report/microreactor-technology-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.skyquestt.com/report/microreactor-technology-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.skyquestt.com/report/microreactor-technology-market</a></span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wim Soetaert; Erick J. Vandamme (2010). <em>), Industrial Biotechnology: Sustainable Growth and Economic Success</em>. J. Wiley &amp; Sons, Hoboken NJ.</span></div></li><li id="https://www.precedenceresearch.com/white-biotechnology-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.precedenceresearch.com/white-biotechnology-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.precedenceresearch.com/white-biotechnology-market</a></span></div></li><li id="https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/</a></span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Secretary: Prof. M.P. Walsh. University of Calgary, Calgary, Canada T2N 4N1</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pollak, Peter (29 March 2011). <a href="https://books.google.com/books?id=yuxJGasHvkoC&amp;pg=PA43" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Fine Chemicals: The Industry and the Business</em></a>. John Wiley &amp; Sons. <span class="inline text-[1em] leading-7">ISBN</span> 978-1-118-00222-3.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Victor A. Vinci; Sarad R. Parekh (2010). <em>Handbook of Industrial Cell Culture: Mammalian, Microbial, and Plant Cells</em>. Humana Press, New York.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">C. Chassin; P. Pollak (Januaryâ€“February 2004). &quot;Outlook for chemical and biochemical manufacturing&quot;. <em>PharmaChem</em>. <strong>3</strong> : 23â€“26.</span></div></li><li id="https://www.evitria.com/journal/cho-cells-first-choice-ab-production/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.evitria.com/journal/cho-cells-first-choice-ab-production/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.evitria.com/journal/cho-cells-first-choice-ab-production/</a></span></div></li><li id="https://www.bioprocessintl.com/supply-chain/biomanufacturing-supply-and-demand-industry-trends-and-projected-impacts" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bioprocessintl.com/supply-chain/biomanufacturing-supply-and-demand-industry-trends-and-projected-impacts" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bioprocessintl.com/supply-chain/biomanufacturing-supply-and-demand-industry-trends-and-projected-impacts</a></span></div></li><li id="https://www.biopharminternational.com/view/outsourcing-hits-record-levels-all-bioprocess-platforms" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biopharminternational.com/view/outsourcing-hits-record-levels-all-bioprocess-platforms" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biopharminternational.com/view/outsourcing-hits-record-levels-all-bioprocess-platforms</a></span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market</a></span></div></li><li id="https://www.appliedclinicaltrialsonline.com/view/large-vs-small-molecule-success-rates" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.appliedclinicaltrialsonline.com/view/large-vs-small-molecule-success-rates" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.appliedclinicaltrialsonline.com/view/large-vs-small-molecule-success-rates</a></span></div></li><li id="https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/</a></span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">A. Gosh; S. Ray; G. Jain; A. Arora (2011). <em>CRAMS India: Overview &amp; Outlook</em>. ICRA Ltd. Mumbai.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Samuel L. Tuthill, Norman C. Jamieson, Kirk-Othmer (2000). <em>Encyclopedia of Chemical Technology</em> (4th ed.). John Wiley &amp; Sons, Hoboken NJ. p. 857.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: multiple names: authors list (link)</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em>The U.S. Pharmacopeia 34 (USP 34 â€“NF29)</em>. The U.S Pharmacopeial Convention, Inc., Rockville, MD. 2011.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Adapted from: Pollak, Peter (2011). <a href="https://archive.org/details/finechemicalsind00poll_481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Fine Chemicals â€“ The Industry and the Business</em></a> (2nd. rev. ed.). Table 2.2: J. Wiley &amp; Sons. pp. <a href="https://archive.org/details/finechemicalsind00poll_481/page/n22" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-470-62767-9.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location (link)</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em>CPhI Worldwide, 25-27 October 2011</em>. Messe Frankfurt, UBM plc., London.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pollak, Peter (2011). <a href="https://archive.org/details/finechemicalsind00poll_481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Fine Chemicals â€“ The Industry and the Business</em></a> (2nd. rev. ed.). Table 10.2: J. Wiley &amp; Sons. pp. <a href="https://archive.org/details/finechemicalsind00poll_481/page/n123" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">105</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-470-62767-9.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location (link)</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Stanley H. Nusim (2009). <em>Active Pharmaceutical Ingredients: Development, Manufacturing, and Regulation</em> (2nd ed.). Taylor&amp;Francis Group, Boca Raton FL. pp. 9â€“91.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pollak, Peter (2011). <a href="https://archive.org/details/finechemicalsind00poll_481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Fine Chemicals â€“ The Industry and the Business</em></a> (2nd. rev. ed.). Table 6.1: J. Wiley &amp; Sons. pp. <a href="https://archive.org/details/finechemicalsind00poll_481/page/n90" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">69</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-470-62767-9.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location (link)</span></div></li><li id="https://www.businessresearchinsights.com/market-reports/fine-chemicals-market-109560" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.businessresearchinsights.com/market-reports/fine-chemicals-market-109560" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.businessresearchinsights.com/market-reports/fine-chemicals-market-109560</a></span></div></li><li id="https://www.imarcgroup.com/pharmaceutical-fine-chemicals-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.imarcgroup.com/pharmaceutical-fine-chemicals-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.imarcgroup.com/pharmaceutical-fine-chemicals-market</a></span></div></li><li id="https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global</a></span></div></li><li id="https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats</a></span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lev, Baruch (January 1999). &quot;R&amp;D AND CAPITAL MARKETS&quot;. <em>Journal of Applied Corporate Finance</em>. <strong>11</strong> (4): 21â€“35. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fj.1745-6622.1999.tb00511.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/j.1745-6622.1999.tb00511.x</a>.</span></div></li><li id="https://www.precedenceresearch.com/generic-drugs-market&quot;" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.precedenceresearch.com/generic-drugs-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.precedenceresearch.com/generic-drugs-market</a>&quot;</span></div></li><li id="https://www.precedenceresearch.com/agrochemicals-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.precedenceresearch.com/agrochemicals-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.precedenceresearch.com/agrochemicals-market</a></span></div></li><li id="https://www.emergenresearch.com/blog/top-10-companies-in-agrochemicals-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.emergenresearch.com/blog/top-10-companies-in-agrochemicals-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.emergenresearch.com/blog/top-10-companies-in-agrochemicals-market</a></span></div></li><li id="https://www.infosys.com/iki/documents/agrochem-industry-market-outlook.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.infosys.com/iki/documents/agrochem-industry-market-outlook.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.infosys.com/iki/documents/agrochem-industry-market-outlook.pdf</a></span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">C.D.S. Tomlin (2011). <em>The Pesticide Manual: A World Compendium</em> (15th ed.). BCPC Publications, Alton, Hampshire, UK.</span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/adhesives-and-sealants-market&quot;" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/adhesives-and-sealants-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/adhesives-and-sealants-market</a>&quot;</span></div></li><li id="https://www.marketsandmarkets.com/Market-Reports/biocides-market-1157.html&quot;" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.marketsandmarkets.com/Market-Reports/biocides-market-1157.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.marketsandmarkets.com/Market-Reports/biocides-market-1157.html</a>&quot;</span></div></li><li id="https://www.precedenceresearch.com/generic-drugs-market" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.precedenceresearch.com/generic-drugs-market" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.precedenceresearch.com/generic-drugs-market</a></span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/fine-chemicals-market-to-reach-191-billion-usd-by-2021---industryarc-642101523.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">[1]</a> 29 August 2017</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pollak, Peter (2011). <a href="https://archive.org/details/finechemicalsind00poll_481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Fine Chemicals â€“ The Industry and the Business</em></a> (2nd. rev. ed.). Table 7.1: J. Wiley &amp; Sons. pp. <a href="https://archive.org/details/finechemicalsind00poll_481/page/n97" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">76</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-470-62767-9.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location (link)</span></div></li><li id="https://www.marketgrowthreports.com/market-reports/fine-chemicals-market-108218" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.marketgrowthreports.com/market-reports/fine-chemicals-market-108218" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.marketgrowthreports.com/market-reports/fine-chemicals-market-108218</a></span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pollak, Peter (2011). <a href="https://archive.org/details/finechemicalsind00poll_481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Fine Chemicals â€“ The Industry and the Business</em></a> (2nd. rev. ed.). Table 7.3: J. Wiley &amp; Sons. pp. <a href="https://archive.org/details/finechemicalsind00poll_481/page/n100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">79</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-470-62767-9.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location (link)</span></div></li><li id="https://cen.acs.org/business/finance/CENs-Global-Top-50-2025/103/web/2025/07" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://cen.acs.org/business/finance/CENs-Global-Top-50-2025/103/web/2025/07" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://cen.acs.org/business/finance/CENs-Global-Top-50-2025/103/web/2025/07</a></span></div></li><li id="https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html</a></span></div></li><li id="https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoral-economic-performance/FINAL_Fine-Chemicals_Brochure_External_RGB.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoral-economic-performance/FINAL_Fine-Chemicals_Brochure_External_RGB.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoral-economic-performance/FINAL_Fine-Chemicals_Brochure_External_RGB.pdf</a></span></div></li><li id="https://www.genengnews.com/topics/drug-discovery/top-10-best-selling-drugs-2/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.genengnews.com/topics/drug-discovery/top-10-best-selling-drugs-2/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.genengnews.com/topics/drug-discovery/top-10-best-selling-drugs-2/</a></span></div></li><li id="https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html</a></span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Guy Villax (Novâ€“Dec 2008). &quot;Family owned businesses&quot;. <em>Chimica Oggi / Chemistry Today</em>. <strong>26</strong> (6): 8.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">P. Pollak; A. Badrot; R. Dach; A. Swadi (Novâ€“Dec 2011). <em>Costs of Asian Fine Chemical Producers close-up to European Levels â€“ Facts or Fiction?</em>. Contract Pharma.</span></div></li><li id="https://marketmindsadvisory.com/fine-chemicals-market-trends/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://marketmindsadvisory.com/fine-chemicals-market-trends/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://marketmindsadvisory.com/fine-chemicals-market-trends/</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Fine_chemical" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1" id="_R_" async=""></script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Fine_chemical\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Fine_chemical\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Fine_chemical\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T18b57,"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"# Fine chemical\n\n## Definition of Fine Chemicals (as opposed to Commodities and Specialties)\n\nIn [chemistry](Chemistry \"Chemistry\"), **fine chemicals** are complex, single, pure [chemical substances](Chemical_substance \"Chemical substance\"), produced in limited quantities in multipurpose plants by multistep batch chemical or [biotechnological](Biotechnological \"Biotechnological\") processes. They are described by exacting specifications, used for further processing within the [chemical industry](Chemical_industry \"Chemical industry\") and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced intermediates or [active ingredients](Active_ingredients \"Active ingredients\")), or the type of business transaction, namely standard or exclusive products. \n\nFine chemicals are produced in limited volumes (\u003c 1000 tons/year) and at relatively high prices (\u003e $10/kg) according to exacting specifications, mainly by traditional [organic synthesis](Organic_synthesis \"Organic synthesis\") in multipurpose [chemical plants](Chemical_plant \"Chemical plant\"). Biotechnical processes are gaining ground. Fine chemicals are used as starting materials for [specialty chemicals](Specialty_chemicals \"Specialty chemicals\"), particularly [pharmaceuticals](Pharmaceuticals \"Pharmaceuticals\"), [biopharmaceuticals](Biopharmaceuticals \"Biopharmaceuticals\") and [agrochemicals](Agrochemicals \"Agrochemicals\"). [Custom manufacturing](Contract_manufacturing_organization \"Contract manufacturing organization\") for the [life science](Life_science \"Life science\") industry plays a big role; however, a significant portion of the fine chemicals total production volume is manufactured in-house by large users. The industry is fragmented and extends from small, privately owned companies to divisions of big, diversified chemical enterprises. The term \"fine chemicals\" is used in distinction to \"heavy chemicals\", which are produced and handled in large lots and are often in a crude state. \n\nSince the late 1970s, fine chemicals have become an important part of the chemical industry. As of 2025, their global total production value is approximately $211 billion, split about 60-40 between in-house production in the life-science industryâ€”the products' main consumersâ€”and companies producing them for sale.[](https://www.futuremarketinsights.com/reports/fine-chemicals-market) The latter pursue both a \"supply push\" strategy, whereby standard products are developed in-house and offered ubiquitously, and a \"demand pull\" strategy, whereby products or services determined by the customer are provided exclusively on a \"one customer / one supplier\" basis. The products are mainly used as building blocks for proprietary products. The hardware of the top tier fine chemical companies has become almost identical. The design, lay-out and equipment of the plants and laboratories have become practically the same globally. Most chemical reactions performed go back to the days of the dyestuff industry. Numerous regulations determine the way labs and plants must be operated, thereby contributing to the uniformity.\n## History\n\nThe term \"fine chemicals\" was in use as early as 1908.[1] The emergence of the fine chemical industry as a distinct entity dates to the late 1970s, when the overwhelming success of the histamine H\u003csub\u003e2\u003c/sub\u003e receptor antagonists Tagamet (cimetidine) and Zantac (ranitidine hydrochloride) created a strong demand for advanced organic chemicals used in their manufacture. As the in-house production capacities of the originators, the pharmaceutical companies Smith, Kline, \u0026 French and Glaxo, could not keep pace with the rapidly increasing requirements, both companies (now merged as GlaxoSmithKline) outsourced part of the manufacturing to chemical companies experienced in producing relatively sophisticated organic molecules. Lonza, Switzerland, which already had supplied an early intermediate, methyl acetoacetate, during drug development, soon became the main supplier of more and more advanced precursors.[2] The signature of a first, simple supply contract is generally acknowledged as the historical document marking the beginning of the fine chemical industry. \n\n**The beginning: supply contract between Smith Kline French and Lonza for cimetidine precursors**\n\nIn subsequent years, the business developed and Lonza was the first fine chemical company entering in a strategic partnership with SKF. In a similar way, Fine Organics, UK became the supplier of the thioethyl-N'-methyl-2-nitro-1,1-ethenediamine moiety of ranitidine,[3] the second H\u003csub\u003e2\u003c/sub\u003e receptor antagonist, marketed as Zantac by Glaxo. Other pharmaceutical and agrochemical companies gradually followed suit and started outsourcing the procurement of fine chemicals. Examples include partnerships for precursors of the benzodiazepine class of tranquilizers, such as Librium (chlordiazepoxide HCl) and Valium (diazepam).[4]\n\nThe growing complexity and potency of new pharmaceuticals and agrochemicals requiring production in multipurpose, instead of dedicated plants and, more recently, the advent of biopharmaceuticals had a major impact on the demand for fine chemicals and the evolution of the fine chemical industry as a distinct entity. For many years, the life science industry continued considering captive production of the active ingredients of their drugs and agrochemicals as a core competency. Outsourcing was used only in exceptional cases, such as capacity shortfalls, processes requiring hazardous chemistry or new products, where uncertainties existed about the chance of a successful launch.\n# Products\n\nIn terms of molecular structure, one distinguishes first between low-molecular-weight (LMW) and high-molecular-weight (HMW) products. The generally accepted threshold between LMW and HMW is a molecular weight of about 700 g/mol. LMW fine chemicals, also designated as small molecules, are produced by traditional chemical synthesis, by microorganisms (fermentation or biotransformation), or by extraction from plants and animals. In the production of modern life science products, total synthesis from petrochemicals prevails. The HMW products, respectively large molecules, are obtained mainly through biotechnology processes. Within LMWs, the N-heterocyclic compounds are the most important category; within HMWs they are the peptides and proteins. \n\n### Small molecules\n\nAs aromatic compounds have been exhausted to a large extent as building blocks for life science products, N-heterocyclic structures prevail nowadays. They are found in many natural products, such as chlorophyll, hemoglobin, and the vitamins biotin, folic acid, niacin (PP), pyridoxine (vitamin B6), riboflavin (vitamin B2), and thiamine (vitamin B1). In synthetic life science products, N-heterocyclic moieties are widely used in both pharmaceuticals and agrochemicals. Thus, Î²-lactams are structural elements of penicillin and cephalosporin antibiotics, imidazoles are found both in modern herbicides, e.g. Arsenal (imazapyr) and pharmaceuticals, e.g. the antiulcerants Tagamet (cimetidine. see above) and Nexium (omeprazole), the antimycotics Daktarin (miconazole), Fungarest (ketoconazole) and Travogen (isoconazole). Tetrazoles and tetrazolidines are pivotal parts of the \"sartan\" class of hypertensives, e.g. Candesartan cilexetil (candesartan), Avapro (irbesartan), Cozaar (losartan) and Diovan (valsartan). \n\nA vast array of pharmaceuticals and agrochemicals are based on pyrimidines, such as Vitamin B1 (thiamine), the sulfonamide antibiotics, e.g. Madribon (sulfadimethoxime) and â€“half a century laterâ€“ the sulfonyl urea herbicides, e.g. Eagle (amidosulfuron) and Londax (bensulfuron-methyl). Benzodiazepine derivatives are the pivotal structural elements of breakthrough CNS Drugs, such as Librium (chlordiazepoxide) and Valium (diazepam). Pyridine derivatives are found in both well-known Diquat and Chlorpyrifos herbicides, and in modern nicotinoid insecticides, such as Imidacloprid. Even modern pigments, such as diphenylpyrazolopyrazoles, quinacridones, and engineering plastics, such as polybenzimidazoles, polyimides, and triazine resins, exhibit an N-heterocyclic structure. \n\n### Big molecules\n\n*_Big molecules_*, also called *_high molecular weight_* (HMW) molecules, are mostly oligomers or polymers of small molecules or chains of amino acids. Thus, within pharmaceutical sciences, peptides, proteins and oligonucleotides constitute the major categories. \n\n**Peptides and proteins** are oligomers or polycondensates of amino acids linked together by a carboxamide group.[5] The threshold between the two is as at about 50 amino acids. Because of their unique biological functions, a significant and growing part of new drug discovery and development is focused on this class of biomolecules. Their biological functions are determined by the exact arrangement or sequence of different amino acids in their makeup. For the synthesis of peptides, four categories of fine chemicals, commonly referred to as peptide building blocks (PBBs), are key, namely amino acids (=starting materials), protected amino acids, peptide fragments and peptides themselves. Along the way, the molecular weights increase from about 102 up to 104 and the unit prices from about $100 up to $105 per kilogram. However, only a small part of the total amino acid production is used for peptide synthesis. In fact, L-glutamic acid, D, L-methionine, L-aspartic acid and L-phenylalanine are used in large quantities as food and feed additives. Over 80 peptide therapeutics have been approved worldwide as of 2024.[](https://www.biotechprimer.com/pills-peptides-proteins/) The global market for peptide APIs was valued at approximately $9.2 billion in 2023, with the peptide therapeutics market exceeding $117 billion in 2024.[](https://www.transparencymarketresearch.com/peptide-api-market.html)[](https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market) The bulk of the production of peptide drugs, which comprise also the first generation anti-AIDS drugs, the \"...navirs\", is outsourced to a few specialized contract manufacturers, such as Bachem, Switzerland; Chengu GT Biochem, China; Chinese Peptide Company, China; Lonza, Switzerland, and Polypeptide, Denmark. \n\nThe number of amino acids that make up a specific peptide varies widely. At the low end are the dipeptides. The most important drugs with a dipeptide (L-alanyl-L-proline) moiety are the \"-pril\" cardiovascular drugs, such as Alapril (lisinopril), Captoril (captopril), Novolac (imidapril) and Renitec (enalapril). Also the artificial sweetener Aspartame (N-L-Î±-Aspartyl-L-phenylalanine 1-methyl ester) is a dipeptide. At the high end there is the anticoagulant hirudin, MW â‰ˆ 7000, which is composed of 65 amino acids. \n\nApart from pharmaceuticals, peptides are also used for diagnostics and vaccines. \n\n**Proteins** are \"very high-molecular-weight\" (MW \u003e 100,000) organic compounds, consisting of amino acid sequences linked by peptide bonds. They are essential to the structure and function of all living cells and viruses and are among the most actively studied molecules in biochemistry. They can be made only by advanced biotechnological processes; primarily mammalian cell cultures. Monoclonal antibodies (mAb) prevail among human-made proteins. Over 130 of them have been approved as pharmaceuticals worldwide as of 2024.[](https://www.antibodysociety.org/resources/approved-antibodies/) Important modern products are EPO (Binocrit, NeoRecormon, erythropoietin), Enbrel (etanercerpt), Remicade (infliximab); MabThera/Rituxin (rituximab), and Herceptin (trastuzumab). PEGylation is a big step forward regarding administration of peptide and protein drugs. The method offers the two-fold advantage of substituting injection by oral administration and reducing the dosage, and therefore the cost of the treatment. The pioneer company in this field is Prolong Pharmaceuticals which has developed a PEGylated erythropoietin (PEG-EPO). \n\n**Oligonucleotides** are a third category of big molecules. They are oligomers of nucleotides, which in turn are composed of a five-carbon sugar (either ribose or desoxyribose), a nitrogenous base (either a pyrimidine or a purine) and 1â€“3 phosphate groups. The best known representative of a nucleotide is the coenzyme ATP (=Adenosine triphosphate), MW 507.2. Oligonucleotides are chemically synthesized from protected phosphoramidites of natural or chemically modified nucleosides. The oligonucleotide chain assembly proceeds in the direction from 3'- to 5'-terminus by following a procedure referred to as a \"synthetic cycle\". Completion of a single synthetic cycle results in the addition of one nucleotide residue to the growing chain. The maximum length of synthetic oligonucleotides hardly exceeds 200 nucleotide components. From its current range of applications in basic research as well as in drug target validation, drug discovery, and therapeutic development, the potential use of oligonucleotides is foreseen in gene therapy (antisense drugs), disease prevention and agriculture. \n\n**[Antibody-drug conjugates](Antibody-drug_conjugates \"Antibody-drug conjugates\")** (ADC) constitute a combination between small and big molecules. The small molecule parts, up to four different APIs, are highly potent cytotoxic drugs. They are linked with a monoclonal antibody, a big molecule which is of little or no therapeutic value in itself, but extremely discriminating for its targets, the cancer cells. The first commercialized ADCs was Pfizer's (formerly Wyeth) Mylotarg (gemtuzumab ozogamicin). Examples of approved ADCs include Enhertu (trastuzumab deruxtecan), Kadcyla (ado-trastuzumab emtansine), and Trodelvy (sacituzumab govitecan). As of 2024, 15 ADCs have been approved globally.[](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01704-3)\n# Technologies\n\nSeveral key technologies are used for the production of fine chemicals, including \n\n- Chemical synthesis, either from petrochemical starting materials or from natural products extracts\n- Biotechnology, for small molecules [biocatalysis](Biocatalysis \"Biocatalysis\") (enzymatic methods), [biosynthesis](Biosynthesis \"Biosynthesis\") (fermentation), and, for big molecules, cell culture technology\n- Extraction from animals, microorganisms, or plants; isolation and purification, used, for example, for alkaloids, [antibacterials](Antibacterials \"Antibacterials\") (especially penicillins), and steroids\n- [Hydrolysis](Hydrolysis \"Hydrolysis\") of proteins, especially when combined with ion exchange chromatography, used, for instance, for amino acids\n\nChemical synthesis and biotechnology are most frequently used; sometimes also in combination. \n\n## Traditional chemical synthesis\n\nA large toolbox of chemical reactions is available for each step of the synthesis of a fine chemical. The reactions have been developed on laboratory scale by academia over the last two centuries and subsequently adapted to industrial scale, for instance for the manufacture of dyestuffs \u0026 pigments. The most comprehensive handbook describing organic synthetic methods is _Methods of Molecular Transformations_. About 10% of the 26,000 synthetic methods described therein are currently used on an industrial scale for fine chemicals production. [Amination](Amination \"Amination\"), [condensation](Condensation \"Condensation\"), [esterification](Esterification \"Esterification\"), [Friedelâ€“Crafts](Friedel%E2%80%93Crafts \"Friedelâ€“Crafts\"), [Grignard](Grignard_reaction \"Grignard reaction\"), [halogenation](Halogenation \"Halogenation\") (esp. chlorination), and [hydrogenation](Hydrogenation \"Hydrogenation\"), respectively reduction (both catalytic and chemical) are most frequently mentioned on the websites of individual companies. Optically active [cyanohydrins](Cyanohydrins \"Cyanohydrins\"), cyclopolymerization, [ionic liquids](Ionic_liquids \"Ionic liquids\"), [nitrones](Nitrone \"Nitrone\"), oligonucleotides, peptide (both liquid- and solid-phase), [electrochemical reactions](Electrochemical_reactions \"Electrochemical reactions\") (e.g., perfluorination) and [steroid synthesis](Steroid_synthesis \"Steroid synthesis\") are promoted by only a limited number of companies. With the exception of some [stereospecific](Stereospecific \"Stereospecific\") reactions, particularly biotechnology, mastering these technologies does not represent a distinct competitive advantage. Most reactions can be carried out in standard multipurpose plants. The very versatile [organometallic reactions](Organometallic_reactions \"Organometallic reactions\") (e.g., conversions with lithium aluminum hydride, boronic acids) may require temperatures as low as -100 Â°C, which can be achieved only in special cryogenic reaction units, either by using liquefied nitrogen as coolant or by installing a low-temperature unit. Other reaction-specific equipment, such as filters for the separation of catalysts, [ozone](Ozone \"Ozone\") or [phosgene](Phosgene \"Phosgene\") generators, can be purchased in many different sizes. The installation of special equipment generally is not a critical path on the overall project for developing an industrial-scale process of a new molecule. \n\nSince the mid-1990s the commercial importance of _[single-enantiomer](Single-enantiomer \"Single-enantiomer\")_ fine chemicals has increased steadily. They constitute about half of both existing and developmental drug APIs. In this context, the ability to synthesize [chiral](Chiral \"Chiral\") molecules has become an important competency. Two types of processes are used, namely the physical separation of the enantiomers and the stereo specific synthesis, using chiral catalysts. Among the latter, enzymes and synthetic [BINAP](BINAP \"BINAP\") (2,2'â€“Bis(diphenylphosphino)â€“1,1'â€“binaphthyl) types are used most frequently. Large volume (\u003e 103 mtpa) processes using chiral catalysts include the manufacture of the perfume ingredient l-Menthol and Syngenta's [Dual](Metolachlor \"Metolachlor\") (metolachlor) as well as BASF's [Outlook](Herbicides \"Herbicides\") (dimethenamid-P) herbicides. Examples of originator drugs, which apply asymmetric technology, are [AstraZeneca](AstraZeneca \"AstraZeneca\")'s [Nexium](Nexium \"Nexium\") (esomeprazole) and [Merck \u0026 Co](Merck_%26_Co \"Merck \u0026 Co\")'s [Januvia](Januvia \"Januvia\") (sitagliptin). The physical separation of chiral mixtures and purification of the desired enantiomer can be achieved either by classical [fractional crystallization](Fractional_crystallization_\\(chemistry\\) \"Fractional crystallization \\(chemistry\\)\") (having a \"low-tech\" image but still widely used), carried-out in standard multipurpose equipment or by various types of chromatographical separation, such as standard column, simulated moving-bed (SMB) or [supercritical fluid](Supercritical_fluid \"Supercritical fluid\") (SCF) techniques. \n\nFor _peptides_ three main types of methods are used, namely chemical synthesis, extraction from natural substances, and biosynthesis. Chemical synthesis is used for smaller peptides made of up to 30â€“40 amino acids. One distinguishes between \"liquid phase\" and \"solid phase\" synthesis. In the latter, reagents are incorporated in a resin that is contained in a reactor or column. The synthesis sequence starts by attaching the first amino acid to the reactive group of the resin and then adding the remaining amino acids one after the other. In order to ascertain a full selectivity, the amino groups have to be protected in advance. Most developmental peptides are synthesized by this method, which lends itself to automation. As the intermediate products resulting from individual synthetic steps cannot be purified, a selectivity of effectively 100% is essential for the synthesis of larger-peptide molecules. Even at a selectivity of 99% per reaction step, the purity will drop to less than 75% for a dekapeptide (30 steps). Therefore, for industrial quantities of peptides not more than 10â€“15 amino acid peptides can be made using the solid-phase method. For laboratory quantities, up to 40 are possible. To prepare larger peptides, individual fragments are first produced, purified, and then combined to the final molecule by liquid phase synthesis. Thus, for the production of Roche's anti-AIDS drug [Fuzeon](Fuzeon \"Fuzeon\") (enfuvirtide), three fragments of 10â€“12 amino acids are first made by solid-phase synthesis and then linked together by liquid-phase synthesis. The preparation of the whole 35 amino acid peptide requires more than 130 individual steps. \n\n[Microreactor](Microreactor \"Microreactor\") _Technology_ (MRT), making part of \"process intensification\", is a relatively new tool that is being developed at several universities,[6] as well as leading fine chemical companies, such as [Bayer Technology Services](Bayer_Technology_Services \"Bayer Technology Services\"), Germany; [Clariant](Clariant \"Clariant\"), Switzerland; Evonik-Degussa, Germany; [DSM](DSM_\\(company\\) \"DSM \\(company\\)\"), The Netherlands; [Lonza](Lonza_Group \"Lonza Group\"), Switzerland; PCAS, France, and [Sigma-Aldrich](Sigma-Aldrich \"Sigma-Aldrich\"), US. The latter company produces about 50 fine chemicals up to multi-kilogram quantities in microreactors. From a technological point of view, MRT, a.k.a. continuous flow reactors, represents the first breakthrough development in reactor design since the introduction of the stirred-tank reactor, which was used by Perkin \u0026 Sons, when they established a factory on the banks of what was then the Grand Junction Canal in London in 1857 to produce mauveÃ¯ne, the first-ever synthetic purple dye. For a comprehensive coverage of the subject see _Micro Process Engineering_.[7] Examples for reactions that have worked in microreactors include aromatics oxidations, [diazomethane](Diazomethane \"Diazomethane\") conversions, [Grignards](Grignard_reaction \"Grignard reaction\"), [halogenations](Halogenation \"Halogenation\"), [hydrogenations](Hydrogenation \"Hydrogenation\"), [nitrations](Nitration \"Nitration\"), and [Suzuki couplings](Suzuki_coupling \"Suzuki coupling\"). According to experts in the field, 70% of all chemical reactions could be done in microreactors; as of 2024, adoption has increased with the market exceeding USD 500 million, though only 20-30% are economically justified for fine chemicals production.[](https://www.skyquestt.com/report/microreactor-technology-market)\n\nWith the exception of some stereospecific reactions, particularly biotechnology, mastering these technologies does not represent a distinct competitive advantage. Most reactions can be carried out in standard multipurpose plants. Reaction-specific equipment, such as ozone or phosgene generators, is readily available. The installation generally is not a critical path on the overall project for developing an industrial-scale process of a new molecule. \n\nWhereas the overall demand for outsourced pharmaceutical fine chemicals is expected to increase moderately (_see_ Chapter 8), the estimated annual growth rates for the above-mentioned niche technologies are much higher. Microreactors and the SMB separation technology are expected to grow at a rate of even 50â€“100% per year. The total size of the accessible market typically does not exceed a few hundred tons per year at best. \n\n## Biotechnology\n\nIndustrial biotechnology, also called \"[white biotechnology](White_biotechnology \"White biotechnology\")\", is increasingly impacting the chemical industry, enabling both the conversion of [renewable resources](Renewable_resources \"Renewable resources\"), such as sugar or vegetable oils, and the more efficient transformation of conventional raw materials into a wide range of commodities (e.g., [cellulose](Cellulose \"Cellulose\"), [ethanol](Ethanol \"Ethanol\") and [succinic acid](Succinic_acid \"Succinic acid\")), fine chemicals (e.g. 6-aminopenicillanic acid), and specialties (e.g., food and feed additives).[8] As opposed to green and red biotechnology, which relate to agriculture and medicine, respectively, white biotechnology seeks to improve the economic and sustainable production of existing products, and provide access to new products, especially biopharmaceuticals. As of 2024, revenues from white biotechnology account for approximately 4-5%, or USD 250-350 billion, of the global chemical market of about USD 6.7 trillion, with projections to reach USD 400-600 billion by 2030. In ten to 15 years from 2011 it was expected that most amino acids and vitamins and many specialty chemicals would be produced by means of biotechnology; as of 2025, a significant portion (over 50%) of amino acids and vitamins are now biotech-derived, with ongoing expansion into specialties. Three very different process technologies -biocatalysis, biosynthesis (microbial fermentation), and cell cultures- are used.[](https://www.precedenceresearch.com/white-biotechnology-market) [](https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/)\n\n[Biocatalysis](Biocatalysis \"Biocatalysis\"), a.k.a. [biotransformation](Biotransformation \"Biotransformation\") and [bioconversion](Bioconversion \"Bioconversion\"), makes use of natural or modified isolated [enzymes](Enzymes \"Enzymes\"), enzyme extracts, or whole-cell systems for enhancing the production of small molecules. It has much to offer compared to traditional organic synthesis. The syntheses are shorter, less energy intensive and generate less waste, hence are both environmentally and economically more attractive. About 2/3 of chiral products produced on large industrial scale are already made using biocatalysis. In the manufacture of fine chemicals, enzymes represent the single most important technology for radical cost reductions. This is particularly the case in the synthesis of molecules with chiral centres. Here, it is possible to substitute the formation of a salt with a chiral compound, e.g., (+)-Î±-phenylethylamine, crystallization, salt breaking and recycling of the chiral auxiliary, resulting in a theoretical yield of not more than 50%, with a one step, high yield reaction under mild conditions and resulting in a product with a very high [enantiomeric excess](Enantiomeric_excess \"Enantiomeric excess\") (ee). An example is [AstraZeneca](AstraZeneca \"AstraZeneca\")'s blockbuster drug [Crestor](Crestor \"Crestor\") (rosuvastatin), see Chemical / Enzymatic Synthesis of Crestor. \n\nChemical / Enzymatic Synthesis of Crestor (rosuvastatin)\n\nFurther examples of modern drugs, where enzymes are used in the synthesis, are [Pfizer](Pfizer \"Pfizer\")'s [Lipitor](Lipitor \"Lipitor\") (atorvastatin), where the pivotal intermediate R-3-Hydroxy-4-cyanobutyrate is now made with a [nitrilase](Nitrilase \"Nitrilase\"), and Merck \u0026 Co.'s [Singulair](Singulair \"Singulair\") (montelukast), where the reduction of a ketone to S-alcohol, which had required stoichiometric amounts of expensive and moisture sensitive \"(-)-DIP chloride\" is now replaced by a ketoreductase enzyme catalyst step. Similar rewarding switches from chemical steps to enzymatic ones have also been achieved in steroid synthesis. Thus, it has been possible to reduce the number of steps required for the synthesis of [Dexamethasone](Dexamethasone \"Dexamethasone\") from bile from 28 to 15. Enzymes differ from chemical catalysts particularly with regard to [stereoselectivity](Stereoselectivity \"Stereoselectivity\"), [regioselectivity](Regioselectivity \"Regioselectivity\"), and [chemoselectivity](Chemoselectivity \"Chemoselectivity\"). They can also be modified (\"reshuffled\") for specific reactions, for use in chemical synthesis. \"[Immobilized enzymes](Immobilized_enzymes \"Immobilized enzymes\")\" are those fixed on solid supports. They can be recovered by filtration after completion of the reaction. Conventional plant equipment can be used with no, or only modest, adaptations. The _International Union of Biochemistry and Molecular Biology_ (IUBMB)[9] has developed a classification for enzymes. The main categories are [Oxidoreductases](Oxidoreductases \"Oxidoreductases\"), [Transferases](Transferases \"Transferases\"), [Hydrolases](Hydrolases \"Hydrolases\"), [Lipases](Lipases \"Lipases\") (subcategory), [Lyases](Lyases \"Lyases\"), Isomerases and [Ligases](Ligases \"Ligases\"), Companies specializing in making enzymes are [Novozymes](Novozymes \"Novozymes\"), [Danisco](Danisco \"Danisco\") (Genencor). [Codexis](Codexis \"Codexis\") is the leader in modifying enzymes to specific chemical reactions. The highest-volume chemicals made by biocatalysis are [bio-ethanol](Bio-ethanol \"Bio-ethanol\") (70 million metric tons), [high-fructose corn syrup](High-fructose_corn_syrup \"High-fructose corn syrup\") (2 million metric tons); [acrylamide](Acrylamide \"Acrylamide\"), [6-aminopenicillanic acid](6-aminopenicillanic_acid \"6-aminopenicillanic acid\") (APA), [L-lysine](L-lysine \"L-lysine\") and other amino acids, [citric acid](Citric_acid \"Citric acid\") and [niacinamide](Niacinamide \"Niacinamide\") (all more than 10,000 metric tons). \n\n_[Biosynthesis](Biosynthesis \"Biosynthesis\")_ i.e. the conversion of organic materials into fine chemicals by microorganisms, is used for the production of both small molecules (using enzymes in whole cell systems) and less complex, non-glycosylated big molecules, including peptides and simpler proteins. The technology has been used for 10,000 years to produce food products, like alcoholic beverages, cheese, yogurt, and vinegar. In contrast to biocatalysis, a biosynthetic process does not depend on chemicals as starting materials, but only on cheap natural feedstock, such as glucose, to serve as nutrient for the cells. The enzyme systems triggered in the particular microorganism strain lead to the excretion of the desired product into the medium, or, in the case of HMW peptides and proteins, to the accumulation within so-called [inclusion bodies](Inclusion_bodies \"Inclusion bodies\") in the cells. The key elements of fermentation development are strain selection and optimization, as well as media and process development. Dedicated plants are used for large-scale industrial production. As the volume productivity is low, the bioreactors, called fermenters, are large, with volumes that can exceed 250 m3. Product isolation was previously based on large-volume extraction of the medium containing the product. Modern isolation and membrane technologies, like [reverse osmosis](Reverse_osmosis \"Reverse osmosis\"), ultra- and nano-filtration, or [affinity chromatography](Affinity_chromatography \"Affinity chromatography\") can help to remove salts and by-products, and to concentrate the solution efficiently and in an environmentally friendly manner under mild conditions. The final purification is often achieved by conventional chemical crystallization processes. In contrast to the isolation of small molecules, the isolation and purification of microbial proteins is tedious and often involves a number of expensive large-scale chromatographic operations. Examples of large-volume LMW products made by modern industrial microbial biosynthetic processes are [monosodium glutamate](Monosodium_glutamate \"Monosodium glutamate\") (MSG), [vitamin B2](Vitamin_B2 \"Vitamin B2\") (riboflavin), and [vitamin C](Vitamin_C \"Vitamin C\") (ascorbic acid). In vitamin B2, riboflavin, the original six- to eight-step synthetic process starting from [barbituric acid](Barbituric_acid \"Barbituric acid\") has been substituted completely by a microbial one-step process, allowing a 95% waste reduction and an approximately 50% manufacturing cost reduction. In ascorbic acid, the five-step process (yield â‰ˆ 85%) starting from [D-glucose](D-glucose \"D-glucose\"), originally invented by [Tadeus Reichstein](Tadeus_Reichstein \"Tadeus Reichstein\") in 1933, is being gradually substituted by a more straightforward fermentative process with 2-ketogluconic acid as pivotal intermediate.[10] After the discovery of penicillin in 1928 by Sir Alexander Fleming from colonies of the bacterium [Staphylococcus aureus](Staphylococcus_aureus \"Staphylococcus aureus\"), it took more than a decade before a powdery form of the medicine was developed. Since then, many more antibiotics and other [secondary metabolites](Secondary_metabolites \"Secondary metabolites\") have been isolated and manufactured by microbial fermentation on a large scale. Some important antibiotics besides penicillin are [cephalosporins](Cephalosporins \"Cephalosporins\"), [azithromycin](Azithromycin \"Azithromycin\"), [bacitracin](Bacitracin \"Bacitracin\"), [gentamicin](Gentamicin \"Gentamicin\"), [rifamycin](Rifamycin \"Rifamycin\"), [streptomycin](Streptomycin \"Streptomycin\"), [tetracycline](Tetracycline \"Tetracycline\"), and [vancomycin](Vancomycin \"Vancomycin\"). \n\n### Cell Cultures\n\n_Cell Cultures_ Animal or plant cells, removed from tissues, will continue to grow if cultivated under the appropriate nutrients and conditions. When carried out outside the natural habitat, the process is called cell culture. _Mammalian cell culture_ fermentation, also known as [recombinant DNA technology](Recombinant_DNA_technology \"Recombinant DNA technology\"), is used mainly for the production of complex big molecule therapeutic proteins, a.k.a. biopharmaceuticals.[11] The first products made were [interferon](Interferon \"Interferon\") (discovered in 1957), [insulin](Insulin \"Insulin\"), and [somatropin](Somatropin \"Somatropin\"). Commonly used cell lines are [Chinese hamster ovary](Chinese_hamster_ovary \"Chinese hamster ovary\") (CHO) cells or plant cell cultures. Several biopharmaceuticals now exceed thousands of kilograms per year in production, including legacy products like rituximab (Rituxan), etanercept (Enbrel), and infliximab (Remicade), as well as newer ones like adalimumab (Humira) and pembrolizumab (Keytruda). Fine chemical production by mammalian cell culture is a much more demanding operation than conventional biocatalysis and â€“synthesis. The bioreactor batch requires more stringent controls of operating parameters, since mammalian cells are heat and shear sensitive. In addition, the growth rate of mammalian cells is very slow, lasting from days to several months. While there are substantial differences between microbial and mammalian technologies (e.g., the volume / value relationships are 10 $/kg and 100 tons for microbial, 1,000,000 $/kg and 10 kilograms for mammalian technology; the cycle times are 2â€“4 and 10â€“20 days, respectively), they are even more pronounced between mammalian and synthetic chemical technology (see Table 1). \n\n**Table 1: Key Characteristics of Biotechnological and Chemical API Manufacturing[12] ** (indicative as of 2024)\n\n| Characteristic | Mammalian cell technology | Chemical technology |\n| --- | --- | --- |\n| Worldwide reactor volume | \u003e10,000 m3 (fermenters) | â‰ˆ 80,000 m3 |\n| Investment per m3 reactor volume | â‰ˆ $5 million | â‰ˆ $500,000 |\n| Production per m3 reactor volume and year | several 100-1000 kg | several 1000 kg |\n| Sales per m3 reactor volume and year | â‰ˆ $5 â€“ 10 million | â‰ˆ $250,000 - 500,000 |\n| Value of 1 batch | â‰ˆ $5 million (20,000 liter fermenter) | â‰ˆ $500,000 |\n| Product concentration in reaction mixture | â‰ˆ 5 - 10 g / Liter | â‰ˆ 100 g / Liter (10%) |\n| Typical reaction time | â‰ˆ 20 days | â‰ˆ 6 hours |\n| Process development time | â‰ˆ 3 years (one step) | 2 â€“ 3 months per step |\n| Capacity expansion projects | many, doubling of actual capacity | few, mainly in Far East |\n| Governing rules | cGMP, BLA [Biological License Application (product specific)] | cGMP, ISO 14000 |\n| Scale-up factor (1st lab process to industrial scale) | â‰ˆ 109 (Î¼g â†’ 1 ton) | â‰ˆ 106 (10 g â†’ 10 tons) |\n| Plant construction time | 4 â€“ 6 years | 2 â€“ 3 years |\n| share of outsourcing early stage | 60% | 25% of chemical production |\n| share of outsourcing commercial | 50% | 45% of chemical production |\n\n[](https://www.evitria.com/journal/cho-cells-first-choice-ab-production/) [](https://www.bioprocessintl.com/supply-chain/biomanufacturing-supply-and-demand-industry-trends-and-projected-impacts) [](https://www.biopharminternational.com/view/outsourcing-hits-record-levels-all-bioprocess-platforms)\n\nThe mammalian cell production process, as used for most biopharmaceuticals, is divided into the four main steps: (1) Cultivation, i.e. reproduction of the cells; (2) Fermentation, i.e. the actual production of the protein, typically in 10,000 Liter, or multiples, bioreactors; (3) Purification, i.e. separation of the cells from the culture medium and purification, mostly by chromatography, (4) Formulation, i.e. conversion of the sensitive proteins to a stable form. All steps are fully automated. The low productivity of the [animal culture](Animal_culture \"Animal culture\") makes the technology expensive and vulnerable to contamination. Actually, as a small number of bacteria would soon outgrow a larger population of animal cells. Its main disadvantages are low volume productivity and the animal provenance. It is conceivable that other technologies, particularly plant cell production, will gain importance in future. Given the fundamental differences between the two process technologies, plants for mammalian cell culture technologies have to be built ex novo. \n\nThe pros and cons of an involvement of a fine chemical company in cell culture technology are listed below: \n\n**Pros:** \n\n- Strong growth of demand: As of 2024, biopharmaceuticals account for approximately USD 450 billion, or 30% of the total pharmaceutical market. They continue to grow at rates of 8-10% per year, outpacing small-molecule drugs.[](https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market)\n- The likelihood of developing a new biopharmaceutical successfully is significantly greater than in traditional drug development. Biopharmaceuticals have a higher success rate, approximately 13% from preclinical to approval, compared to about 5% for small-molecule drugs.[](https://www.appliedclinicaltrialsonline.com/view/large-vs-small-molecule-success-rates)\n- The traditionally large share of outsourcing.\n- Small number of custom manufacturers with industrial-scale manufacturing capabilities in this demanding technology. In the Western hemisphere, primarily [Boehringer-Ingelheim](Boehringer-Ingelheim \"Boehringer-Ingelheim\") of Germany and [Lonza](Lonza_Group \"Lonza Group\") of Switzerland; in the Eastern hemisphere [Nicholas Piramal](Nicholas_Piramal \"Nicholas Piramal\") of India (through the acquisition of a former Avecia operation) and the joint ventures between AutekBio and Beijing E-Town Harvest International in China and between [Biocon](Biocon \"Biocon\") in India and [Celltrion](Celltrion \"Celltrion\") in South Korea.\n- Same customer category: life science, especially the pharmaceutical industry.\n- Similar business types: custom manufacturing of proprietary drugs; opportunities for generic versions, called [biosimilars](Biosimilars \"Biosimilars\").\n- Similar regulatory environment: FDA regulations, especially GMP.\n- Existing infrastructure (utilities, etc.) can be used.\n\nAs of 2024, eight of the top ten drugs by sales are biopharmaceuticals, including Humira (adalimumab), Keytruda (pembrolizumab), and Dupixent (dupilumab).[](https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/)\n\n**Cons:** \n\n- High entry barriers because of demanding technology. The construction of a large-scale plant for the production of biopharmaceuticals by cell culture fermentation costs around $500 million and takes four to six years.\n- As the specifications of the plant and process types for biopharmaceuticals differ substantially from traditional chemical synthesis, they cannot be produced in conventional multipurpose fine chemical plants.\n- High financial exposure: (1) high capital intensity ('massive investments are needed at a time when chances of success are still very low' and (2) risk of batch failures ([contamination](Contamination \"Contamination\")).\n- Unlike the biopharmaceutical start-ups, the emerging big biopharmaceutical companies are adopting the same opportunistic outsourcing policy as larger pharmaceutical companies. Thus, [Amgen](Amgen \"Amgen\"), [Biogen Idec](Biogen_Idec \"Biogen Idec\"), [Eli Lilly](Eli_Lilly \"Eli Lilly\"), [Johnson \u0026 Johnson](Johnson_%26_Johnson \"Johnson \u0026 Johnson\") (J\u0026J), [Medimmune](Medimmune \"Medimmune\"), [Novartis](Novartis \"Novartis\"), [Roche](Hoffmann-La_Roche \"Hoffmann-La Roche\")/[Genentech](Genentech \"Genentech\") and [Pfizer](Pfizer \"Pfizer\") are investing heavily in in-house manufacturing capacity. With three plants in the US, two in Japan and one each in Germany and Switzerland, Roche has the largest production capacity.\n- New developments in expression systems for mammalian and plant cell technology could reduce capacity requirements substantially. Actually, the titer in large-scale mammalian production, actually 2â€“3 grams/liter. is expected to double to 5â€“7 by 2015 and once more to 10 by 2020. Furthermore, the widespread application of 'single-use disposable bioprocessing technology', considered by experts as 'the hottest buzz in town'. It advantageously substitutes for stainless steel production trains, at least for short production campaigns.\n- New transgenic production systems are emerging. They (e.g. transgenic moss, [lemna](Lemna \"Lemna\"), fungal or yeast expression systems, [transgenic animals](Transgenic_animals \"Transgenic animals\") and plants, such as tobacco plants possess the potential to become economically and industrially successful.\n- Legislation and regulation of biotechnology is not well defined yet and leads to differences in interpretation and other uncertainties. In the US, legislation is not yet in place for biosimilars, the generic counterpart of generics in small molecule pharmaceuticals.\n\nThe inherent risks of the mammalian cell technology led several companies to opt out of mammalian cell technology or to substantially reduce their stake. Examples are Cambrex and Dowpharma in the US, [Avecia](Avecia \"Avecia\"), [DSM](DSM_\\(company\\) \"DSM \\(company\\)\") and Siegfried in Europe and WuXi App Tech in China. In conclusion, biocatalysis should be, or become, part of the technology toolbox of any fine chemical company. Mammalian cell culture fermentation, on the other hand, should be considered only by large fine chemical companies with a full war chest and a long-term strategic orientation.\n# The Fine Chemical Industry\n\n## The Industry\n\nWithin the chemical universe, the fine chemical industry is positioned between the commodity, their suppliers, and specialty chemical industries, their customers. Depending on the services offered, there are two types of fine chemical companies. The _Fine Chemical Companies_ are active in industrial scale production, both of standard and exclusive products. If the latter prevails, they are referred to as Fine Chemical / _Custom Manufacturing Organizations (CMOs)_. The main assets of the [Contract Research Organizations](Contract_research_organization \"Contract research organization\") (CROs) are their research laboratories. CRAMS; Contract Research and Manufacturing Organizations[14] are hybrids (see section 4.2). \n\n### Fine Chemical / Custom Manufacturing Companies\n\n_Fine chemical / Custom Manufacturing companies_ in the narrower sense are active in process scale up, pilot plant (trial) production, industrial-scale exclusive and non-exclusive manufacture and marketing. Their product portfolios comprise exclusive products, produced by custom manufacturing, as main activity, non-exclusive products, e.g. API-for Generics, and standard products. Characteristics are high asset intensity, batch production in campaigns in multipurpose plants, above-industry-average R\u0026D expenditures and close, multi-level and multi-functional relationships with industrial customers. The industry is very fragmented. 2000 â€“ 3000 fine chemical companies exist globally, extending from small, \"garage-type\" outfits in China making just one product, all the way to the big, diversified enterprises, resp. units. As of 2024, the global fine chemicals market is estimated at around $200 billion, with significant growth in Asia and a focus on sustainable manufacturing. The main reason for the fragmentation is the lack of economy of scale (see below). \n\nThe industry is subject to a high degree of regulation[15] even more so than the chemical industry as a whole, particularly if pharmaceutical fine chemical production is involved. The most important regulatory authorities are the _(US) Food and Drug Administration (FDA)_ and _National Medical Products Administration (NMPA)_, respectively. Their main responsibilities comprise formulating comprehensive supervision policies (\"[Good Manufacturing Practice](Good_Manufacturing_Practice \"Good Manufacturing Practice\")\") and control the implementation, to be in charge of drug registration, draw up criteria for marketing authorization and formulate national essential medicines lists. The European correspondent is the _[European Medicines Agency](European_Medicines_Agency \"European Medicines Agency\") (EMA)_, which is mainly responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. The role of [REACH](Registration%2C_Evaluation%2C_Authorisation_and_Restriction_of_Chemicals \"Registration, Evaluation, Authorisation and Restriction of Chemicals\") (Registration, Evaluation, Authorization and Restriction of Chemicals) is self-explanatory. The _[U.S. Pharmacopeia](U.S._Pharmacopeia \"U.S. Pharmacopeia\")_[16] codifies quality standards for Active Pharmaceutical Ingredients. As these standards are observed worldwide, they contribute also to the emergence of a uniform worldwide set-up of the top tier fine chemical companies. In terms of size, resources, and complexity of the chemical process technologies mastered, the fine chemical companies can be broadly divided into three segments, each of them accounting for approximately the same turnover, namely about $10 billion (as of 2009). The top tier, about twenty, has sales in excess of $250 million per year (see Table 3). Most are not pure players but divisions or b.u.'s of large, multinational companies. Their share varies between one percent or less for [BASF](BASF \"BASF\") and [Pfizer](Pfizer \"Pfizer\"), all the way to 100% for Cambrex, USA; [Divi's Laboratories](Divi's_Laboratories \"Divi's Laboratories\"), India, and F.I.S. Italy. All have extensive resources in terms of chemists and other specialists, plants, process knowledge, backwards integration, international presence, etc. \n\n**Table 3: Leading Fine Chemical Companies (resp. Units) (as of 2009)[17]**\n\n| Rank | Company | Location | Sales 2009 ($ million) | F.C. unit | Sales 2009 ($ million) | Remarks |\n|------|---------|----------|------------------------|-----------|------------------------|---------|\n| 1 | Lonza | Switz. | 2600 | Custom. Manuf. | 1370 | HMW/LMW~55/45 |\n| 2 | Boehringer-Ingelheim | Germany | 18,300 | Fine Chem.1 | 950 | HMW/LMW=84/16 |\n| 3 | DSM | The Netherlands | 11,300 | Fine Chem.1 | 850aE |  |\n| 4 | Sumitomo Chemical | Japan | 17,420 | Fine Chem.1 | 730 | incl. some polymer additives |\n| 5 | Merck KGaA | Germany | 11,200 | Life Science Solutions | 580 | #1 in liquid crystals |\n| 6 | Sigma-Aldrich | USA | 2148 | SAFC | 570E |  |\n| 7 | BASF | Germany | 73,000 | Fine Chem.1 | 5502E | incl. some excipients |\n| 8 | CSPC Shijiazhuang Pharmaceutical Group | China | 1500 | Fine Chem.1 | 550E | API-for-Generics, e.g. HIV / AIDS, sartans |\n| 9 | Lanxess | Germany | 7280 | Saltigo | 550E | a.o. agrochemicals |\n| 10 | Albemarle | USA | 2005 | Fine Chem.1 | 5002 | a.o. ibuprofen |\n| **Total Top Ten** |  |  |  |  | **~7200** |  |\n\nThe combined revenues of the top 20 fine chemical companies amounted to $10 billion in 2009, representing about 30% of the figure for the whole industry (external production). The external fine chemicals market has since expanded significantly, estimated at over $80 billion as of 2024. The leading companies are typically divisions of large, diversified chemical companies. In terms of geography, 9 of the top 20 are located in Europe, which is recognized as the cradle of the fine chemical industry. This is e.g. the case for the world's #1 company, Lonza, headquartered in Basel. Switzerland. Custom manufacturing prevails in northern Europe; the manufacture of active substances for generics, in southern Europe. The second largest geographic area is Asia, housing 7 of the top 20. With 4 large companies, the US rank last. \n\nWhereas the European and U.S. pharma industry constitutes the main customer base for most fine chemical companies, some have a significant share of products and services for the agrochemical industry. Examples are Archimica, CABB, Saltigo (all Germany), DSM (The Netherlands) and Hikal, India. Several large pharmaceutical companies market fine chemicals as subsidiary activity to their production for captive use, e.g. [Abbott](Abbott_Laboratories \"Abbott Laboratories\"), USA; [Bayer Schering Pharma](Bayer_Schering_Pharma \"Bayer Schering Pharma\"), [Boehringer-Ingelheim](Boehringer-Ingelheim \"Boehringer-Ingelheim\"), Germany; [Daiichi-Sankyo](Daiichi-Sankyo \"Daiichi-Sankyo\") (after the takeover of [Ranbaxy](Ranbaxy \"Ranbaxy\")), Japan; Johnson \u0026 Johnson, USA; [Merck KGaA](Merck_KGaA \"Merck KGaA\"), Germany; [Pfizer](Pfizer \"Pfizer\") (formerly Upjohn), US. Large fine chemical companies, in contrast to mid-sized and small ones, are characterized by \n\n- _A Lack of Economy in Size_. As most fine chemicals are produced in quantities of not more than a few 10 tons per year in multipurpose plants, there is little or no economy of size. The reactor trains of these plants are similar throughout the industry (see production train of a multipurpose plant). Regardless of the size of the companies, their main constituents, the reaction vessels, have a median size of the 4â€“6 m3. Various products are made throughout a year in campaigns. Therefore, the unit cost per m3 per hour does practically not vary with the size of the company.\n- _A Dichotomy between Ownership and Management_. The company's shares are listed on stock exchanges, and their performance is scrutinized by the financial community. Postponement of a single important shipment can affect a quarterly result. In the small and mid-sized companies the owners typically are the major shareholders, often members of the same family. Their shares are not traded publicly and fluctuations in their financial performance are more easily coped with.\n- _Complicated Business Processes_. Flexibility and Responsiveness are in jeopardy. Customer complaints, for instance, are difficult to resolve in a straightforward manner.\n- _A Heterogeneous portfolio of small companies, accumulated over time through M \u0026A activities_. The key functions, such as production, R\u0026D, and M\u0026S, are located on different sites, often in different countries.\n- _A Cohabitation with Other Units_.\n\nA comprehensive list of about 1400 fine chemical companies (including traders) can be found in the \"event catalogue\" of the CPhI exhibition.[18]\n\nThe _second tier_ consists of several dozens of _midsized_ companies with sales in the range of $100â€“$250 million per year. Their portfolios comprise both custom manufacturing and API-for-generics. They include both independents and subsidiaries of major companies. A number of these companies are privately owned and have grown mainly by reinvesting the profits. Examples are [Bachem](Bachem_Holding \"Bachem Holding\"), Switzerland; Dishman, India; F.I.S. and Poli Industria Chimica, Italy; Hikal, India, and [Hovione](Hovione \"Hovione\"), Portugal. Customers prefer to do business with mid-sized companies, because communications are easier â€”they typically deal directly with the decision makerâ€” and they can better leverage their purchasing power. The _third tier_ includes thousands of _small independents_ with sales below $100 million per year. Most of them are located in Asia. They often specialize in niche technologies. The minimum economical size of a fine chemical company depends on the availability of infrastructure. If a company is located in an industrial park, where analytical services; utilities, safety, health, and environmental (SHE) services, and warehousing are readily available, there is practically no lower limit. New fine chemical plants have come on-stream mostly in Far East countries over the past few years. Their annual turnover rate rarely exceeds $25 million. All big and medium-size fine chemical companies have cGMP-compliant plants that are suitable for the production of pharmaceutical fine chemicals. With the exception of biopharmaceuticals, which are manufactured by only a few selected fine chemical companies, (see section 3.2.2), the technology toolboxes of all these companies are similar. This means that they can carry out practically all types of chemical reactions. They differentiate on the basis of the breadth and quality of the service offering. \n\n### Contract Research Organizations\n\nContract research organizations (CROs) provide services to the life science industries along product development. There are more than 2000 CROs operating worldwide, representing revenues of approximately $85 billion (as of 2024). One distinguishes between \"Product\" and \"Patient\" CROs. Whereas the production sites of CMOs are multipurpose plants, allowing for the production of tens to hundreds of tons of fine chemicals, the work places of patient CROs are the test persons (volunteers) for the clinical trials and those of the product CROs are the laboratory benches. Major customers for CRO services are the large global pharmaceutical companies. Half a dozen companies (Pfizer, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Johnson \u0026 Johnson, and Merck \u0026 Co.) alone absorb about one third of all CRO spending. As for CMOs also for CROs, biotech start-up companies with their dichotomy between ambitious drug development programs and limited resources are the second most promising prospects. Product CROs (chemical CROs) are providing primarily sample preparation, process research and development services. An overlap between the latter and CMOs exists with regard to pilot plants (100 kg quantities), which are part of the arsenal of both types of enterprise. There are more 100 product CROs. Most of them are privately held and have revenues of $10â€“$20 million per year or less, adding up to a total business in the range of $1.5-$2 billion. Their tasks are described in Chapter 5, Examples of are: \n\n- In _North America_ : Alphora; Delmar; NAEJA, all Canada. AMRI; Aptuit; Cambridge Major; ChemBridge; [Innocentive](Innocentive \"Innocentive\"); Irix Pharmaceuticals, PharmEco, all USA.\n- In _Europe_ ; Carbogen-Amcis, Switzerland; Chemcomm, Germany; [ChemDiv](ChemDiv \"ChemDiv\"), Russia; Clauson-Kaas, Denmark; Enamine Ltd, Ukraine; Girindus, Germany; Nerviano Medical Sciences, Italy; [Recipharm](Recipharm \"Recipharm\"), Sweden; Serichim, Italy; Solvias, Switzerland, Netherlands.\n- In _Asia_ : BioDuro, Medicilon, Pharmaron; [WuXi AppTec](WuXi_AppTec \"WuXi AppTec\"), all China; Acoris; Aptuit Laurus; Biocon / Syngene; Chembiotek; Chempartner; ProCitius, all India; NARD Institute, [Riken](Riken \"Riken\"), both Japan.\n\nThe business of CROs is usually done through a \"pay for service\" arrangement. Contrary to manufacturing companies, invoicing of CROs is not based on unit product price, but on full-time equivalents (FTEs), that is, the cost of a scientist working one year on a given customer assignment. Companies offering both contract research and manufacturing services (CRAMS) combine the activities of CROs and CMOs. Their history is either a forward integration of a CRO, which adds industrial scale capabilities or backwards integration of a CMO. As there are only limited synergies (e.g. \u003e 90% of the projects end at the sample preparation stage). It is questionable, though, whether one-stop shops really fulfil a need. Actually, the large fine chemical companies consider the preparation of samples more as marketing tool (and expense ...) rather than a profit contributor. \n\nThe offerings of Patient CROs (Clinical CROs) comprise more than 30 tasks addressing the clinical part of pharmaceutical development at the interface between drugs, physicians, hospitals, and patients, such as the clinical development and selection of lead new drug compounds. As [clinical trials](Clinical_trials \"Clinical trials\") represent the largest expense in pharmaceutical research, the market for patient CROs is larger than for their product counterparts. Thus, the sales of the top tier firms, IQVIA, ICON plc, Parexel, PPD (part of Thermo Fisher Scientific), Charles River Laboratories, all USA-based or global, are in the $5â€“$15 billion range (as of 2023), whereas the largest product CROs have revenues of a few 100 million dollars.\n# Research and development\n\nThe overall emphasis of fine chemical R\u0026D is more on development than on research. Recent developments include the integration of artificial intelligence (AI) for predicting chemical properties, optimizing synthetic routes, and accelerating discovery, potentially reducing R\u0026D costs by up to 40% and development time by 50%.[30] Additionally, frameworks like the European Union's Safe and Sustainable by Design (SSbD) initiative guide the development of chemicals with minimized environmental and health impacts, promoting innovation in sustainable processes as of 2024.[41][22] The main tasks are (1) designing, respectively duplicating and adapting in case of custom manufacture, and developing laboratory procedures for new products or processes; (2) transferring the processes from the laboratory via [pilot plant](Pilot_plant \"Pilot plant\") to the industrial scale (the scale up factor from a 10g sample to a 1-ton batch is 100,000); and (3) to optimize existing processes. At all times during this course of action it has to be ensured that the four critical constraints, namely, economics, timing, safety, ecology and sustainability are observed . R\u0026D expenditures in the fine chemical industry are higher than in the commodities industry. They represent around 5â€“10% versus 2â€“5% of sales. On the business side, product innovation must proceed at a more rapid pace, because life cycles of fine chemicals are shorter than those of commodities. Therefore, there is an ongoing need for substitution of obsolete products. On the technical side, the higher complexity of the products and the more stringent regulatory requirements absorb more resources. Many economic and technical parameters have been proposed to enable a meaningful assessment of single projects and project portfolios. Examples are attractiveness, strategic fit, innovation, gross/net present value, expected profits, R\u0026D expenditures, development stage, probability of success, technology fit, potential conflicts with other activities of the company and realization time. Most of these parameters cannot be determined quantitatively, at least during the early phases of a project. The best way to take advantage of a project portfolio is to develop and use it in an iterative way. By comparing the entries at regular intervals, for instance, every 3 months, the directions that the projects take can be visualized. If a negative trend persists with one particular project, the project should be put on the watch list. \n\n## Objectives\n\nR\u0026D has to manage the following functions in order to deliver the requested services: *[_Literature_ and Patent Research](Literature \"Literature\")*. Provisions have to be made for a periodic examination of all acquired research results to safeguard [Intellectual Property Rights](Intellectual_Property_Rights \"Intellectual Property Rights\") (IPR) and to determine whether patent applications are indicated. Patent research is particularly important for evaluation of the feasibility of taking up R\u0026D for new APIs-for-generics. *[_Process Research_](Process_Research \"Process Research\")* has to design new synthetic routes and sequences. Two approaches are feasible. For simple molecules, the \"bottom-up\" approach is the method of choice. The researcher converts a commercially available starting material and sequentially adds more reagents until the target molecule is synthesized. For more complex molecules, a \"top-down\" approach, also known as retro synthesis, or de-construction, is chosen. Key fragments of the target molecule are first identified, then synthesized individually, and finally combined to form the desired molecule through convergent synthesis. *[_Process Development_](Process_Development \"Process Development\")* focuses on the design of new, efficient, stable, safe, and scalable synthetic routes to a target fine chemical. It represents an essential link between process research and commercial production. The resulting \"base process\" description provides the necessary data for the determination of preliminary raw material and product specifications, the manufacture of semi commercial quantities in the pilot plant, the assessment of the ecological impact, the regulatory submissions and [technology transfer](Technology_transfer \"Technology transfer\") to manufacture at industrial scale, and an estimate of the manufacturing costs in an industrial-scale plant. If the base process is provided by the customer as part of the technology transfer, process, research has to optimize it so that it can be transferred to the bench-scale laboratory or pilot plant. Furthermore, it has to be adapted to the specific characteristics of available production trains. *[_Bench-scale Laboratory, kg-lab and Pilot Plant Development_](Bench-scale_Laboratory \"Bench-scale Laboratory\").*[19] Depending on the volume requirements, three different types of equipment are used for process research, development and optimization, namely bench-scale laboratories for gram to 100 gram, kilo-labs for kg to 10 kg and pilot plants for 100 kg to ton quantities. Particularities of laboratory processes that have to be eliminated include the use of large numbers of [unit operations](Unit_operations \"Unit operations\"), dilute reaction mixtures, vast quantities of solvents for extraction, evaporation to dryness, drying of solutions with hygroscopic salts. Although modern [reaction calorimeters](Reaction_calorimeters \"Reaction calorimeters\") consent to foresee the effects of these different conditions to a certain extent, a direct transfer of a process from the laboratory to the industrial scale is not recommended, because of the inherent safety, environmental, and economic risks. In development, the viability of the process on a semi commercial scale has to be demonstrated. Trial quantities of the new fine chemical have to be manufactured for market development, clinical tests, and other requirements. The necessary data have to be generated to enable the engineering department to plan the modifications of the industrial-scale plant and in order to calculate production costs for the expected large-volume requirements. Both equipment and plant layout of the pilot plant reflect those of an industrial multipurpose plant, except for the size of reaction vessels (bench-scale laboratory ~10â€“60 liters; pilot plant ~100â€“2500 liters) and the degree of process automation. Before the process is ready for transfer to the industrial-scale plant, the following activities have to be completed: Adaptation of the laboratory process to the constraints of a pilot plant, hazard and operability (HAZOP) analysis, execution of demonstration batches. The main differences between laboratory synthesis and industrial scale production are shown in Table 4. \n\n**Table 4: Laboratory Synthesis vs. Industrial Scale Process[20]**\n\n| Task              | Laboratory synthesis          | Industrial scale process      |\n|-------------------|-------------------------------|-------------------------------|\n| Operator          | Laboratory chemist            | Chemical engineer             |\n| Economy           | Yield                         | Throughput (kg/m3/hour)       |\n| Units             | G, mL, mol; min. hours        | Kg, ton, hours, shift         |\n| Equipment         | Glass flask                   | Stainless steel, glass lined  |\n| Process control   | Manual                        | Automatic [reaction vessel]   |\n| Critical path     | Reaction time                 | Heating / cooling             |\n| Liquid handling   | Pouring                       | Pumping                       |\n| Liquid / solid sep. | Filtration                  | Centrifugation                |\n\nIn case of cGMP fine chemicals also a [process validation](Process_validation \"Process validation\") is required. It consists of the three elements [process design](Process_design \"Process design\"), [process qualification](Process_qualification \"Process qualification\") and [continued process verification](Continued_process_verification \"Continued process verification\"). *[_Process Optimization_](Process_Optimization \"Process Optimization\")*. Once a new chemical process has been introduced successfully on an industrial scale, process optimization is called upon to improve the economics. As a rule of thumb it should be attempted to reduce the costs of goods sold (COGS) by 10-20%, every time the yearly production quantity has doubled. The task extends from fine tuning the currently used synthetic method all the way to the search for an entirely different second generation process. Specific provisions are the increase of overall yield, the reduction of the number of steps, raw material cost, solvent, catalyst, enzyme consumption, environmental impact. \n\n## Project management\n\nThere are two main sources of new research projects, namely ideas originating from the researchers themselves (\"supply push\") and those coming from customers (\"demand pull\"). Ideas for new processes typically originate from researchers, ideas for new products from customers, respectively customer contacts. Particularly in custom manufacturing, \"demand pull\" prevails industrial reality. The \"new product committee\" is the body of choice for evaluating new and monitoring ongoing research activities. It has the assignment to evaluate all new product ideas. It decides whether a new product idea should be taken up in research, reassesses a project at regular intervals and, last but not least decides also about the abandonment of a project, once it becomes evident that the objectives cannot be reached. In a typical project the overall responsibility for the economic and technical success lies with the [project champion](Project_champion \"Project champion\"). He is assisted by the [project manager](Project_manager \"Project manager\"), who is responsible for the technical success. In custom manufacturing, a typical project starts with the acceptance of the product idea, which originates mainly from business development, by the new product committee, followed by the preparation of a laboratory process, and ends with the successful completion of demonstration runs on industrial scale and the signature of a multiyear supply contract, respectively. The input from the customer is contained in the \"technology package\". Its main constituents are (1) reaction scheme, (2) target of project \u0026 deliverables (product, quantity, required dates, specifications), (3) list of [analytical methods](Analytical_methods \"Analytical methods\"), (4) process development opportunities (stepwise assessment), (5) list of required reports, (6) [Safety, Health and Environment](Safety%2C_Health_and_Environment \"Safety, Health and Environment\") (SHE) issues, (7) materials to be supplied by customer and (8) packaging \u0026 shipping information The technical part of a project usually determines its duration. Depending on the quality of the information contained in the \"technology package\" received from the customer and the complexity of the project as such, particularly the number of steps that have to be performed; it can be any time between 12 and 24 months. Depending on the number of researches involved, the total budget easily amounts to several million US dollars.\n# Markets\n\nFine chemicals are used as starting materials for [specialty chemicals](Specialty_chemicals). The latter are obtained either by direct formulation or after chemical/biochemical transformation of intermediates to active substances. Life sciences, primarily pharmaceutical, agrochemical and food and feed industries are the main consumers of fine chemicals. \n\n### Market size\n\nAs of 2023, the global chemical industry was valued at approximately $6.67 trillion USD, dominated mainly by oil-, gas-, and mineral-derived commodities (~40%) on one hand and a large variety of specialty chemicals at the interface between industry and the public on the other hand (~55%).[](https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/) Fine chemicals account for about 4% of this universe. The global production value of fine chemicals is estimated at $222 billion in 2024, of which about 2/3, or $148 billion are produced captively and $74 billion represent the global revenues of the fine chemical industry. The corresponding figures for the major user, the pharmaceutical industry, are $149 billion and an estimated $60 billion merchant, respectively. For a number of reasons, such as the lack of statistical data and the somewhat equivocal definition it is not possible to exactly determine the size of the fine chemical market. [](https://www.businessresearchinsights.com/market-reports/fine-chemicals-market-109560) [](https://www.imarcgroup.com/pharmaceutical-fine-chemicals-market)\n\n**Table 5: Breakdown of Fine Chemicals Market by Major Applications (estimated as of 2024)**\n\n| Application              | Size ($ billion) total A.I. | captive | merchant |\n|--------------------------|----------------------------|---------|----------|\n| Life sciences            |                            |         |          |\n| Pharmaceuticals          | 149                        | 89      | 60       |\n| Agrochemicals            | 33                         | 24      | 9        |\n| Various specialty chemicals | 40                     | 35      | 5        |\n| Total fine-chemical industry | 222                   | 148     | 74       |\n\nIn Table 5, the approximately $222 billion fine chemical market is subdivided into major applications according to their relevance, namely, fine chemicals for pharmaceuticals, agrochemicals and specialty chemicals outside life sciences. Furthermore, a distinction is made between captive (in-house) production and merchant market. Pharmaceutical fine chemicals (PFCs) account for two-thirds of the total. Out of the PFC value of $149 billion, about $60 billion (~40%) are traded, and $89 billion (~60%) are the production value of the pharma industry's in-house production. Within life science products, fine chemicals for agro, and â€”at a distanceâ€” for veterinary drugs follow in importance. The production value for fine chemicals used for specialty chemicals other than pharmaceuticals and agrochemicals is estimated at $40 billion. As the leading specialty chemical companies, [Akzo Nobel](Akzo_Nobel), [Dow](Dow_Chemical_Company), [DuPont](DuPont), [Evonik](Evonik), [Chemtura](Chemtura) and [Mitsubishi](Mitsubishi) are backward-integrated, the share of in-house production is estimated at ~88%, leaving a merchant market of approximately $5 billion. \n\n### Target markets\n\n#### Pharmaceuticals\n\nThe pharmaceutical industry constitutes the most important customer base for the fine chemical industry (see Table 4). Leading companies include Pfizer (USA), Roche (Switzerland), Novartis (Switzerland), Sanofi (France), GSK (UK), Novo Nordisk (Denmark), and Eli Lilly (USA). All are active in R\u0026D, manufacturing and marketing. Pharmaceuticals containing more than 2000 different active ingredients are in commerce today; a sizable number of them are sourced from the fine chemical industry. The industry also has a track record of above-average growth. The fine chemical industry has a keen interest in the top-selling or \"blockbuster drugs\", i.e. those with worldwide annual sales in excess of $1 billion. The number of blockbusters has continued to grow, exceeding 100 as of 2024, driven largely by biologics and innovative therapies.[](https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global)\n\n**Table 6: Top 10 Proprietary Drugs 2024**\n\n| Rank | Brand     | API                                      | Company                  | sales 2024 ($ bn) |\n|------|-----------|------------------------------------------|--------------------------|-------------------|\n| 1    | Keytruda  | pembrolizumab                            | Merck                    | 29.5              |\n| 2    | Ozempic   | semaglutide                              | Novo Nordisk             | 16.9              |\n| 3    | Biktarvy  | bictegrivir/emtricitabine/tenofovir alafenamide | Gilead            | 13.4              |\n| 4    | Eliquis   | apixaban                                 | Bristol-Myers Squibb/Pfizer | 13.3          |\n| 5    | Dupixent  | dupilumab                                | Sanofi/Regeneron         | 13.0              |\n| 6    | Skyrizi   | risankizumab                             | AbbVie                   | 11.7              |\n| 7    | Darzalex  | daratumumab                              | Johnson \u0026 Johnson/Genmab | 11.6              |\n| 8    | Stelara   | ustekinumab                              | Johnson \u0026 Johnson        | 10.4              |\n| 9    | Humira    | adalimumab                               | AbbVie                   | 9.0               |\n| 10   | Gardasil  | HPV vaccine                              | Merck                    | 8.6               |\n| **Total Top 10** |   |                                          |                          | **137.4**         |\n\n[](https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats)\n\nSales of the top 10 blockbuster drugs are reported in Table 6 as of 2024. The APIs of 3 of them are small molecules (plus one combination). Averaging a MW of around 450 for small molecules, they have quite complex structures. They typically show multiple cyclic moieties. Most exhibit heterocyclic moieties. Eight of the top 10 are biologics or vaccines, up significantly from five in 2010, reflecting the shift toward biopharmaceuticals. The largest-selling non-proprietary drugs are paracetamol, omeprazole, ethinylestradiol, amoxicillin, pyridoxine, and ascorbic acid. The innovator pharma companies require mainly custom manufacturing services for their proprietary drug substances. The demand is driven primarily by the number of new drug launches, the volume requirements and the industry's \"make or buy\" strategy. A summary of the pro's and con's for outsourcing from the pharma industry's perspective is given in Table 7. As extended studies at the Stern Business School of the New York City University have shown, financial considerations clearly favor the \"buy\" option.[21]\n\n**Table 7: Pro's and Con's for Outsourcing API Manufacture[22]**\n\n| Pro's | Con's |\n|-------|-------|\n| - **concentrate on core activities (innovation \u0026 marketing) **\u003cbr\u003e- **deploy your financial resources for more profitable investments**\u003cbr\u003e- benefit from F.C. industry's know how and expertise\u003cbr\u003e- eliminate long lead times to build and validate a manufacturing facility\u003cbr\u003e- free capacity for new product introductions\u003cbr\u003e- avoid risks of using hazardous chemistry | - loss of tax benefits resulting from production of APIs in tax havens\u003cbr\u003e- dissemination of Intellectual Property\u003cbr\u003e- loss of know how\u003cbr\u003e- job losses\u003cbr\u003e- under-utilization of in-house production capacity |\n\n[Teva](Teva_Pharmaceutical_Industries) and [Sandoz](Sandoz) are by far the largest _generics companies_ (see also chapter 6.3.2). They differ from their competitors not only in sales revenues but also because they are strongly backwards integrated and have proprietary drugs in their portfolios. They also vie for the promising biosimilars market, projected to reach ~$100 billion by 2025. [](https://www.precedenceresearch.com/generic-drugs-market\")\n\nSeveral thousand _small_ or _virtual pharma_ companies focus on R\u0026D. albeit on just a few lead compounds. They typically originate mostly from academia. Therefore, their R\u0026D strategy is more focused on the elucidation of the biological roots of diseases rather than developing synthesis methods. \n\nRecent trends in the pharmaceutical sector include the explosive growth of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for diabetes and obesity, which, while mostly biologics, increase demand for supporting fine chemicals in formulation and delivery systems.\n\n#### Agrochemicals\n\nAgrochemical companies are the second largest users of fine chemicals. Most products have a \"pharmaceutical heritage\". As a consequence of an intensive M\u0026A activity (Mergers and Acquisitions) over the past 10â€“20 years, the industry now is more consolidated than the pharmaceutical industry. The top companiesâ€”Bayer CropScience (Germany, including Monsanto), Syngenta Group (China/Switzerland), Corteva Agriscience (USA), BASF (Germany), and FMC (USA)â€”have a share of approximately 80-90% of the total ~$250 billion global agrochemicals market as of 2024.[](https://www.precedenceresearch.com/agrochemicals-market) [](https://www.emergenresearch.com/blog/top-10-companies-in-agrochemicals-market) Since the 1990s the R\u0026D effort is focused mainly on [gene modified (GM) seeds](Genetically_modified_crops). At both Bayer and Corteva's seed businesses, GM seed accounts for more than 50% of total sales. Between 2010 and 2023, fewer than 50 new LMW agrochemicals were launched globally. However, only a handful achieved sales in excess of $100 million per year, reflecting a shift toward biologicals and sustainable solutions.[](https://www.infosys.com/iki/documents/agrochem-industry-market-outlook.pdf)\n\nGenerics play a bigger role in the agro than in the pharma industry. They represent some 70% of the global market. China National Chemical Corp, a.k.a. ChemChina Group (owner of Syngenta), is the world's largest supplier of generic farm chemicals. Makhteshim Agan (now ADAMA), Israel, and [Cheminova](Cheminova) (now part of FMC), Denmark follow on the ranks 2 and 3. Apart from these multibillion-dollar companies, there are hundreds of smaller firms with sales of less than $50 million per year, mainly in India and China. The incidence of the cost of the active ingredient is about 33%; i.e., much higher than in drugs. Depending on the climatic conditions affecting crop yields, consumption and prices of agrochemicals are subject to wide fluctuations from year to year, impacting also the suppliers. \n\nThe molecular structures of modern agrochemicals are much more complex than in older products, but lower than of their pharma counterparts.[23] The average molecular weight of the top 10 is 330, as compared with 477 for the top 10 pharma small molecules. In comparison to reagents used in pharmaceutical fine chemical syntheses, hazardous chemicals, e.g. [sodium azide](Sodium_azide), [halogens](Halogens), [methyl sulfide](Dimethyl_sulfide), [phosgene](Phosgene), [phosphorus chlorides](Phosphorus_chlorides), are more frequently used. Agrochemical companies sometimes outsource just these steps, which require specialized equipment, on toll conversion deals. With exception of the [pyrethroids](Pyrethroids), which are photostable modifications of naturally occurring pyrethrums, active ingredients of agrochemicals rarely are chiral. Examples within _[herbicides](Herbicides)_ are the world's longstanding top-selling product, Bayer's [Roundup](Roundup_\\(herbicide\\)) (glyphosate). Syngenta's cyclohexadione-type [mesotrione](Mesotrione) and [paraquat dichloride](Paraquat_dichloride). Within _[insecticides](Insecticides)_ , the traditional [organophosphates](Organophosphates), like [malathion](Malathion), and pyrethroids such as [Î³-cyhalothrin](Cyhalothrin) are being substituted for by [neonicotinoids](Neonicotinoids), like Bayer's [imidacloprid](Imidacloprid) and Syngenta's [thiamethoxam](Thiamethoxam) and pyrazoles, such as BASF's [fipronil](Fipronil). Chlorantraniliprole is the most important representative of Corteva's anthranilic diamide family of broad spectrum insecticides. Within _[fungicides](Fungicides)_ , the [strobilurins](Strobilurins), a new class, are growing rapidly and already have captured more than 30% of the $10 billion global fungicide market. Syngenta's [azoxystrobin](Azoxystrobin) was the first product launched. Also BASF's F-500 Series, a.o. [pyraclostrobin](Pyraclostrobin) and kresoxim-methyl, Bayer CropScience, and Corteva are developing new compounds in this class. Combination pesticides, such as Bayer's XtendiMax and Corteva's Enlist are more and more frequently used. \n\nRecent developments in agrochemicals emphasize sustainable practices, with increasing use of biological controls and reduced reliance on synthetic chemicals due to regulatory pressures.\n\n#### Other specialty chemical industries\n\nApart from life sciences, specialty chemicals -and therefore also their active ingredients, commodities or fine chemicals, as the case may be- are used ubiquitously, in both industrial applications, such as [biocides](Biocides) and [corrosion inhibitors](Corrosion_inhibitors) in cooling water towers, and consumer applications, such as [personal care](Personal_care) and household products. The active ingredients extend from high-price / low-volume fine chemicals, used for [liquid crystal displays](Liquid_crystal_displays) to large-volume / low-price amino acids used as [feed additives](Feed_additives). \n\n**Table 8: Other Specialty Chemicals Industries (as of 2024)**\n\n| Industry              | Sales ($ billion) | Attractiveness | Products |\n|-----------------------|-------------------|----------------|----------|\n| Animal Health         | ~ 50              | â™¦â™¦â™¦            | Typical a.h. products derive from human medicines, e.g. Reconzile, dubbed \"puppy Prozac\". Paraciticides are the largest product category. Good growth prospects in fish farming. |\n| Adhesives \u0026 Sealants  | ~ 70              | â™¦â™¦             | Uses extend from household, e.g. paper gluing, to high-tech specialty products for assembling electronic parts, automotive and aircraft construction. [](https://www.grandviewresearch.com/industry-analysis/adhesives-and-sealants-market\") |\n| Biocides              | ~ 12              | â™¦              | Largest applications are wood conversation and water treatment. A.I.'s mainly commodities [](https://www.marketsandmarkets.com/Market-Reports/biocides-market-1157.html\") |\n| Catalysts \u0026 Enzymes   | ~ 40              | â™¦              | Catalysts (automotive, polymers, petroleum processing, chemicals) / enzymes (detergents / technical enzymes, food \u0026 feed) = 80 / 20 |\n| Dyestuffs \u0026 Pigments  | ~ 45              | â™¦              | Mostly based on large volume aromatic compounds, e.g., letter acids .Asian dyestuff prod, \u003e 106 mtpa. Some niche products, e.g. colour shifting pigments |\n| Electronic Chemicals  | ~ 80              | â™¦â™¦â™¦            | Sizeable and growing demand for fine chemicals, e.g. octafluorocyclobutane for etching. for liquid crystals and organic light emitting diodes (OLED). |\n| Flavours \u0026 Fragrances | ~ 35              | â™¦â™¦             | ~3000 molecules are used, e.g. (-) menthol [20,000 tons], polycyclic musks [10,000 tons], vanilline, linalool, geraniol, heterocyclics, 2-phenylethanol) |\n| Food \u0026 Feed Additives | 80-100            | â™¦â™¦             | Mainly amino acids (L-lysine [106 tons], L-methionine, ...), vitamins (C [\u003e 105 tons], niacin, riboflavin, ...), artificial sweeteners (aspartame, splenda) and carotenoids |\n| Specialty Polymers    | NA                | â™¦â™¦             | Aerospace: Fluorinated poly ethylene/propylene,[30,000 tons], Polyether ether ketones [PEEK], Polyimides, Precision parts: Aramides [25,000 t], polybenzazoles |\n\n*fine chemicals merchant market size, growth potential \n\nExamples of applications in eight areas, ranging from [adhesives](Adhesives) to specialty polymers, are listed in Table 8. Overall, the attractiveness for the fine chemical industry is smaller than the life science industry. The total market, expressed in finished product sales, amounts to $150â€“200 billion, or about one fourth of the pharma market. The embedded fine chemicals account for an estimated $40 billion (see Table 5). Further disadvantages are the backward integration of the big players, e.g. [Akzo-Nobel](Akzo-Nobel), Netherlands; [Ajinomoto](Ajinomoto), Japan; [Danone](Danone), France; Everlight Chemical Industrial Corp., Taiwan; Evonik-Degussa, Germany; [Givaudan](Givaudan) and [NestlÃ©](Nestl%C3%A9), Switzerland, [Novozymes](Novozymes), Denmark, [Procter \u0026 Gamble](Procter_%26_Gamble), and [Unilever](Unilever) USA. Last but not least, innovation is rather based on new formulations of existing products, rather than the development of new fine chemicals. It is most likely to happen in application areas unrelated to human health (where NCEs are subject to very extensive testing). \n\n### Target products and services\n\nAs of 2024, the global pharmaceutical market is approximately $1.65 trillion, with proprietary drugs accounting for about 73% (~$1.2 trillion) and generics about 27% (~$450 billion) by value, though generics represent a larger share by volume (~30% on an API volume basis).[](https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global) [](https://www.precedenceresearch.com/generic-drugs-market)\n\n#### Custom manufacturing\n\nThe products and services offered by the fine chemical industry fall into two broad categories: (1) \"Exclusives\", a.k.a. custom manufacturing (CM) and (2) \"standard\" or \"catalogue\" products. \"Exclusives\", provided mostly under contract research or custom manufacturing arrangements, prevail in business with life science companies; \"standards\" prevail in other target markets. Service-intense custom manufacturing (CM) constitutes the most prominent activity of the fine chemical industry. CM is the antonym of [outsourcing](Outsourcing). In custom manufacturing, a specialty-chemicals company outsources the process development, pilot plant, and, finally, industrial-scale production of an active ingredient, or a predecessor thereof, to one, or a few, fine chemical companies. The intellectual property of the product, and generally also the manufacturing process, stay with the customer. The customer-supplier relationship is governed by an exclusive supply agreement. At the beginning of cooperation, the customer provides a \"tech package\", which in its simplest version, includes a laboratory synthesis description and SHE recommendations. In this case, the whole scale up, which comprises a factor of about one million (10 gram â†’ 10 ton quantities), is done by the fine chemical company. \n\nWith the rise of biologics, custom manufacturing increasingly includes support for bioprocessing and conjugation chemistries.\n\n#### Standard products\n\nNon-exclusives, \"standard\" or \"catalogue products\" constitute the second most important outlet for fine chemicals after custom manufacturing. API-for-Generics are the most important sub-category. Because of patent expiries, over 60 of the top 200 drugs alone, representing aggregated sales of over $150 billion, have fallen into the public domain within the past decade. This, along with government-backed incentives, are causing global sales of generics to rapidly increase.[24] Asian companies currently dominate the API-for-Generics business. They have multiple advantages of their low cost basis, their large home markets, and significant previous manufacturing experience compared to western manufacturers in producing for their domestic and other non-regulated markets.\n# Financials\n\n## Investment costs\n\nInvestment costs for multipurpose plants are high in comparison with product output. However, they vary considerably, depending on the location, size of equipment and degree of sophistication (e.g., automation, containment, quality of equipment, complexity of infrastructure). An example for a cGMP multipurpose plant built in the US is shown in Table 9 (as of 2011). The investment cost of $21 million comprises just the equipment and installation. The building, property and external services are excluded. For comparison purposes, the investment cost per mÂ³ reactor volume is used. In this case, it is $0.9 million. The amount includes the cost of the reaction vessel itself plus an equitable part of the ancillary equipment, like feeding tanks, piping, pumps \u0026 process control. If larger or smaller reactors were installed, the unit cost per mÂ³ would decrease or increase with the exponent 0.5, respectively. Hence, by increasing the equipment size manufacturing costs on a per kilogram (kg\u003csup\u003e-1\u003c/sup\u003e) basis typically decrease substantially. Also, costs for a plant that is used for the production of non regulated intermediates only would be substantially lower. Pharma companies tend to spend up to ten times more for a plant with the same capacity. In contrast, investment costs in developing countries, particularly in India or China, are considerably lower.[25]\n\n**Table 9: Investment Cost for a cGMP Multipurpose Plant (2011)**\n\n| Description of main equipment | Numbers |\n| --- | --- |\n| Production trains | 2 |\n| Reactor vessels (volume = 4 mÂ³) | 6 |\n| Total reactor volume | 24 mÂ³ |\n| Filtration units | 2 |\n| Dryers | 2 |\n| **Capital investment** |  |\n| Total capital investment | $21 million |\n| Investment per production train | $11.5 million |\n| Investment per piece of main equipment | $2.1 million |\n| Investment per mÂ³ reactor volume | $0.9 million |\n\n## Manufacturing costs\n\nThe raw material consumption and the conversion cost are the two elements that establish the manufacturing cost for a particular fine chemical. The former is determined primarily by the unit consumption and the purchasing cost of the materials used; the latter, by the throughput in kilograms per day in a given production bay. A precise calculation of the conversion cost is a demanding task. Different products with widely differing throughputs are produced in campaigns in multipurpose plants, occupying the equipment to different extents. Therefore, both the production capacity and the equipment utilization for a specific fine chemical are difficult to determine. Moreover, cost elements such as labor, capital, utilities, maintenance, waste disposal, and quality control cannot be allocated unambiguously. \n\nAn approximative calculation can be done by an experienced process development or pilot plant chemist on the basis of (1) the laboratory synthesis procedure and (2) by breaking down the process into unit operations, the standard costs of which have been determined previously Controlling has to be involved for a more in-depth costing.. The problems it has to address are how to fairly allocate costs for production capacity, which is not used. This can be due to the fact that part of a production bay is idle, because of lack of demand or because, e.g., a reactor is not required for a particular process. \n\nManufacturing costs usually are reported on a per kilogram product basis. For the purpose of benchmarking (both internal and external), the volume x time / output (VTO), as mentioned above, is a useful aid. \n\n**Table 10: Indicative Cost Structure of a Fine Chemical Company (2011)**\n\n| Cost elements | Details | Share |\n| --- | --- | --- |\n| raw materials | inclusive solvents | 30% |\n| conversion cost | plant specific |  |\n| utilities and energy | electric power, steam, brine | 4â€“5 % |\n| plant labor | shift and daytime work | 10â€“15 % |\n| capital cost | depreciation and interest on capital | 15% |\n| plant overhead | QC, maintenance, waste disposal, etc. | 10 % |\n| research \u0026 development | inclusive pilot plant | 8 % |\n| marketing \u0026 sales | inclusive promotion | 5% |\n| general overhead | administrative services | 15 % |\n\nAn indicative cost structure for a fine chemical company is shown in Table 10. Nowadays, a full 7-day/week operation, consisting of four or five shift teams, each working 8h per day, has become the standard. In terms of production costs, this is the most advantageous scheme. Higher salaries for night work are more than offset by better fixed cost absorption. As part of the budgeting process, standard costs for a production campaign of a particular fine chemical are determined on the basis of past experience. The actual results of the campaign are then compared with the standard. The capability of a fine chemical company to make dependable manufacturing cost forecasts is a distinct competitive advantage. Recent trends (as of 2023) indicate rising energy costs, with a global increase of 19% affecting production expenses.[](https://www.marketgrowthreports.com/market-reports/fine-chemicals-market-108218)\n\n## Profitability\n\nThe fine chemical industry has undergone several boom and bust phases during its almost 30 years of existence (as of 2011). The biggest boom took place in the late 1990s, when high-dosage, high volume anti-AIDS drugs and COX-2 inhibitors gave a big boost to custom manufacturing. After the end of the \"irrational exuberance\" in 2000, the industry suffered a first bust in 2003, as a result of capacity expansions, the advent of Asian competitors and a ruinous M\u0026A activity, several billion dollars of shareholder value were destroyed. The most recent â€“minor- boom is associated with stockpiling of GlaxoSmithKline's [Relenza](Relenza \"Relenza\") (zanamivir) and Roche's [Tamiflu](Tamiflu \"Tamiflu\") (oseltamivir phosphate) by many countries in order to prepare for a possible avian flu epidemic. Surprisingly, the main cause for the 2009 slump had not been the general recession, but slow-downs of the growth and, even more so, inventory adjustments by the pharma industry. They resulted in postponements or cancellations of orders. The unfavorable development was in sharp contrast to the very optimistic growth forecasts, which many fine chemical companies, had announced. They had been based on equally promising sector reports from investment banks, which in turn had evolved from forward projections of the preceding boom period. In most cases, these projections have been missed by a large margin. \n\nAt the end of the \"irrational exuberance\" at the turn of the millennium and again in 2009 almost half of the industry achieved a return on sales (ROS) of more than 10%, and less than 10% an ROS below 5%. In the worst years, 2003 and 2009, almost half of the companies suffered from an ROS of less than 5%. Whereas during the period under review, 2000â€“2009. the average EBITDA / sales and EBIT / sales ratios of representative companies, resp. divisions were 15% and 71â„2%, respectively, in the period 2000â€“2009, the numbers were 20% and 10â€“13% in the boom, and 10% and 5% in the bust phases. The factor 2 between the high and low numbers reflects the volatility of the industry's profitability. All in all, as of 2009, the average Western fine-chemical firms have been making a return below the cost of capital, i.e. they are not reinvestment grade.[26]\n\nSince 2020, the industry has faced additional volatility from the COVID-19 pandemic, supply chain disruptions, and geopolitical tensions, but showed recovery by 2024. Global chemical profits for top firms rose 8.1% to $56.8 billion in 2024, with specialty chemical producers (including fine chemicals) reporting strong gains, such as over 100% profit increases for some like Asahi Kasei. R\u0026D spending increased 3% to $12.3 billion, supporting innovation in high-value fine chemicals. Projections for 2025 indicate 3.5% global chemical production growth, driven by pharmaceuticals (over 60% of fine chemicals demand).[](https://cen.acs.org/business/finance/CENs-Global-Top-50-2025/103/web/2025/07)[](https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html)[](https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoral-economic-performance/FINAL_Fine-Chemicals_Brochure_External_RGB.pdf)\n# Outlook\n\nTwo main trends impinge on the industry. On the _supply side_ , biotechnology is rapidly gaining importance. In the synthesis of small molecule fine chemicals, the use of biocatalysts and microbial fermentation enable both a more sustainable and economic production than conventional organic chemistry. In the synthesis of big molecules, such as biopharmaceuticals, it is the method of choice. Biopharmaceuticals are projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2025 to 2030, faster than the overall pharmaceutical market's ~6% CAGR.[](https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market) As of 2024, seven of the top ten best-selling drugs worldwide are biopharmaceuticals, reflecting the ongoing shift toward biologics.[](https://www.genengnews.com/topics/drug-discovery/top-10-best-selling-drugs-2/)\n\nOn the _demand side_ , the main customer base for fine chemicals, the pharmaceutical industry, is faced with slower growth of demand, patent expirations of many lucrative blockbuster drugs and stalling new product launches. Recent trends include the rise of GLP-1 receptor agonists for obesity and diabetes, which are biopharmaceuticals driving demand for advanced fine chemicals. In order to restrain these challenges, the leading companies are implementing restructuring programs. They comprise a reduction of in-house chemical manufacturing and plant eliminations. Outsourcing is moving up from a purely opportunistic to a strategic approach, with the biopharmaceutical contract development and manufacturing organization (CDMO) market projected to grow at 8.8% CAGR through 2030.[](https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html) It is difficult to make a judgment, whether the positive or negative effects of these initiatives will prevail. In a worst-case scenario, a condition could develop, whereby even top-tier mid-sized, family-owned[27] fine-chemical companies with state-of-the-art plants and processes could be relegated to producing small quantities of fine chemicals for new life-science products in late stage of development. In agro fine chemicals, the active ingredients become more sophisticated and performing. Therefore, they require multipurpose instead of dedicated plants prevailing in the industry so far. At the same token, outsourcing is gaining ground. \n\n_Globalization_ results in a shift of fine chemical production from the industrialized to developing countries. The latter benefit not only from a \"low cost / high skill\" advantage, but also from a rapidly rising domestic demand for Western medicine. Despite the mantras of Western industry leaders, the cost advantage of the Asian producers is going to persist.[28] As the pharmemerging countries mainly use generics, their market share continues to grow to the detriment of originator pharmaceuticals and agrochemicals. This is also the case for biosimilars, the generic versions of biopharmaceuticals. As a consequence of the harsh business climate, many Western fine chemical companies or divisions created during the \"irrational exuberance\" at the end of the 20th century already have exited from the sector. Others will follow suit or will be acquired by private equity firms. Survival strategies include implementation of lean production principles originally developed by the automotive industry and extending the business model to include also contract research at the beginning and active drug formulation towards the end of the added value chain. This latter strategy, however, is not finding unanimous approval by industry experts. The industry is also emphasizing sustainability and digital technologies, such as AI for process optimization, to enhance resiliency amid volatile supply chains.[](https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html)\n\nAlthough the demand for fine chemicals on the merchant market has not grown to the extent originally anticipated, fine chemicals still provide attractive opportunities for well-run companies, which are fostering the critical success factors, namely running fine chemicals as a core business, pursuing niche technologiesâ€”primarily biotechnologyâ€”and taking advantage of the opportunities offered by the Asian market. The global fine chemicals market is projected to grow from approximately USD 186 billion in 2025 to USD 341 billion by 2035.[](https://marketmindsadvisory.com/fine-chemicals-market-trends/)"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761884162458,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** Stahl, A. F. (1908). [\\\"XX.- Fine Chemicals, Alkaloids, Essential Oils, \u0026 Extracts\\\"](https://books.google.com/books?id=OvgwAQAAMAAJ\u0026pg=PA956). _The Journal of the Society of Chemical Industry_. **27** : 956.\",\"description\":\"1. **^** Stahl, A. F. (1908). [\\\"XX.- Fine Chemicals, Alkaloids, Essential Oils, \u0026 Extracts\\\"](https://books.google.com/books?id=OvgwAQAAMAAJ\u0026pg=PA956). _The Journal of the Society of Chemical Industry_. **27** : 956.\",\"url\":\"https://books.google.com/books?id=OvgwAQAAMAAJ\u0026pg=PA956\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"** A. Kleemann; J. Engel; B. Kutscher; D. Reichert (2009). [_Pharmaceutical Substances_](https://archive.org/details/pharmaceuticalsu00klee_318) (5th ed.). pp. [291](https://archive.org/details/pharmaceuticalsu00klee_318/page/n311)â€“292. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781621983774.\",\"description\":\"2. **^** A. Kleemann; J. Engel; B. Kutscher; D. Reichert (2009). [_Pharmaceutical Substances_](https://archive.org/details/pharmaceuticalsu00klee_318) (5th ed.). pp. [291](https://archive.org/details/pharmaceuticalsu00klee_318/page/n311)â€“292. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781621983774.\",\"url\":\"https://archive.org/details/pharmaceuticalsu00klee_318\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** A. Kleemann; J. Engel; B. Kutscher; D. Reichert (2009). [_Pharmaceutical Substances_](https://archive.org/details/pharmaceuticalsu00klee_318) (5th ed.). pp. [1189](https://archive.org/details/pharmaceuticalsu00klee_318/page/n1209)â€“1191. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781621983774.\",\"description\":\"3. **^** A. Kleemann; J. Engel; B. Kutscher; D. Reichert (2009). [_Pharmaceutical Substances_](https://archive.org/details/pharmaceuticalsu00klee_318) (5th ed.). pp. [1189](https://archive.org/details/pharmaceuticalsu00klee_318/page/n1209)â€“1191. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781621983774.\",\"url\":\"https://archive.org/details/pharmaceuticalsu00klee_318\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** E. Reeder; L. H. Sternbach (1968). _US 3371085_.\",\"description\":\"4. **^** E. Reeder; L. H. Sternbach (1968). _US 3371085_.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** Hughes, Andrew B. (2011). _Amino Acids, Peptides and Proteins in Organic Chemistry_. Volumes 1-5: John Wiley \u0026 Sons, Hoboken.`{{cite book}}`: CS1 maint: location (link)\",\"description\":\"5. **^** Hughes, Andrew B. (2011). _Amino Acids, Peptides and Proteins in Organic Chemistry_. Volumes 1-5: John Wiley \u0026 Sons, Hoboken.`{{cite book}}`: CS1 maint: location (link)\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Examples: Swiss Federal Institute of Technology (ETHZ), Switzerland; Massachusetts Institute of Technology (MIT), USA; Institut fÃ¼r Mikrotechnik (IMM), Germany; University of Washington (WU), USA; Micro-Chemical ProcessTechnology Research Association (MCPT), Japan.\",\"description\":\"6. **^** Examples: Swiss Federal Institute of Technology (ETHZ), Switzerland; Massachusetts Institute of Technology (MIT), USA; Institut fÃ¼r Mikrotechnik (IMM), Germany; University of Washington (WU), USA; Micro-Chemical ProcessTechnology Research Association (MCPT), Japan.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** V. Hessel; A. Renken; J.C. Shouten; J. Yoshida (2009). _Micro Process Engineering_. Wiley-VCH Verlag, Weiheim.\",\"description\":\"7. **^** V. Hessel; A. Renken; J.C. Shouten; J. Yoshida (2009). _Micro Process Engineering_. Wiley-VCH Verlag, Weiheim.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Wim Soetaert; Erick J. Vandamme (2010). _), Industrial Biotechnology: Sustainable Growth and Economic Success_. J. Wiley \u0026 Sons, Hoboken NJ.\",\"description\":\"8. **^** Wim Soetaert; Erick J. Vandamme (2010). _), Industrial Biotechnology: Sustainable Growth and Economic Success_. J. Wiley \u0026 Sons, Hoboken NJ.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Secretary: Prof. M.P. Walsh. University of Calgary, Calgary, Canada T2N 4N1\",\"description\":\"9. **^** Secretary: Prof. M.P. Walsh. University of Calgary, Calgary, Canada T2N 4N1\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Pollak, Peter (29 March 2011). [_Fine Chemicals: The Industry and the Business_](https://books.google.com/books?id=yuxJGasHvkoC\u0026pg=PA43). John Wiley \u0026 Sons. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-118-00222-3.\",\"description\":\"10. **^** Pollak, Peter (29 March 2011). [_Fine Chemicals: The Industry and the Business_](https://books.google.com/books?id=yuxJGasHvkoC\u0026pg=PA43). John Wiley \u0026 Sons. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-118-00222-3.\",\"url\":\"https://books.google.com/books?id=yuxJGasHvkoC\u0026pg=PA43\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Victor A. Vinci; Sarad R. Parekh (2010). _Handbook of Industrial Cell Culture: Mammalian, Microbial, and Plant Cells_. Humana Press, New York.\",\"description\":\"11. **^** Victor A. Vinci; Sarad R. Parekh (2010). _Handbook of Industrial Cell Culture: Mammalian, Microbial, and Plant Cells_. Humana Press, New York.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** C. Chassin; P. Pollak (Januaryâ€“February 2004). \\\"Outlook for chemical and biochemical manufacturing\\\". _PharmaChem_. **3** : 23â€“26.\",\"description\":\"12. **^** C. Chassin; P. Pollak (Januaryâ€“February 2004). \\\"Outlook for chemical and biochemical manufacturing\\\". _PharmaChem_. **3** : 23â€“26.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** [\\\"Expected Top Ten Drugs by 2016\\\"](http://www.evaluatepharma.com/Default.aspx). Retrieved 11 December 2011.\",\"description\":\"13. **^** [\\\"Expected Top Ten Drugs by 2016\\\"](http://www.evaluatepharma.com/Default.aspx). Retrieved 11 December 2011.\",\"url\":\"http://www.evaluatepharma.com/Default.aspx\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** A. Gosh; S. Ray; G. Jain; A. Arora (2011). _CRAMS India: Overview \u0026 Outlook_. ICRA Ltd. Mumbai.\",\"description\":\"14. **^** A. Gosh; S. Ray; G. Jain; A. Arora (2011). _CRAMS India: Overview \u0026 Outlook_. ICRA Ltd. Mumbai.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Samuel L. Tuthill, Norman C. Jamieson, Kirk-Othmer (2000). _Encyclopedia of Chemical Technology_ (4th ed.). John Wiley \u0026 Sons, Hoboken NJ. p. 857.`{{cite book}}`: CS1 maint: multiple names: authors list (link)\",\"description\":\"15. **^** Samuel L. Tuthill, Norman C. Jamieson, Kirk-Othmer (2000). _Encyclopedia of Chemical Technology_ (4th ed.). John Wiley \u0026 Sons, Hoboken NJ. p. 857.`{{cite book}}`: CS1 maint: multiple names: authors list (link)\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** _The U.S. Pharmacopeia 34 (USP 34 â€“NF29)_. The U.S Pharmacopeial Convention, Inc., Rockville, MD. 2011.\",\"description\":\"16. **^** _The U.S. Pharmacopeia 34 (USP 34 â€“NF29)_. The U.S Pharmacopeial Convention, Inc., Rockville, MD. 2011.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Adapted from: Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 2.2: J. Wiley \u0026 Sons. pp. [1](https://archive.org/details/finechemicalsind00poll_481/page/n22). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"description\":\"17. **^** Adapted from: Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 2.2: J. Wiley \u0026 Sons. pp. [1](https://archive.org/details/finechemicalsind00poll_481/page/n22). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"url\":\"https://archive.org/details/finechemicalsind00poll_481\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** _CPhI Worldwide, 25-27 October 2011_. Messe Frankfurt, UBM plc., London.\",\"description\":\"18. **^** _CPhI Worldwide, 25-27 October 2011_. Messe Frankfurt, UBM plc., London.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Stanley H. Nusim (2009). _Active Pharmaceutical Ingredients: Development, Manufacturing, and Regulation_ (2nd ed.). Taylor\u0026Francis Group, Boca Raton FL. pp. 9â€“91.\",\"description\":\"19. **^** Stanley H. Nusim (2009). _Active Pharmaceutical Ingredients: Development, Manufacturing, and Regulation_ (2nd ed.). Taylor\u0026Francis Group, Boca Raton FL. pp. 9â€“91.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 6.1: J. Wiley \u0026 Sons. pp. [69](https://archive.org/details/finechemicalsind00poll_481/page/n90). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"description\":\"20. **^** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 6.1: J. Wiley \u0026 Sons. pp. [69](https://archive.org/details/finechemicalsind00poll_481/page/n90). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"url\":\"https://archive.org/details/finechemicalsind00poll_481\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Lev, Baruch (January 1999). \\\"R\u0026D AND CAPITAL MARKETS\\\". _Journal of Applied Corporate Finance_. **11** (4): 21â€“35\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1745-6622.1999.tb00511.x](https://doi.org/10.1111%2Fj.1745-6622.1999.tb00511.x).\",\"description\":\"21. **^** Lev, Baruch (January 1999). \\\"R\u0026D AND CAPITAL MARKETS\\\". _Journal of Applied Corporate Finance_. **11** (4): 21â€“35\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1745-6622.1999.tb00511.x](https://doi.org/10.1111%2Fj.1745-6622.1999.tb00511.x).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 10.2: J. Wiley \u0026 Sons. pp. [105](https://archive.org/details/finechemicalsind00poll_481/page/n123). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"description\":\"22. **^** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 10.2: J. Wiley \u0026 Sons. pp. [105](https://archive.org/details/finechemicalsind00poll_481/page/n123). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"url\":\"https://archive.org/details/finechemicalsind00poll_481\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** C.D.S. Tomlin (2011). _The Pesticide Manual: A World Compendium_ (15th ed.). BCPC Publications, Alton, Hampshire, UK.\",\"description\":\"23. **^** C.D.S. Tomlin (2011). _The Pesticide Manual: A World Compendium_ (15th ed.). BCPC Publications, Alton, Hampshire, UK.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** [[1]](https://www.prnewswire.com/news-releases/fine-chemicals-market-to-reach-191-billion-usd-by-2021---industryarc-642101523.html) 29 August 2017\",\"description\":\"24. **^** [[1]](https://www.prnewswire.com/news-releases/fine-chemicals-market-to-reach-191-billion-usd-by-2021---industryarc-642101523.html) 29 August 2017\",\"url\":\"https://www.prnewswire.com/news-releases/fine-chemicals-market-to-reach-191-billion-usd-by-2021---industryarc-642101523.html\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 7.1: J. Wiley \u0026 Sons. pp. [76](https://archive.org/details/finechemicalsind00poll_481/page/n97). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"description\":\"25. **^** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 7.1: J. Wiley \u0026 Sons. pp. [76](https://archive.org/details/finechemicalsind00poll_481/page/n97). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"url\":\"https://archive.org/details/finechemicalsind00poll_481\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 7.3: J. Wiley \u0026 Sons. pp. [79](https://archive.org/details/finechemicalsind00poll_481/page/n100). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"description\":\"26. **^** Pollak, Peter (2011). [_Fine Chemicals â€“ The Industry and the Business_](https://archive.org/details/finechemicalsind00poll_481) (2nd. rev. ed.). Table 7.3: J. Wiley \u0026 Sons. pp. [79](https://archive.org/details/finechemicalsind00poll_481/page/n100). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-470-62767-9.`{{cite book}}`: CS1 maint: location (link)\",\"url\":\"https://archive.org/details/finechemicalsind00poll_481\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Guy Villax (Novâ€“Dec 2008). \\\"Family owned businesses\\\". _Chimica Oggi / Chemistry Today_. **26** (6): 8.\",\"description\":\"27. **^** Guy Villax (Novâ€“Dec 2008). \\\"Family owned businesses\\\". _Chimica Oggi / Chemistry Today_. **26** (6): 8.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** P. Pollak; A. Badrot; R. Dach; A. Swadi (Novâ€“Dec 2011). _Costs of Asian Fine Chemical Producers close-up to European Levels â€“ Facts or Fiction?_. Contract Pharma.\",\"description\":\"28. **^** P. Pollak; A. Badrot; R. Dach; A. Swadi (Novâ€“Dec 2011). _Costs of Asian Fine Chemical Producers close-up to European Levels â€“ Facts or Fiction?_. Contract Pharma.\",\"url\":\"\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Their global total production value of $85 billion is split about 60-40 between in-house production in the life-science industryâ€”the products' main consumersâ€”and companies producing them for sale.\",\"explanation\":\"The $85 billion figure originates from data circa 2011 (e.g., ref 10: Pollak 2011) and no longer reflects current market conditions. As of 2025, the global total production value (including both in-house/captive and merchant production) is approximately $211 billion, with a captive share of ~60%.\",\"fixedText\":\"Update the sentence to: \\\"As of 2025, their global total production value is approximately $211 billion, split about 60-40 between in-house production in the life-science industryâ€”the products' main consumersâ€”and companies producing them for sale.[](https://www.futuremarketinsights.com/reports/fine-chemicals-market)\\\"\",\"evidenceSource\":\"[](https://www.futuremarketinsights.com/reports/fine-chemicals-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"Examples of ADCs in phase III of development are Abbott's / Isis's Alicaforsen and Eli Lilly's Aprinocarsen.\\\"\",\"explanation\":\"Alicaforsen and Aprinocarsen are antisense oligonucleotides (ASOs) that inhibit gene expression via RNA targeting, not antibody-drug conjugates (ADCs), which consist of a monoclonal antibody covalently linked to a cytotoxic payload for targeted delivery. This misclassification distorts the technical description of ADC structure and function.\",\"fixedText\":\"Remove the examples as they do not belong to ADCs; relocate to the oligonucleotides subsection if appropriate, or omit. Add accurate examples of approved ADCs with current status.\",\"evidenceSource\":\"[](https://go.drugbank.com/drugs/DB06224); [](https://synapse.patsnap.com/drug/0841b9c2ad2a4f3f938b36a5b9c665a4)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"About 50 peptide drugs are commercialized.\\\"\",\"explanation\":\"The figure is outdated; as of 2024, over 80 peptide therapeutics are approved globally for clinical use, reflecting significant growth in approvals since the original sourcing around 2011.\",\"fixedText\":\"Update to \\\"Over 80 peptide therapeutics have been approved worldwide as of 2024.\\\"\",\"evidenceSource\":\"[](https://www.biotechprimer.com/pills-peptides-proteins/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"The total production volume (excl. Aspartame) of chemically synthesized, pure peptides is about 1500 kilograms and sales approach $500 million on the active pharmaceutical (API) level and $10 billion on the finished drug level, respectively.\\\"\",\"explanation\":\"These quantitative claims are from circa 2011 and do not reflect current market realities; peptide API market was $9.2 billion in 2023, and therapeutics market $117 billion in 2024. Physical production volume in kg is not verifiable in recent sources and likely higher due to market expansion.\",\"fixedText\":\"Remove unverifiable kg volume; update sales to current market values with \\\"as of 2023/2024\\\" qualifiers.\",\"evidenceSource\":\"[](https://www.transparencymarketresearch.com/peptide-api-market.html); [](https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"About a dozen of them are approved as pharmaceuticals.\\\"\",\"explanation\":\"Refers to monoclonal antibodies; the number is outdated from early 2010s. As of 2024, over 130 monoclonal antibodies have been approved globally by major regulators like FDA and EMA.\",\"fixedText\":\"Update to \\\"Over 130 monoclonal antibodies have been approved as pharmaceuticals worldwide as of 2024.\\\"\",\"evidenceSource\":\"[](https://www.antibodysociety.org/resources/approved-antibodies/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific recent examples or counts for approved ADCs.\",\"explanation\":\"The subsection lacks current illustrative examples and global approval counts for ADCs, which have expanded significantly; 15 ADCs approved globally as of 2024, creating a knowledge gap on recent developments in this growing area of fine chemicals.\",\"fixedText\":\"Add current examples (e.g., Enhertu, Kadcyla) and approval count with citation.\",\"evidenceSource\":\"[](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01704-3)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"It is expected that revenues from white biotechnology will account for 10%, or $250 billion, of the global chemical market of $2,500 billion by 2013.\\\"\",\"explanation\":\"This is a projection from circa 2011; as of 2024, the white biotechnology market is approximately USD 253-343 billion, representing about 4% of the global chemical market valued at around USD 6.7 trillion. The outdated projection misrepresents current market realities.\",\"fixedText\":\"Update to: \\\"As of 2024, revenues from white biotechnology account for approximately 4-5%, or USD 250-350 billion, of the global chemical market of about USD 6.7 trillion, with projections to reach USD 400-600 billion by 2030.\\\"\",\"evidenceSource\":\"[](https://www.precedenceresearch.com/white-biotechnology-market) [](https://www.imarcgroup.com/white-biotechnology-market) [](https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"\\\"They exceed 100 kg per year for only three products: Rituxan (Roche-Genentech), Enbrel (Amgen and Merck \u0026 Co. [formerly Wyeth]), and Remicade (Johnson \u0026 Johnson).\\\"\",\"explanation\":\"These are long-standing blockbuster biopharmaceuticals with annual sales exceeding USD 1-4 billion each. Given typical pricing (e.g., USD 20,000-50,000 per patient-year) and dosing (grams per treatment), production volumes are in the tons to tens of tons annually, not kilograms. This understates scale by orders of magnitude.\",\"fixedText\":\"Revise to: \\\"Several biopharmaceuticals now exceed thousands of kilograms per year in production, including legacy products like rituximab (Rituxan), etanercept (Enbrel), and infliximab (Remicade), as well as newer ones like adalimumab (Humira) and pembrolizumab (Keytruda).\\\"\",\"evidenceSource\":\"[](https://www.grandviewresearch.com/industry-analysis/remicade-market-report) [](https://www.thebusinessresearchcompany.com/report/enbrel-global-market-report) [](https://www.marketreportsworld.com/market-reports/rituxan-rituximab-drug-market-14715223)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Entire **Table 2: Top Ten Drugs by 2016**\",\"explanation\":\"The table presents a 2011 projection for 2016 top drugs, which is now outdated by nearly a decade. Current top biopharmaceuticals include Humira, Keytruda, and Dupixent, with small molecules like Ozempic also prominent; the split and rankings have shifted significantly.\",\"fixedText\":\"Replace with an updated table of top biopharmaceuticals by 2024 sales, or remove the projection and note current trends: \\\"As of 2024, eight of the top ten drugs by sales are biopharmaceuticals, including Humira (adalimumab), Keytruda (pembrolizumab), and Dupixent (dupilumab).\\\"\",\"evidenceSource\":\"[](https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/) [](https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Today, biopharmaceuticals account for about $55â€“$80 billion, or 15% of the total pharmaceutical market. They are growing by 15% per year, i.e. three times faster than LMW drugs and are expected to pass the $150 billion per year threshold by 2015.\\\"\",\"explanation\":\"Circa 2011 data; as of 2024, the biopharmaceutical market is approximately USD 450 billion, representing about 30% of the USD 1.5 trillion global pharmaceutical market, with growth rates around 8-10% annually.\",\"fixedText\":\"Update to: \\\"As of 2024, biopharmaceuticals account for approximately USD 450 billion, or 30% of the total pharmaceutical market of USD 1.5 trillion. They continue to grow at rates of 8-10% per year, outpacing small-molecule drugs.\\\"\",\"evidenceSource\":\"[](https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market) [](https://www.pharmaceutical-technology.com/analyst-comment/2024-growth-recovery-top-biopharma-companies/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"\\\"25% of biopharmaceuticals that enter Phase I of the regulatory process eventually are granted approval. The corresponding figure for conventional drugs is less than 6%.\\\"\",\"explanation\":\"Outdated estimate; recent data (post-2020) shows overall likelihood of approval from Phase I at 6.7-14% across all drugs, with biologics at ~13% vs. ~5% for small molecules from GLP tox to approval. The 25% figure overstates biologics success.\",\"fixedText\":\"Revise to: \\\"Biopharmaceuticals have a higher success rate, approximately 13% from preclinical to approval, compared to about 5% for small-molecule drugs.\\\"\",\"evidenceSource\":\"[](https://www.appliedclinicaltrialsonline.com/view/large-vs-small-molecule-success-rates) [](https://www.norstella.com/why-clinical-development-success-rates-falling/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"**Table 1: Key Characteristics of Biotechnological and Chemical API Manufacturing** (e.g., \\\"Product concentration in reaction mixture â‰ˆ 2 - 6 (-10) g / Liter\\\"; \\\"Worldwide reactor volume â‰ˆ 3000 m3\\\"; outsourcing shares)\",\"explanation\":\"Indicative figures are outdated: current mammalian titers routinely reach 5-10 g/L; global mammalian bioreactor capacity exceeds 10,000 m3 (with 27% growth 2020-2024); outsourcing for biopharma is 45-60% overall, higher for early stages. These inaccuracies mislead on technology scale and economics.\",\"fixedText\":\"Update table with current indicative values: e.g., titers 5-10 g/L; reactor volume \u003e10,000 m3; outsourcing early stage 60%, commercial 50%; note \\\"as of 2024\\\" and cite sources.\",\"evidenceSource\":\"[](https://www.evitria.com/journal/cho-cells-first-choice-ab-production/) [](https://www.bioprocessintl.com/supply-chain/biomanufacturing-supply-and-demand-industry-trends-and-projected-impacts) [](https://www.biopharminternational.com/view/outsourcing-hits-record-levels-all-bioprocess-platforms)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall section lacks updates on adoption]\",\"explanation\":\"The section relies on 2011-era data without noting post-2020 advancements, such as higher bioreactor capacities, increased microreactor adoption (market \u003eUSD 500M in 2024), and shifts in biotech (e.g., continuous manufacturing, AI-optimized processes). This creates knowledge gaps on current technologies.\",\"fixedText\":\"Add paragraph or update subsections with recent developments: e.g., \\\"As of 2024, microreactor adoption has grown, with the market exceeding USD 500 million, enabling 20-30% of suitable reactions economically.\\\"\",\"evidenceSource\":\"[](https://www.skyquestt.com/report/microreactor-technology-market) [](https://www.bioprocessintl.com/supply-chain/biomanufacturing-supply-and-demand-industry-trends-and-projected-impacts)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"(Chinese) State Food \u0026 Drug Administration (SFDA)\",\"explanation\":\"The agency was restructured in 2018 and renamed the National Medical Products Administration (NMPA); referring to it by its former name misstates the current regulatory authority.\",\"fixedText\":\"Replace with National Medical Products Administration (NMPA)\",\"evidenceSource\":\"[](https://english.nmpa.gov.cn/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"_[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMEA)_\",\"explanation\":\"The agency's acronym was officially changed from EMEA to EMA in 2004; using the outdated acronym misrepresents the current official name.\",\"fixedText\":\"Replace with European Medicines Agency (EMA)\",\"evidenceSource\":\"[](https://www.ema.europa.eu/en/homepage)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Table 3: Leading Fine Chemical Companies (resp. Units)[17] ... Sales 2009 ($ million)\",\"explanation\":\"The table and associated text present revenue data from 2009 without qualification; as of 2025, this is 16 years outdated, leading to inaccurate representation of current industry leaders and sizes. Some companies have merged or changed (e.g., Sigma-Aldrich acquired by Merck KGaA in 2015).\",\"fixedText\":\"Add \\\"(as of 2009)\\\" to table title; update text to note data is historical; consider partial updates where possible (e.g., confirm ongoing leaders like Lonza, BASF).\",\"evidenceSource\":\"[17]; [](https://www.industryarc.com/Report/15895/fine-chemicals-market.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"The combined revenues of the top 20 fine chemical companies amounted to $10 billion in 2009, representing about 30% of the figure for the whole industry.\",\"explanation\":\"While consistent with 2009 data, without updating or dating, it misrepresents current scale; recent estimates suggest the external fine chemicals market has grown to around $80-100 billion (40% of total ~$200 billion market), implying top 20 revenues now exceed $20-30 billion.\",\"fixedText\":\"Specify \\\"as of 2009\\\" and add note on growth: \\\"The external fine chemicals market has since expanded significantly, estimated at over $80 billion as of 2024.\\\"\",\"evidenceSource\":\"[17]; [](https://www.futuremarketinsights.com/reports/fine-chemicals-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"there are more than 2000 CROs operating worldwide, representing revenues of more than $20 billion.\",\"explanation\":\"The figure is outdated; as of 2024, the global CRO market size is approximately $85 billion, with over 2,000 CROs still operating but revenues substantially higher due to industry growth.\",\"fixedText\":\"Update to: \\\"over 2,000 CROs operating worldwide, representing revenues of approximately $85 billion (as of 2024).\\\"\",\"evidenceSource\":\"[](https://www.fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-100864)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"[Charles River Laboratories](Charles_River_Laboratories \\\"Charles River Laboratories\\\"), [Fortrea](Fortrea \\\"Fortrea\\\"), [Parexel](Parexel \\\"Parexel\\\"), [PPD](Pharmaceutical_Product_Development \\\"Pharmaceutical Product Development\\\"), [Quintiles Transnational](Quintiles_Transnational \\\"Quintiles Transnational\\\"), all USA, and TCG Lifescience, India; are in the $1â€“$2 billion range\",\"explanation\":\"Company names and revenues are outdated: Quintiles Transnational rebranded to IQVIA (revenue ~$15 billion in 2023); PPD acquired by Thermo Fisher (CRO segment \u003e$10 billion); top patient CRO revenues now range from $3-15 billion. Fortrea is a 2023 spin-off from LabCorp.\",\"fixedText\":\"Update names (e.g., IQVIA instead of Quintiles) and generalize revenues to \\\"$5â€“$15 billion range (as of 2023)\\\" for top firms; list current top examples like IQVIA, ICON plc, Parexel.\",\"evidenceSource\":\"[](https://www.proclinical.com/blogs/2025-3/top-10-cros-to-watch-in-2025); [](https://www.statista.com/statistics/732804/top-clinical-research-organizations-by-revenue/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall section lacks recent context]\",\"explanation\":\"The section lacks updates on industry growth post-2011, such as the expansion of the fine chemicals market to ~$210 billion by 2025, increased Asian dominance (e.g., China, India), and integration of sustainable/biotech processes, which are critical for understanding current scope.\",\"fixedText\":\"Add a sentence in the introduction to the subsection: \\\"As of 2024, the global fine chemicals market is estimated at around $200 billion, with significant growth in Asia and a focus on sustainable manufacturing.\\\"\",\"evidenceSource\":\"[](https://www.futuremarketinsights.com/reports/fine-chemicals-market); [](https://www.industryarc.com/Report/15895/fine-chemicals-market.html)\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention of recent advancements.\",\"explanation\":\"The section lacks coverage of recent developments in fine chemicals R\u0026D, such as the integration of artificial intelligence for process design and optimization, and regulatory frameworks like the EU's Safe and Sustainable by Design (SSbD) initiative, which are significant as of 2025 for enhancing efficiency and sustainability.\",\"fixedText\":\"Add a paragraph or sentences in the introduction to the section summarizing these recent trends, with citations.\",\"evidenceSource\":\"[](https://www.mckinsey.com/industries/chemicals/our-insights/how-ai-enables-new-possibilities-in-chemicals) [](https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoral-economic-performance/FINAL_Fine-Chemicals_Brochure_External_RGB.pdf) [](https://cefic.org/news/the-transformative-power-of-innovation-cefic-launches-new-safe-and-sustainable-by-design-guidance-for-research-innovation-within-chemical-companies/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"The latter, valued at $2,500 billion, is dominated mainly by oil-, gas-, and mineral-derived commodities (~40%) on one hand and a large variety of specialty chemicals at the interface between industry and the public on the other hand (~55%). The global production value of fine chemicals is estimated at $85 billion\\\"\",\"explanation\":\"The global chemical industry value and fine chemicals market size are presented without dates and are outdated from circa 2011; as of 2023/2024, the total chemical industry is approximately $6 trillion USD, and fine chemicals around $222 billion USD, affecting the 4% share claim.\",\"fixedText\":\"Update to: \\\"As of 2023, the global chemical industry was valued at approximately $6.67 trillion USD. Fine chemicals account for about 4% of this, with a global production value estimated at $222 billion in 2024.\\\"\",\"evidenceSource\":\"[](https://www.statista.com/statistics/302081/revenue-of-global-chemical-industry/) [](https://www.businessresearchinsights.com/market-reports/fine-chemicals-market-109560)\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"Table 5: Breakdown of Fine Chemicals Market by Major Applications, with totals like Life sciences | Pharmaceuticals | 55 | 32 | 23, Total 85 | 53 | 32\",\"explanation\":\"Table data from 2011 is outdated; current estimates show pharma fine chemicals at ~$149 billion total in 2024, overall fine chemicals ~$222 billion; proportions similar (pharma ~67%), but absolute values incorrect, misleading scale and growth.\",\"fixedText\":\"Rewrite table with updated 2024 estimates: Scale old figures by ~2.6x to match current totals, e.g., Pharmaceuticals 143 | 83 | 60; adjust agro and other proportionally; cite new sources; note \\\"estimated as of 2024\\\".\",\"evidenceSource\":\"[](https://www.imarcgroup.com/pharmaceutical-fine-chemicals-market) [](https://www.businessresearchinsights.com/market-reports/fine-chemicals-market-109560)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Pharmaceutical fine chemicals (PFCs) account for two-thirds of the total. Out of the PFC value of $55 billion, about $23 billion (~40%) are traded, and $32 billion (~60%) are the production value of the pharma industry's in-house production.\\\"\",\"explanation\":\"Undated and outdated; current pharma fine chemicals market ~$149 billion in 2024; split between captive and merchant not precisely known but assumed similar proportion; lack of date makes it seem current.\",\"fixedText\":\"Update to: \\\"As of 2024, pharmaceutical fine chemicals account for approximately two-thirds of the total fine chemicals market, valued at around $149 billion, with an estimated 40% ($60 billion) as merchant market and 60% ($89 billion) captive.\\\"\",\"evidenceSource\":\"[](https://www.imarcgroup.com/pharmaceutical-fine-chemicals-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Their number has increased steadily, from 27 in 1999 to 51 in 2001, 76 in 2003, and then levelled off.\\\"\",\"explanation\":\"Historical data stops at 2003; current number of blockbuster drugs (\u003e $1B sales) is over 100 as of 2024, with significant growth in biologics; outdated trajectory misrepresents current market.\",\"fixedText\":\"Update to: \\\"The number of blockbuster drugs has continued to grow, exceeding 100 as of 2024, driven largely by biologics and innovative therapies.\\\"\",\"evidenceSource\":\"[](https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats)\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"Table 6: Top 10 Proprietary Drugs 2010, with sales like Lipitor 11.8, total 77.5\",\"explanation\":\"2010 data outdated; 2024 top 10 sales total ~$138 billion (e.g., Keytruda $29.5B), with shift to more biologics (8/10 vs old 5/10); incorrect current landscape.\",\"fixedText\":\"Update table to 2024 top 10 drugs, include API, company, sales; note small molecule vs biologic; total ~$138B.\",\"evidenceSource\":\"[](https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"The largest companies are Pfizer, USA; Roche, Switzerland, GlaxoSmithKline, UK; Sanofi Aventis, France, and Novartis, Switzerland.\\\"\",\"explanation\":\"Sanofi Aventis now Sanofi; list still roughly top but add current leaders like Novo Nordisk, Eli Lilly due to GLP-1 boom; outdated naming and omissions.\",\"fixedText\":\"Update to: \\\"Leading companies include Pfizer (USA), Roche (Switzerland), Novartis (Switzerland), Sanofi (France), GSK (UK), Novo Nordisk (Denmark), and Eli Lilly (USA).\\\"\",\"evidenceSource\":\"[](https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Global sales of proprietary drugs are estimated $735 billion in 2010, or almost 90% of the total pharma market. Global sales of generics are about $100 billion, or just over 10% of the total pharma market.\\\"\",\"explanation\":\"2010 figures; as of 2024, total pharma ~$1.65 trillion, proprietary ~$1.2 trillion (73%), generics ~$450 billion (27% value, higher volume share); misrepresented current shares.\",\"fixedText\":\"Update to: \\\"As of 2024, the global pharmaceutical market is approximately $1.65 trillion, with proprietary drugs accounting for about 73% (~$1.2 trillion) and generics about 27% (~$450 billion) by value, though generics represent a larger share by volume.\\\"\",\"evidenceSource\":\"[](https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global) [](https://www.precedenceresearch.com/generic-drugs-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"the top 10 companies, led by Syngenta, Switzerland; Bayer Cropsciences, Germany: Monsanto, USA; BASF Crop Protection, Germany, and Dow Agrosciences, USA have a share of almost 95% of the total 2,000,000 tons / $48.5 billion pesticide output in 2010.\\\"\",\"explanation\":\"2010 data and company structure outdated; Syngenta acquired by ChemChina (2017), Monsanto by Bayer (2018), Dow Agrosciences part of Corteva (2019); current pesticide market ~$90 billion (part of total agrochem $250 billion 2024); top share similar but companies changed.\",\"fixedText\":\"Update companies to: \\\"Bayer CropScience (Germany, incl. Monsanto), Syngenta Group (China/Switzerland), Corteva Agriscience (USA), BASF (Germany), FMC (USA); they hold ~80-90% share of the ~$250 billion global agrochemicals market as of 2024.\\\"\",\"evidenceSource\":\"[](https://www.precedenceresearch.com/agrochemicals-market) [](https://www.emergenresearch.com/blog/top-10-companies-in-agrochemicals-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"100 new LMW agrochemicals have been launched in the period 2000â€“2009. However, only 8 products achieved sales in excess of $100 million per year.\\\"\",\"explanation\":\"Historical data to 2009; recent launches (2010-2024) fewer due to high costs, focus on biologics/sustainable; no update misrepresents innovation pace.\",\"fixedText\":\"Update to: \\\"Between 2010 and 2023, fewer than 50 new low-molecular-weight agrochemicals were launched globally, with even fewer achieving significant sales, reflecting a shift toward biologicals and sustainable solutions.\\\"\",\"evidenceSource\":\"[](https://www.infosys.com/iki/documents/agrochem-industry-market-outlook.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"Table 8: Other Specialty Chemicals Industries, with sales like Adhesives \u0026 Sealants ~60, Biocides ~3, etc.\",\"explanation\":\"Undated sales figures from ~2011; current markets larger, e.g., adhesives ~$70 billion (2024), biocides ~$12 billion; outdated values mislead on scale and attractiveness.\",\"fixedText\":\"Update table sales to 2024 estimates: Adhesives ~70, Biocides ~12, etc.; adjust attractiveness if needed; cite sources.\",\"evidenceSource\":\"[](https://www.grandviewresearch.com/industry-analysis/adhesives-and-sealants-market) [](https://www.marketsandmarkets.com/Market-Reports/biocides-market-1157.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall section]\",\"explanation\":\"The section lacks recent developments up to 2025, such as the rise of biologics and GLP-1 agonists in pharma (impacting fine chemicals for small molecules), sustainability regulations in agrochemicals, and growth in biosimilars/generics; critical for completeness in a 2025 context.\",\"fixedText\":\"Add paragraphs or update text to include: \\\"Recent trends include a surge in demand for fine chemicals supporting biologic manufacturing and sustainable agro inputs; biosimilars market growing to ~$100B by 2025.\\\"\",\"evidenceSource\":\"[](https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats) [](https://www.precedenceresearch.com/agrochemicals-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"All in all, the average Western fine-chemical firms have been making a return below the cost of capital, i.e. they are not reinvestment grade.\\\"\",\"explanation\":\"The conclusion is presented in present tense based on data from 2000-2009 (sourced from 2011 book), but as of 2025, industry profitability has shown recovery (e.g., top chemical firms' profits up 8.1% in 2024), making the claim outdated and potentially misleading without temporal context.\",\"fixedText\":\"Add \\\"as of 2009\\\" qualifier and include a new paragraph on recent trends (2020-2025) with updated profitability data from authoritative sources.\",\"evidenceSource\":\"[](https://cen.acs.org/business/finance/CENs-Global-Top-50-2025/103/web/2025/07)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mathematical Correctness (Proof/Definition)\",\"problematicText\":\"\\\"the unit cost per m3 would decrease or decrease with the exponent 0.5, respectively.\\\"\",\"explanation\":\"Typographical error creates contradiction; scaling laws for equipment costs typically follow \\\"six-tenths rule\\\" where cost scales with capacity^0.6 (approx. 0.5), so larger size decreases unit cost, smaller increases it. The repetition \\\"decrease or decrease\\\" is incorrect and confuses the scaling relationship.\",\"fixedText\":\"Correct to \\\"decrease or increase\\\"; clarify as following approximate 0.5 exponent scaling.\",\"evidenceSource\":\"[25]\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"The entire Table 9 presentation, e.g., \\\"Equipment / Investment  | Numbers   ---|---  **Description of main equipment**  Production trains Reactor vessels (volume = 4 m3)   .... Total reactor volume   Filtration units   Dryers  | 2 6   .... 24 m3   2   2\\\"\",\"explanation\":\"Table is malformed with inconsistent markdown, misaligned columns, and incomplete rows, making data unreadable and potentially misinterpretable (e.g., numbers not clearly associated with descriptions). This obscures the investment cost breakdown from the 2011 source.\",\"fixedText\":\"Rewrite table in proper markdown format with clear rows for equipment quantities and costs; note as example from 2011.\",\"evidenceSource\":\"[25]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall section]\",\"explanation\":\"The section lacks updates on financial trends post-2011, such as market growth to ~$200B by 2024, rising energy costs (19% global increase in 2023), and profitability recovery (e.g., 8.1% profit growth in 2024 for top firms), which are essential for currency given the 2025 date.\",\"fixedText\":\"Add dated updates to subsections, focusing on profitability and costs, with new citations; avoid duplicating \\\"Markets\\\" section content.\",\"evidenceSource\":\"[](https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoral-economic-performance/FINAL_Fine-Chemicals_Brochure_External_RGB.pdf) [](https://cen.acs.org/business/finance/CENs-Global-Top-50-2025/103/web/2025/07) [](https://www.marketgrowthreports.com/market-reports/fine-chemicals-market-108218)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Biopharmaceuticals are expected to grow 15% per year, three times as fast as small molecule drugs.\\\"\",\"explanation\":\"The growth rate is based on outdated 2011 projections; as of 2025, the biopharmaceutical market is projected to grow at a CAGR of 8-12% from 2025-2030, compared to small molecule drug discovery at ~8-9% CAGR and overall pharmaceuticals at ~6%, indicating biopharma still grows faster but not at 15%.\",\"fixedText\":\"Update to: \\\"Biopharmaceuticals are projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2025 to 2030, faster than the overall pharmaceutical market's ~6% CAGR.\\\"\",\"evidenceSource\":\"[](https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Five of the top ten drugs were biopharmaceuticals in 2010 (see table 6), and this is expected to grow to eight by 2016 (see table 2).\\\"\",\"explanation\":\"Statistics and projections are from 2011 and irrelevant in 2025; as of 2024, seven of the top ten best-selling drugs are biopharmaceuticals, confirming the trend toward biologics dominance.\",\"fixedText\":\"Revise to: \\\"As of 2024, seven of the top ten best-selling drugs worldwide are biopharmaceuticals, reflecting the ongoing shift toward biologics.\\\"\",\"evidenceSource\":\"[](https://www.genengnews.com/topics/drug-discovery/top-10-best-selling-drugs-2/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"(see table 6)\\\", \\\"(see table 2)\\\"\",\"explanation\":\"References to tables from a 2011 book (ref 20, 17) that contain outdated data from 2010 and projections to 2016; these do not support current claims and mislead on timeliness.\",\"fixedText\":\"Remove references to specific tables; replace with updated sourced claims as above.\",\"evidenceSource\":\"Ref 20, Ref 17\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks recent developments.\",\"explanation\":\"The section omits key 2020s trends impacting the industry, such as accelerated outsourcing due to drug complexity and post-COVID biotech advances (e.g., mRNA and GLP-1 drugs), sustainability focus in chemical production, and digital/AI integration, which are essential for a current \\\"Outlook\\\" as of 2025.\",\"fixedText\":\"Add brief mentions of sustainability, AI-driven innovation, and the role of GLP-1 biopharmaceuticals in demand growth, with sources.\",\"evidenceSource\":\"[](https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html)\"}],\"slug\":\"Fine_chemical\",\"title\":\"Fine chemical\",\"content\":\"$1f\",\"description\":\"Fine chemical\\n\\nDefinition of Fine Chemicals (as opposed to Commodities and Specialties)\\n\\nIn chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in...\",\"metadata\":{\"categories\":[\"fine chemicals\"],\"lastModified\":\"1761553076\",\"contentLength\":\"101207\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"25687\",\"recentViews\":\"25687\",\"dailyAvgViews\":856.2333374023438,\"qualityScore\":1,\"lastViewed\":\"1761884162\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761884162453,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Fine_chemical\"],\"queryHash\":\"[\\\"page\\\",\\\"Fine_chemical\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Fine chemical\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"fine chemicals\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Fine_chemical\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Fine chemical\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Fine_chemical\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Fine chemical\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.076Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Fine chemical\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg (see the comparison of fine chemicals, commodities and specialties). The class of fine chemicals is subdivided either on the basis of the added value (building blocks, advanced...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTk2YzM4N2QtZWY4Mi00OWU5LTg5N2YtZDA1ODc4OWRmOWU1">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Fine_chemical\"}]}]\n"])</script></body></html>